Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
11-15-2019 10:00 AM

The Epigenetic And Immune Landscapes Of HPV+ Tumor
Microenvironments
Steven F. Gameiro, The University of Western Ontario
Supervisor: Mymryk, Joe S., The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree
in Microbiology and Immunology
© Steven F. Gameiro 2019

Follow this and additional works at: https://ir.lib.uwo.ca/etd

Recommended Citation
Gameiro, Steven F., "The Epigenetic And Immune Landscapes Of HPV+ Tumor Microenvironments"
(2019). Electronic Thesis and Dissertation Repository. 6700.
https://ir.lib.uwo.ca/etd/6700

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Human papillomaviruses (HPVs) are responsible for approximately 4.5% of the global cancer
burden. Virtually all cervical cancers (CESC) are caused by HPVs, as well as a subset of head
and neck squamous cell carcinomas (HNSC). Our studies began by using data from over 800
CESC and HNSC samples from The Cancer Genome Atlas (TCGA) to test a model proposed
from in vitro studies of an HPV-dependent deregulation of the cyclin-dependent kinase
inhibitor 2A (CDKN2A) locus. Similar to the proposed models, we found that the HPV+
TMEs—regardless of tissue of origin—expressed significantly higher levels of KDM6A which
demethylates the repressive tri-methylated lysine 27 on histone 3—critical for tightly
regulating expression from the aforementioned locus. Furthermore, we also found that CpG
methylation of the CDKN2A locus was consistently altered in HPV-positive (HPV+) tumors.
We next wanted to test another in vitro model that proposed an HPV-dependent transcriptional
downregulation of genes that encode for essential products of the class I major
histocompatibility complex I (MHC-I) antigen presentation system. Utilizing the same large
TCGA cohorts, we unexpectedly found that these genes were expressed at high levels in HPV+
tumors. The high mRNA levels of the MHC-I antigen presentation apparatus could be a
consequence of the higher intratumoral levels of interferon-gamma (IFNγ) observed in HPV+
carcinomas, which correlated with signatures of increased infiltration by T- and NK-cells. In
addition, we also found increased expression of the class II MHC antigen presentation system
in HPV+ HNSC. Furthermore, we observed that HPV+ HNSC TMEs exhibited a strong bias
towards a Th1 response which was characterized by increased infiltration with multiple types
of immune cells and expression of their effector molecules. Moreover, the HPV+ HNSC TME
also expressed high levels of multiple T-cell exhaustion markers that were indicative of a Tcell-inflamed phenotype. Overall, these analyses have provided significant insight into the
validity of models proposed from experiments conducted in relatively artificial in vitro culture
systems. Importantly, these studies have illustrated, in great detail, the strikingly profound
differences in both the epigenetic and immune landscapes between the tumor
microenvironments of HPV+ and HPV-negative carcinomas.
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Summary for Lay Audience
Human papillomaviruses (HPVs) are responsible for approximately 4.5% of the global cancer
burden. Virtually all cervical cancers (CESC) are caused by HPVs, as well as a subset of head
and neck squamous cell carcinomas (HNSC). CESC and HNSC are the 4th and 7th most
common cancers worldwide, respectively. The distinctive etiological factors that are involved
in CESC and HNSC tumorigenesis—such as the expression of exogenous oncogenic viral
antigens in HPV-positive (HPV+), but not HPV-negative (HPV–), carcinomas—provides us
with a unique opportunity to study differences in the tumor microenvironments of HPV+ and
HPV– carcinomas in 2 distinct anatomical regions. Much of the existing literature that
underpins the foundation for this body of work utilizes artificial in vitro model systems.
However, their lack of heterogeneity, tumor microenvironment, and infiltrating immune cells
severely limit their ability to recapitulate actual human cancers. Therefore, this work
capitalizes on genomic and transcriptomic “big” data acquired through next-generation “omics” technologies from actual human tumors, which allow for an insightful elucidation of
mechanistic processes under the influence of a native heterogeneous environment. Utilizing
computational methods, this work explores and profiles the epigenetic and immune landscapes
between the tumor microenvironments of HPV+ and HPV– carcinomas present in actual
human malignancies. The studies presented in this thesis identify strikingly profound
differences in the epigenetic and immune landscapes of the tumor microenvironments of these
2 etiologically-distinct carcinomas, regardless of their tissue of origin. Furthermore, they also
provide insight into the validity of 2 important models of high-risk HPV-mediated sabotage of
intracellular epigenetic and immune networks that were previously proposed from artificial in
vitro culture studies. In addition, these studies identify potentially useful therapeutic targets
and advocate for the utility of novel immunotherapy treatment modalities. Moreover, they also
identify potentially predictive biomarkers of clinical outcomes that could have implications for
treatment deintensification.
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Out of the night that covers me,
Black as the pit from pole to pole,
I thank whatever gods may be
For my unconquerable soul.
In the fell clutch of circumstance
I have not winced nor cried aloud.
Under the bludgeonings of chance
My head is bloody, but unbowed.
Beyond this place of wrath and tears
Looms but the Horror of the shade,
And yet the menace of the years
Finds, and shall find, me unafraid.
It matters not how strait the gate,
How charged with punishments the scroll,
I am the master of my fate:
I am the captain of my soul.
-Invictus
by William Ernest Henley
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Chapter 1

1

Introduction

1.1 A Brief History of Papillomavirus Research
The earliest evidence of human papillomavirus (HPV) infections came from ancient Greek
and Roman texts that described lesions akin to present-day genital warts. At the time, such
lesions were associated with sexual promiscuity, which hinted at their infectious etiology
(Bafverstedt, 1967; zur Hausen, 2009). However, it wasn’t until the start of the 20th century
that the viral origins and contagious nature of warts were explicitly demonstrated through
cell-free transmission experiments conducted in Italy (reviewed in Syrjanen and Syrjanen,
2008). In the 1930s, landmark experiments conducted by Richard Shope identified the first
animal papillomavirus (PV)—the cottontail rabbit papillomavirus (CRPV)—through the
isolation and characterization of contagious cutaneous papillomas that grew on wild
cottontail rabbits (Shope and Hurst, 1933). In addition to causing benign lesions, some
CRPV-induced papillomas progressed to carcinomas (Rous and Beard, 1935). This
fundamental observation led to the identification of CRPV as the first DNA tumor virus.
Up until the 1950s, CRPV infection of rabbits served as an important model for the study
of viral carcinogenesis (reviewed in Syrjanen and Syrjanen, 2008). However, the discovery
of polyomaviruses (PyVs) replaced CRPV as a model of virally-induced tumorigenesis,
since they were easily propagated in culture, could transform cells in vitro, and were
tumorigenic to other experimental animals (Javier and Butel, 2008). With the dawn of
molecular cloning in the 1970s, scientists were now able to study the biochemical
properties of PVs through the cloning of their genomes. Specifically, open reading frames
(ORFs) were being identified as putative viral genes, and their functions elucidated through
reverse genetics (Chen et al., 1982; Danos et al., 1982).
Anecdotal reports regarding the spontaneous conversion of genital warts into squamous
cell carcinomas initiated extensive experiments in which the aim was to establish an
association between HPV infection and cancer (zur Hausen, 1977; zur Hausen et al., 1974).
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Indeed, in 1982 the first three reports of HPV sequences isolated from human tumors were
published (Gissmann et al., 1982; Green et al., 1982; Zachow et al., 1982). Shortly
thereafter, in situ DNA hybridization experiments on genital cancer biopsies and cervical
cancer-derived cell lines identified two novel HPV genotypes—HPV type 16 (HPV16) and
HPV type 18 (HPV18)—which were subsequently confirmed to be present in virtually all
cervical cancers (Boshart et al., 1984; Durst et al., 1983). These ground-breaking
discoveries definitively identified HPV16 and 18 as the causative agents of cervical cancer.
In the 1990s, a large-scale epidemiological study provided evidence that various HPV
types—HPV16, 18, 31, 33, and 35—were the main risk factors for cervical cancer (Munoz
et al., 1992). In the early 2000s, a seminal paper by Gillison et al., showed evidence of a
causal association between HPV infection and a subset of head and neck cancers (Gillison
et al., 2000). Today, it is well-established that infection with specific HPV types can give
rise to cervical, other anogenital, and head and neck cancers (zur Hausen, 2002). Through
almost a century of research initiatives, certain HPV types have emerged as potent human
biological carcinogens.

1.2 Papillomaviruses at a Glance
PVs are ubiquitous entities, having successfully infected and co-evolved with at least 54
different non-human host species—mostly mammals, but also birds and reptiles (Rector
and Van Ranst, 2013). Their ability to transmit through direct physical contact and general
inability to cause fatal disease have allowed PVs to establish successful niches and coevolve with their host-species (Chen et al., 2018). Typically, infections with PVs—
regardless of the host species they infect—causes papillomas (warts), which are simply
benign hyperplastic growths of epithelial cells (Rector and Van Ranst, 2013). However, in
some instances, papillomas can progress to carcinomas, and this phenomenon of malignant
progression is in part responsible for PVs being some of the most intensively researched
viruses in the world, specifically those that infect humans.
In humans, there are currently over 200 established HPV types that have been isolated,
sequenced, and their clones deposited to the International HPV Reference Center (Muhr et
al., 2018). This diverse group of human-specific PVs all share an exclusive tropism for
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either cutaneous or mucosal epithelia. The cutaneous HPV types are responsible for the
development of common warts (papillomas), which are typically self-limiting, small and
grainy growths that occur most often on hands (Mammas et al., 2009). In extremely rare
cases, individuals with an autosomal recessive genetic mutation are profoundly susceptible
to infection with certain cutaneous HPV types that can lead to a skin disorder that is
clinically termed epidermodysplasia verruciformis (EV) (Gewirtzman et al., 2008).
Patients with EV have a genetic defect in two genes that are critical for cutaneous
immunity, illustrating the importance of the immune system in keeping HPV infections
under control (Lane et al., 2003). Symptomatically, patients succumb to a lifelong battle
with uncontrollable growth of scaly macules (skin discoloration) and papules (inflamed
cutaneous lesions) that can undergo malignant transformation (de Oliveira et al., 2003).
In contrast, mucosal HPV types are responsible for mucosal lesions that occur in the
anogenital or oral tracts (Doorbar et al., 2012). These mucosal warts, like their
aforementioned cutaneous counterparts, are typically benign or low-grade and are often
self-limiting. However, in some instances, infection with certain types of HPVs can lead
to the formation of lesions that have a much higher propensity to progress to carcinomas.
These epitheliotropic viruses are highly transmissible, with the highest incidence occurring
at the onset of sexual activity (Cutts et al., 2007). In fact, mucosal HPVs are the most
common sexually transmitted viral infection worldwide and it is estimated that most
sexually active individuals, regardless of sex, will acquire it at some point during their life
(Crosbie et al., 2013; Dunne et al., 2007). Accordingly, these mucosa-associated HPV
types are designated as either low-risk (LR) or high-risk (HR) based on their oncogenic
potential (Tommasino, 2014). The prototypical LR HPVs, HPV6 and 11, are responsible
for the majority of anogenital and oral warts with about 90% being cleared naturally within
2 years (Bharti et al., 2013). Whereas, the prototypical HR HPV types 16 and 18 are
responsible for a small number of mucosal lesions, but the frequency of progression to
premalignant lesions that further develop into carcinomas is much higher compared to their
low-risk counterparts (Doorbar et al., 2012). Indeed, 12 HR HPV types—including HPV16
and 18— are designated by the World Health Organization’s (WHO) International Agency
for Research on Cancer (IARC) as Group 1 biological agents: “carcinogenic to humans”
(Bouvard et al., 2009). In contrast, LR HPV types are classified by IARC as having
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inadequate evidence of carcinogenicity (Group 3). These differences in carcinogenic
potential between LR and HR HPV infections can be attributed to variations in viral
oncoprotein functions, along with differences in viral promoter activities and gene
expression patterns (Doorbar et al., 2012; Klingelhutz and Roman, 2012).

1.3 Human Papillomavirus Biology
HPVs belong to the Papillomaviridae family of viruses and are divided into five
phylogenetic genera—designated Alpha, Beta, Gamma, Mu, and Nu—based on DNA
sequence analysis (Bernard et al., 2010). The majority of research initiatives have focused
on the Alphapapillomaviruses because of their impact on human health. This genus
includes the mucosal wart causing LR types as well as the HR types that cause cancer. At
the population level, HPV16 is the most frequently detected Alphapapillomavirus, and its
high association with carcinogenesis makes this type the most clinically relevant
(Schiffman et al., 2016). Indeed, because of its potent carcinogenicity, HPV16 is the beststudied PV and will henceforth be considered in this thesis as the archetypal example.
HPV16 is a small DNA tumor virus with a non-enveloped icosahedral capsid that is
approximately 55 nm in diameter (Figure 1.1A). This naked capsid is primarily composed
of the major capsid protein L1, and to a much smaller extent the minor capsid protein L2.
(Doorbar et al., 2015). The virions consist of a single, double-stranded circular DNA
genome that is made up of 7,908 base pairs (bp) that contains 8 open reading frames (ORFs)
encoded on one DNA strand (Figure 1.1B). The genome is organized into 3 major regions:
(i) a non-coding region, called the upstream regulatory region (URR)—alternatively called
the long control region (LCR)—that contains cis-regulatory elements essential for viral
DNA replication and controlling gene expression; (ii) an early region that encodes for the
early genes—E1, E2, E4, E5, E6, and E7—that are involved in a plethora of functions
including viral replication and cell transformation; and (iii) a late region that encodes for
the major (L1) and minor (L2) capsid proteins (Tommasino, 2014). Select functions of the
early and late gene products are summarized in Figure 1.1C. Furthermore, due to their
relatively small genome size and subsequent limited coding capacity, viral gene expression
is coordinated by multiple promoters that create a complex configuration of mRNA
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Figure 1.1. The HPV16 capsid and genome organization with select functions
highlighted.
Schematic representation of the HPV16 icosahedral capsid (A) and genome organization
(B). Summary of select functions of the viral products encoded by HPV16 (C). Regions
with similar functions are indicated with similar colors: the non-coding region is in gray,
the early region that encodes for the early genes involved in viral replication is in green,
the early region that encodes for the early genes involved in cellular transformation is in
red, and the late region that encodes for the capsid proteins is in blue. Adapted from
Tommasino, 2014.
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transcripts that undergo extensive alternative splicing that enables viral gene products to
be expressed at different phases throughout the viral replicative cycle (Graham, 2010).
The replicative cycle of HPVs is unique because of the intimate link to the differentiation
program of epidermal keratinocytes (Figure 1.2). In order for HPVs to successfully
replicate, they require access to the basal layer cells of the epithelium through microwounds or hair follicles (Doorbar et al., 2012). Once at the basal layer, entry into the host
cell is mediated by the viral L1 major capsid protein interacting with heparan sulfate
proteoglycans on the cell surface (Shafti-Keramat et al., 2003). This interaction triggers the
internalization of the virion via a clathrin-dependent endocytic mechanism (Day et al.,
2003). Once internalized, the virus undergoes endosomal transport and subsequent
uncoating in the late endosomes. The low pH environment found in late endosomes triggers
viral egress by promoting the interaction between the viral L2 minor capsid protein and
cellular protein SNX17 (Bergant Marusic et al., 2012). Importantly, the L2 protein—
complexed with viral DNA—ensures the correct entry of the viral genome into the host
cell nucleus (Doorbar et al., 2012; Schelhaas et al., 2012). Once in the nucleus, there is an
initial phase of viral genome amplification that is followed by maintenance of the viral
episome at a low-copy number—often proposed to be around 50-200 copies per cell
(McBride, 2008; Parish et al., 2006; Pyeon et al., 2009). Viral replication is mediated
through the usurpation of the host cells’ high-fidelity cellular polymerases. Whereas
maintenance of viral genome integrity and accurate segregation to daughter cells during
mitosis is ensured by the E1 and E2 viral proteins, which are both necessary and sufficient
for PV replication (McBride, 2017).
As the basal layer cells migrate upwards, they begin to differentiate and stop proliferating.
During differentiation, the cells undergo several biochemical changes in order to produce
the protective, semi-permeable outer layer of skin that is an essential environmental barrier
necessary for all terrestrial life (Madison, 2003). It is during this growth-arrested,
differentiation stage that the viral E6 and E7 proteins deregulate cell cycle control and force
the quiescent cell to re-enter S phase (Bravo and Felez-Sanchez, 2015; Cheng et al., 1995;
Sherman et al., 1997). This forced re-entry results in viral genome amplification and
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Figure 1.2. The replicative cycle of human papillomaviruses.
HPVs infect keratinocytes present at the basal layer of the epithelium that are exposed
through microwounds. Normal epithelium is shown on the left and HPV-infected
epithelium is shown on the right. The replicative cycle of HPVs is intimately linked to the
differentiation program of epidermal keratinocytes. Once in the basal layer cells, the HPV
genome is established in the nucleus as a low-copy number episome. As the basal layer
cells migrate upwards, they begin to differentiate and stop proliferating. During this
growth-arrested, differentiation stage, the viral E6 and E7 proteins deregulate cell cycle
control and force the quiescent cell to re-enter S phase. Following differentiation, the viral
genome is amplified to a high-copy number. In the upper layers of the epithelium, the L1
and L2 capsid proteins are produced and the viral genome is encapsidated. Newly
assembled virions (purple) are shed into the environment. The different epithelial layers
are indicated on the left. Viral progression through the epithelium is indicated on the right.
Epithelium was created with BioRender. Adapted from Moody and Laimins, 2010.
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hyperproliferation of cells that would have normally exited the cell cycle. Consequently,
deregulated cell cycle progression results in the accumulation of mutations that can lead to
the development of HPV-associated cancers (Bravo and Felez-Sanchez, 2015). Following
differentiation, the expression of E1, E2, E4, and E5 increases substantially, which results
in an amplification of viral genome copy number from 50-200 copies to several 1000s of
copies per cell (Bedell et al., 1991). Finally, in the upper layers of the epithelium, the L1
and L2 capsid proteins are produced and the viral genome is encapsidated. Newly
assembled virions are shed into the environment through the normal epithelial process of
desquamation—shedding of the outermost layer of skin (Bodily and Laimins, 2011;
Madison, 2003). This process occurs in the absence of lysis or necrosis, thereby avoiding
inflammation and contributing to viral persistence.

1.4 Human Papillomavirus Oncogenes and Transformation
The E6 and E7 genes encoded by HR HPVs have been designated as “viral oncogenes”
due to their fundamental roles in cellular transformation. The first evidence of their
carcinogenic properties came from studies on cell lines derived from cervical cancers
(Schwarz et al., 1985). These cervical cancer-derived cells had HR HPV DNA randomly
integrated into their genome, with the E6 and E7 ORFs intact and several other viral genes
disrupted. Their role in carcinogenesis was further highlighted by studies that demonstrated
their ability to induce transformation and immortalize both rodent fibroblasts and human
keratinocytes (Mansur and Androphy, 1993). Indeed, it is now widely accepted that the
products of E6 and E7—often designated as viral oncoproteins—deregulate vital cellular
processes, such as differentiation, cell cycle, DNA repair, senescence, and apoptosis
(Tommasino, 2014). This deregulation facilitates the accumulation of DNA damage that
contributes to the progression of the transformed phenotype. Importantly, the continuous
expression of the E6 and E7 oncogenes seems necessary to maintain the malignant
transformed phenotype, as silencing of E6 and/or E7 expression induces rapid growth
arrest, senescence, or apoptosis in HPV-positive (HPV+) cervical and oral cancer-derived
cell lines. (Goodwin and DiMaio, 2000; Goodwin et al., 2000; Jiang and Milner, 2002;
Rampias et al., 2009; Sima et al., 2008).
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The E7 ORF encodes for a small, acidic phosphoprotein of 98 amino acids (Vousden,
1993). This viral oncoprotein has no enzymatic or DNA-binding activities, instead it
associates with a wide variety of cellular regulatory proteins to inhibit or retarget their
functions (McLaughlin-Drubin et al., 2012; Moody and Laimins, 2010). The HPV E7
oncoprotein is subdivided into three domains: conserved regions 1–3 (CR1–3), based on
amino acid sequence similarities between different HPV types (Phelps et al., 1988). The
CR1 and CR2 are intrinsically disordered, allowing adaptability in their interactions with
a plethora of cellular targets (Dyson and Wright, 2005; Ohlenschlager et al., 2006).
Interestingly, CR1 and CR2 are structurally and functionally similar to certain domains
found in the otherwise unrelated adenovirus E1A and simian vacuolating virus 40 (SV40)
large T antigen (Dyson et al., 1992; Phelps et al., 1988; Vousden and Jat, 1989). Indeed,
all 3 contain the LXCXE motif—where X is any amino acid—that is essential for the
interaction with the retinoblastoma tumor suppressor and related family members (Rb)
(Munger et al., 1989).
The Rb protein (pRb) and related family members, p107 and p130, comprise the “pocket
protein” family of cell cycle regulators that control the G1–S phase transition through the
regulation of the E2F family of transcription factors (Dyson, 1998). In general, E2F
transcription factors will localize and bind to E2F-binding sites that are found within the
promoters of numerous genes involved in regulating cell cycle progression, differentiation,
and apoptosis (DeGregori and Johnson, 2006). In the context of a normal cell, the Rb
pocket protein complex directly binds to the transactivation domain of E2F, thereby
repressing transcription from E2F-dependent promoters (Harbour and Dean, 2000). In late
G1, the phosphorylation of Rb by cyclin-dependent kinases (CDKs) leads to its
disassociation from E2F which results in the transcriptional activation of S phase-specific
genes (Stevaux and Dyson, 2002). During HR HPV infection, the E7 oncoprotein will bind
to Rb—mediated by the aforementioned LXCXE motif—disrupting the Rb–E2F complex
and subsequently targeting Rb for proteasomal degradation through the ubiquitindependent pathway (Boyer et al., 1996; Chellappan et al., 1992; Jones et al., 1997). This
forced disassociation from E2F results in the constitutive expression of E2F-responsive
genes, such as cyclin A and cyclin E, that stimulate premature entry into S phase, thereby
reactivating DNA replication (Cheng et al., 1995; Zerfass et al., 1995). Furthermore, E7-
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mediated degradation of Rb also abrogates other Rb-specific activities that are
fundamentally involved in DNA repair and maintaining host genome integrity (Moody and
Laimins, 2010).
In addition, HR HPV E7 also induces epigenetic changes on the host cell transcriptome.
Specifically, E7 expression stimulates the activation of the histone methyltransferase
EZH2, which catalyzes the tri-methylation (me3) of H3K27 (Holland et al., 2008; Hyland
et al., 2011; McLaughlin-Drubin et al., 2011). Furthermore, in vitro studies have also
observed an E7-dependent activation of the histone demethylases KDM6A and KDM6B
that convert H3K27me3 to the di- or mono-methylated forms (Hyland et al., 2011;
McLaughlin-Drubin et al., 2011). This E7-mediated induction of KDMs was also shown,
in vitro, to induce the activation of the tumor suppressor p16, which is a product of the
CDKN2A locus and functions as a negative regulator of the cell cycle via CDK inhibition
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013; Rayess et al., 2012).
Consequently, p16 is found to be expressed at high levels in nearly all HPV-induced
tumors, and is therefore used as a surrogate biomarker of HPV status during pathological
assessment (Hoffmann et al., 2010; Klaes et al., 2001; Sano et al., 1998). In Chapter 2, we
explore the epigenetic landscape by utilizing next-generation “-omics” data from over 800
primary human cervical and head and neck tumors to assess the impact of HPV status on
the transcript levels of key regulators of H3K27 methylation, including EZH2, KDM6A,
and KDM6B. Additionally, we also examine HPV-specific effects on gene expression and
DNA methylation across the entire CDKN2A and adjacent CDKN2B genomic regions.
The E6 ORF encodes for a basic and cysteine-rich protein of 158 amino acids. The main
structural feature of this oncoprotein is the zinc-binding domains present at both the amino
and carboxyl termini (Tommasino, 2014). The two zinc domains, together with an alphahelical structure in between them, form a binding pocket that strictly binds to cellular
targets that contain the LXXLL motif (Nomine et al., 2006; Zanier et al., 2013; Zanier et
al., 2012). Interestingly, even though it can bind to a vast number of cellular targets across
the entirety of its structured surface, all of its primary interactors contain
an LXXLL motif (Vande Pol and Klingelhutz, 2013). The ability to bind to this
aforementioned motif is essential for its intracellular functions, as studies have shown that
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mutants of E6 that fail to bind LXXLL are rendered functionally defective (Cooper et al.,
2003; Zanier et al., 2013). Indeed, this motif plays a central role in E6’s best characterized
role: the ability to induce the degradation of the tumor suppressor p53 (Scheffner et al.,
1990).
A major consequence from the E7-mediated forced re-entry into an unscheduled S phase
is the elevation in the levels of p53, which impedes cell growth and induces apoptosis
(Demers et al., 1994; Jones et al., 1997). The tumor suppressor p53 is a transcription factor
that controls the expression of numerous genes that encode for products that are
instrumental in regulating the cell cycle, DNA repair, and apoptosis. During cellular stress,
such as DNA damage or hypoxia, p53 will trigger cell cycle arrest or apoptosis in order to
safeguard cellular genomic integrity (Levine and Oren, 2009). This strategy of blocking
the cell cycle ensures that damaged DNA does not get replicated and allows the cell to
repair the damage before entering S phase. In some instances, the accumulated damage
may be too great to repair, therefore p53 will induce apoptosis in order to prevent the
generation of potentially transformed daughter cells. During an HPV infection, to
counteract E7-induced cellular suicide, the E6 oncoprotein will interfere with the functions
of p53 (Moody and Laimins, 2010). It accomplishes this feat by binding to the E3 ubiquitin
ligase, E6-associated protein (E6AP), via the conserved cellular LXXLL motif and forming
a trimeric complex with p53, which ultimately leads to the ubiquitylation and subsequent
proteasomal degradation of this indispensable tumor suppressor (Huibregtse et al., 1991;
Scheffner et al., 1993; Scheffner et al., 1990). Indeed, this abrogation of p53’s function
combined with the E7-mediated forced re-entry into S phase, facilitates productive viral
replication. However, due to the persistent nature of an HPV infection, it can result in the
accumulation of DNA damage—that would have otherwise been repaired—leading to
genomic instability that has consequences for tumor development (Moody and Laimins,
2010).
As mentioned previously, the two virally encoded oncoproteins, E6 and E7, are necessary
for maintaining the transformed phenotype; however, the functions highlighted above are
not sufficient to directly transform infected cells (Moody and Laimins, 2010). Therefore,
additional carcinogenic events such as genomic instability must occur for malignant
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transformation to develop. Genomic instability can occur over time with a persistent HPV
infection due to the accumulation of DNA damage that results from the degradation of
tumor suppressor proteins Rb and p53 (White et al., 1994). In addition, genomic instability
has also been shown to occur through an anti-HPV response that is mediated by the
antiviral apolipoprotein B messenger RNA-editing, enzyme-catalytic, polypeptide-like 3
(APOBEC3) family of DNA cytidine deaminases that inadvertently mutate the host cell
genome, resulting in the accumulation of DNA damage over time (Warren et al., 2017).
This is in agreement with the prolonged latency observed between initial HPV infection
and tumor development (Schiffman et al., 2007). This accidental induction of genomic
instability is characteristic of HR HPV-induced malignancies. In fact, the majority of HPVassociated cancers have numerous chromosomal defects such as aneuploidy—gain or loss
of entire chromosomes—and chromosomal rearrangements (Moody and Laimins, 2010;
White et al., 1994; zur Hausen, 1999). Indeed, this genetic instability is thought to be a
precursor to tumor development, occurring before the integration of viral DNA into the
host cell genome (Duensing et al., 2001).
One of the fundamental events in facilitating progression to an HPV-mediated transformed
phenotype is the integration of HR viral DNA into the host cell genome (Moody and
Laimins, 2010). This integration event is generally thought of as a chance event that can
cause the disruption of viral genes that are essential for maintaining normal viral gene
expression (Doorbar et al., 2012; Thorland et al., 2003). Indeed, the integration breakpoints
often occur in the viral genomic area that encodes for the early E2 gene, which plays a
central role in the negative feedback control of the viral oncogenes E6 and E7. Furthermore,
the E6 and E7 ORFs are consistently found to be preserved in a successful oncogenicpromoting integration event (Parfenov et al., 2014; zur Hausen, 2002) (Figure 1.3).
Consequently, disruption of E2 leads to the deregulated expression of the aforementioned
oncogenes, subsequently furthering aberrant cellular proliferation through the abrogation
of cell cycle checkpoints and fostering the accumulation of DNA damage that accelerates
genetic instability. These viral oncoprotein-mediated effects are exacerbated through
integration, causing cells to have a selective growth advantage that promotes
carcinogenesis (Jeon et al., 1995; McBride and Warburton, 2017). In addition, integration
can also lead to the activation of nearby cellular proto-oncogenes or inactivation of tumor
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Figure 1.3. Integration of the HPV16 viral genome into host cell DNA.
During progression to a malignant phenotype, the viral DNA genome often integrates into
host cell DNA. The integration breakpoints often disrupt the viral genomic areas that
encode for E2, E4, E5, and L2. The non-coding regulatory region LCR and the E6 and E7
oncogenes are consistently found to be preserved in a successful oncogenic-promoting
integration event. Adapted from zur Hausen, 2002.
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suppressor genes, as well as aberrant replication issues that lead to the amplification of host
genes around the site of integration (Parfenov et al., 2014; Peter et al., 2006; Thorland et
al., 2003). Moreover, HPV-associated malignancies become reliant on the expression of
the integrated viral oncogenes for sustained proliferation and survival (Goodwin and
DiMaio, 2000; Goodwin et al., 2000; Jiang and Milner, 2002; Rampias et al., 2009; Sima
et al., 2008). While many HPV+ cancers are found to contain integrated copies of the HPV
genome, this is not a universal phenomenon. Indeed, HPV+ carcinomas, such as anogenital
and oral cancers, can contain either extrachromosomal HPV DNA, integrated viral DNA,
or a combination of both (Kristiansen et al., 1994; McBride and Warburton, 2017).
Importantly, unlike other viruses that integrate into the host cell genome, HPV integration
is not a part of its normal replicative cycle, instead it is an accidental “dead-end” event that
abolishes prospective production of viral progeny (McBride, 2017).

1.5 Human Papillomavirus Cancer and Prevention
The WHO’s IARC group have conclusively defined 12 HR HPV types as potent biological
human carcinogens—HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 (Bouvard et al.,
2009). Of the estimated 14 million cancers that occurred worldwide in 2012, 640,000 were
caused by an HPV infection (Plummer et al., 2016). HR HPVs sexually-transmitted mode
of infection plays a significant role in causing approximately 4.5% of the global cancer
burden, of which more than 80% occur in underdeveloped or developing nations (de Martel
et al., 2012). Indeed, persistent infection by HR HPVs are responsible for virtually all cases
of cervical cancers and other anogenital cancers that include vaginal, vulvar, penile, and
anal carcinomas, as well as a significant fraction of head and neck cancers (Mesri et al.,
2014) (Table 1.1). Interestingly, the fraction of cancers attributed to HR HPV infection is
much higher in women (8.6%) than in men (<1%) because of the unique susceptibility of
the cervix to HPV-induced carcinogenesis (Schiffman et al., 2016). Furthermore, the
fraction of cancers induced by HPV also varies significantly by geographical region and
level of economic development (Roden and Stern, 2018). This variation can be partly
explained by the quality of cervical cancer screening initiatives and access to preventative
vaccination programs (Schiffman et al., 2016).
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Table 1.1. Global estimated fraction of new cancers caused by HPV infection in 2012.
Adapted from Schiffman et al., 2016.
New
Attributable Attributable Attributable by sex (n)
Cancer Site
cases (n) to HPV (n) to HPV (%)
Male
Female
Cervix
528,000
528,000
100
–
528,000
Anus
40,000
35,000
88
17,000
18,000
Vagina and vulva
49,000
20,000
41
–
20,000
Penis
26,000
13,000
51
13,000
–
Oropharynx
96,000
29,000
31
24,000
6,000
Oral cavity and
358,000
9,000
2.4
7,000
2,000
larynx
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The causal link between HR HPV infection of the cervix and development of cancer is one
of the most important scientific discoveries of all time. Indeed, for his seminal work in this
ground-breaking discovery, Dr. Harald zur Hausen was awarded the 2008 Nobel Prize in
Physiology or Medicine. Worldwide, cervical cancer is the 4th most frequently diagnosed
cancer and the 4th leading cause of death in women, with approximately 570,000 new cases
and 311,000 deaths in 2018 (Bray et al., 2018). The highest regional incidence and
mortality rates are observed in economically disadvantaged areas, such as countries in subSaharan Africa. In comparison, there is an estimated 7 to 10 times lower incidence and 18
times lower mortality rates in countries with a high Human Development Index, such as
Canada, USA, Australia, and New Zealand (Bray et al., 2018; Small et al., 2017). In fact,
there is an inverse correlation between the income level of a country and cervical cancer
rates (Schiffman et al., 2016). The main etiological factor is infection with HR HPVs, with
99% of cervical cancers containing HR HPV DNA, of which HPV16 accounts for 50–60%,
HPV18 accounts for approximately 20%, and the remaining fraction being caused by the
other oncogenic types mentioned above (Roden and Stern, 2018). In countries with stateof-the-art staging and treatment, 3-year local control rates for all stages ranged from 74–
95%. In contrast, for many underdeveloped countries the 3- to 5-year survival rate for all
stages combined was less than 50% (Small et al., 2017). This huge disparity in prevalence
and mortality rates between high-income and low- to middle-income nations, illustrates the
need for effective screening and vaccination programs that have the potential to virtually
eliminate the burden of cervical cancer from every country, regardless of wealth (Bosch et
al., 2016).
Over a decade ago the WHO’s IARC group definitively established HR HPVs as being the
biological carcinogens responsible for a subset of head and neck squamous cell carcinomas
(HNSC) (Gillison et al., 2015). Indeed, since the seminal study that causally linked HPV
infection with the development of HNSC was published in 2000 (Gillison et al., 2000), it
is now explicitly recognized that infection with HR HPVs causes a significant and
increasing fraction of these carcinomas. HNSC is an umbrella term that encompasses a
heterogenous group of malignancies in the head and neck region that include the oral
cavity, oropharynx, hypopharynx, and larynx (Figure 1.4) (Leemans et al., 2018). HNSC
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Figure 1.4. Subsites of the head and neck region.
Schematic of the subsites present in the head and neck region. The region of the
hypopharynx is highlighted in red, the region of the oropharynx is highlighted in purple,
and the region of the nasopharynx is highlighted in light blue. Head template was created
with BioRender.
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is the 7th most commonly diagnosed cancer worldwide, with approximately 890,000 new
cases and 453,000 deaths in 2018 (Bray et al., 2018). The classical etiological agents
responsible for the majority of these carcinomas are smoking and excessive alcohol
consumption, with HPV infection accounting for approximately 25% of all cases (Kreimer
et al., 2005; Leemans et al., 2018). Accordingly, HNSC can be divided into either HPV+
or HPV-negative (HPV–) malignancies based on their respective carcinogenic origins. The
majority of HPV+ cases in the head and neck region occur in the oropharynx (30.8%), with
a much smaller percentage occurring in the other subsites such as the larynx (2.4%) and
oral cavity (2.2%) (de Martel et al., 2017). Furthermore, HPV16 is the most common HPV
type associated with these carcinomas, with an estimated 83% of HPV+ HNSC being
caused by the potent biological carcinogen (Leemans et al., 2018).
Alarmingly, the global frequency of HPV+ oropharyngeal cancers has increased to
epidemic proportions, from 7.2% in the period of 1990–1994 to 32.7% in the period of
2010–2012, which is most likely a consequence of changes in sexual behavior (D'Souza et
al., 2007). Interestingly, this increase in HPV+ oropharyngeal cancers has been mostly
observed in high-income countries with a concomitant decline in tobacco smoking
(Chaturvedi et al., 2011). In agreement, our group has identified a similar epidemic increase
in Southwestern Ontario, with the fraction of HPV+ oropharyngeal cancers increasing from
25% in the period of 1993–1999 to 62% in the period of 2006–2011 (Nichols et al., 2013a;
Nichols et al., 2013b). In terms of demographic and clinical characteristics, HPV+ HNSC
occurs more frequently in males, affects a younger demographic, and generally patients
exhibit markedly better clinical outcomes compared to their HPV– counterparts (Kang et
al., 2015; Leemans et al., 2018). Indeed, several studies with various cohort sizes have
shown that patients with HPV+ HNSC had a 2- to 5-year overall survival rate that ranged
from 62–95% (Ang et al., 2010; Fakhry et al., 2008; Lassen et al., 2011; Posner et al., 2011;
Rischin et al., 2010). In comparison—from the same aforementioned studies—patients
with HPV– HNSC only had a 2- to 5-year overall survival rate that ranged from 35–74%.
In essence, HPV+ HNSC is considered a distinct epidemiological, molecular, and clinical
entity that is caused by an epitheliotropic sexually transmitted virus and is increasing at an
epidemic rate, specifically in the Western world (Kang et al., 2015; Leemans et al., 2018).

19

In the early 1990s, scientists observed that expression of recombinant HPV L1 proteins—
the major capsid protein—in a range of in vitro systems, self-assembled into virus-like
particles (VLPs) that were devoid of potentially carcinogenic viral DNA (Deschuyteneer
et al., 2010; Roden and Stern, 2018). These “ghost particles” were immunologically similar
to their native counterparts and were able to elicit high and durable titers of neutralizing
antibodies in experimental animal models challenged with infectious, wildtype virus.
Furthermore, these studies illustrated that the protection elicited by these VLPs were typerestricted, which indicated that in order to achieve broad protection against other types of
HPVs, VLPs generated from several major carcinogenic types were necessary (Breitburd
et al., 1995; Suzich et al., 1995). Indeed, these studies provided the proof-of-concept
necessary for the development of the first prophylactic HPV vaccine. Since the initiation
of those pioneering studies, there have been 3 HPV VLP vaccines licensed: (i) Cervarix
(GlaxoSmithKline), a bivalent vaccine targeting both HR HPV16 and 18, which are the
two types responsible for most HPV+ cancers; (ii) Gardasil (Merck Inc.), a quadrivalent
vaccine that targets HR HPV16 and 18, as well as the two most common LR types that
cause the majority of genital warts, HPV6 and 11; and (iii) Gardasil9 (Merck Inc.), a
nonavalent vaccine targeting HPV6, 11, 16, 18 and the next 5 most carcinogenic types—
HPV31, 33, 45, 52, and 58 (de Martel et al., 2017). All 3 vaccines have been shown to be
remarkably safe and highly effective for protection against new infections and
precancerous lesions (Schiffman et al., 2016). Furthermore, all 3 vaccines underwent large,
phase III randomized controlled trials in young women (15–26 years), where they were
shown to be more than 90% effective against genital warts, persistent infections, and
precancerous lesions (Castellsague et al., 2011; Lehtinen et al., 2012; Munoz et al., 2010;
Schiller et al., 2012). It is estimated that 118 million women aged 10–20 have been targeted
by HPV vaccination programs, but unfortunately only 1% of these are in less developed
countries (Bruni et al., 2016). Moreover, these HPV vaccines have the ability to prevent
70–90% of all HPV+ cancers and have been projected to dramatically reduce the global
burden of cervical cancer after 2050 (de Martel et al., 2017; Jit et al., 2014).
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1.6 The Tumor Microenvironment
Normal tissues maintain homeostasis through a dynamic complex of intercellular
communication that ensures a strict balance of cellular proliferation and death. In order to
achieve and maintain normal physiology a plethora of cells need to work in concert. Each
of these cells have an intracellular program that restricts them in their role, location, and
number. In contrast, cancers have lost these internal restraints through activating mutations
in oncogenes and deactivating mutations in tumor suppressor genes. Nevertheless, these
tumor cells are still able to dynamically communicate with diverse non-malignant cellular
populations and extracellular infrastructure within their local environment (Joyce and
Pollard, 2009). Indeed, as these cancerous cells divide and form tumors, they provoke
dramatic molecular, cellular, and physical changes on the surrounding tissue in which they
grow, giving rise to the tumor microenvironment (TME). The TME is comprised of a
convoluted milieu of stroma that includes blood and lymphatic endothelial cells,
fibroblasts, mesenchymal cells, and pericytes, as well as immune cells and the extracellular
matrix (Turley et al., 2015). The diverse biological elements within the TME interact
intimately with tumor cells, often influencing tumor cell survival, invasiveness, and
metastatic dissemination, as well as therapeutic response (Joyce and Pollard, 2009;
Nakasone et al., 2012; Polyak et al., 2009).
While the cellular composition of the TME varies across different cancer types, some
common features seem to be consistent throughout most solid tumors. For example, most
tumors are highly vascularized by disorganized, tortuous and leaky vessels. Furthermore,
the TME often contains infiltration from various innate and adaptive immune cell
populations that can promote both protumor and antitumor effects (Turley et al., 2015).
The utilization of next-generation “-omics” technologies, such as bulk tissue RNAsequencing (RNA-seq), have deconvoluted the composition of the immune landscape
present within the TME (Ali et al., 2016; Aran et al., 2017; Newman et al., 2015). This has
led to the broad classification of the TME immune landscape into 2 classes (Binnewies et
al., 2018) (Figure 1.5). The 1st class is termed infiltrated–excluded, which is defined as
lacking cytotoxic T lymphocytes (CTLs) and proinflammatory mediators in the tumor core,
instead they contain tumor-associated macrophages along the tumor margins that have been
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hypothesized to prevent CTL infiltration (Beatty et al., 2015; Binnewies et al., 2018). These
tumors have been classified as being immunologically “cold” or alternatively, non-T-cellinflamed (Binnewies et al., 2018; Spranger, 2016) (Figure 1.5A). The 2nd class is termed
infiltrated–inflamed, which is characterized by high infiltration of CTLs that express
elevated levels of immune-dampening T-cell exhaustion markers such as LAG3, PD1,
TIGIT, and TIM3 (Binnewies et al., 2018; Wherry, 2011). Moreover, they also contain Tcell activation markers and proinflammatory mediators. These types of tumors are
considered to be immunologically “hot” or alternatively, T-cell-inflamed (Binnewies et al.,
2018; Spranger, 2016) (Figure 1.5B). These broad classes of immune landscape
classifications of the TME illustrate the possible different dynamic interactions that can
occur between malignant and non-malignant cells that can have a substantial impact
on both tumor status and therapeutic response (Binnewies et al., 2018). Indeed,
characterization of the immune landscape of tumors is helping guide the rational design of
therapies that mobilize the immune system to induce long-term remission in cancers
previously considered to be terminal (Byrne and Fisher, 2017; Costa et al., 2018; George
et al., 2017; Holzel et al., 2013). In Chapters 3, 4, and 5 we utilize large datasets generated
by next-generation “-omics” technologies to explore and profile the immune landscapes
between HPV+ and HPV– TMEs originating from either the cervical or head and neck
regions.

1.7 The Cancer Genome Atlas
Historically, tumor-infiltrating leukocyte (TIL) detection within the TMEs of solid tumors
has been primarily performed using immunohistochemistry or flow cytometry (Llosa et al.,
2015). Both of these techniques have taught us a great deal about the tumor immune profile,
but they require antibodies to specific phenotypic markers of cell type or activation status,
can be challenging to standardize, difficult to implement with small tissue samples, and
expensive to perform for the dozens of markers necessary for a comprehensive view of the
immune landscape of a given TME. More recent alternatives capitalize on the plunging
costs of next-generation “-omics” technologies, including next-generation sequencing for
genomics and transcriptomics, as well as genome-wide methylome analysis using highdensity arrays. Indeed, massive collaborative efforts such as The Cancer Genome Atlas
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Figure 1.5. General classification of the types of immune landscapes present in tumor
microenvironments.
The tumor microenvironment can be divided into 2 broad classes based on their immune
landscape. The tumor core of infiltrated–excluded environments lack cytotoxic T
lymphocyte infiltration (CTL) and proinflammatory mediators but contain tumorassociated macrophages (A). In contrast, the environments of infiltrated–inflamed are
characterized by high infiltration with CTLs that express elevated levels of T-cell
exhaustion markers and proinflammatory mediators (B). Created with BioRender. Adapted
from Binnewies et al., 2018.
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(TCGA) have generated genomic, transcriptomic, and methylomic data for over 11,000
tumor samples from 33 cancer types and subtypes (Liu et al., 2018). Capitalizing on this
freely available data, it is possible to estimate the detailed composition and activation status
of tumor-infiltrating immune cells into the TMEs of solid tumors from bulk tissue RNAseq data using computational approaches based on a set of immune-specific marker genes
or expression signatures that correlate with distinct leukocyte populations (Bindea et al.,
2013; Danaher et al., 2017; Gameiro et al., 2018; Gameiro et al., 2019; Gameiro et al.,
2017; Newman et al., 2015; Rooney et al., 2015; Wolf and Samuels, 2018).
The TCGA was a large-scale collaboration between the National Cancer Institute (NCI)
and the National Human Genome Research Institute (NHGRI) to comprehensively
characterize the molecular events in primary cancers and provide these data to the public
for use by cancer researchers worldwide (Liu et al., 2018). This effort, which ended in
2017, generated publicly available, comprehensive, multidimensional maps of genomic
changes in more than 11,000 tumor samples. The TCGA dataset encompasses 33 types of
human tumors, all processed via a uniform genomic data analysis pipeline that collected,
selected, and analyzed these cancer samples in detail. These analyses included whole
exome and/or whole genome sequencing, mRNA sequencing, microRNA sequencing,
DNA copy number profiling, DNA methylation profiling, and reverse-phase protein array
expression profiling. Although comprehensive clinical annotation was not possible for
every TCGA sample, substantial clinical data are available, allowing comparison of many
clinical variables and, in most cases, reasonably robust outcomes assessment. Furthermore,
the quality and quantity of the TCGA molecular datasets have resulted in studies that have
significantly advanced our understanding of cancer biology (The Cancer Genome Atlas
Research Network, 2015; The Cancer Genome Atlas Research Network, 2017).
The TCGA project provides an abundant source of free data available for mining by cancer
researchers in many different ways. Importantly, many other questions unrelated to tumor
immunity can be similarly addressed, such as correlations between gene expression and
chemotherapy response, alterations induced by oncogenic pathogens, or expression of
markers of differentiation, proliferation, or tumor aggressiveness. Additionally, batch-wise
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analysis of this valuable data set for various correlations can also generate novel hypotheses
that can be pursued experimentally. Literally, the seeds of thousands of important analyses
await discovery in this collection of “big” data.

1.8 Thesis Overview
The work presented in this thesis capitalizes on novel state-of-the-art methods that are
being utilized in both the fields of tumor virology and cancer biology. The utilization of
next-generation “-omics” provides genomic and transcriptomic data derived from bulk
tumors that illuminate the dynamic molecular landscapes of tumors under the influence of
their local surroundings. Indeed, these types of analyses provide us with unique insights
into the complexities of the TME that would have otherwise been missed by classical 2dimensional approaches, such as in vitro cell culture systems. By utilizing “big” data
generated from the TCGA, we ensure a globally-uniform process for patient selection,
sample collection, and data acquisition that minimizes artifactual experimental
heterogeneity that can often occur without standardized protocols. Instead, the
heterogeneity in these datasets are restricted to just the patients and cancers from which
they are derived. Utilizing these computational methods, I explore and profile the
epigenetic and immune landscapes between the tumor microenvironments of HPV+ and
HPV– carcinomas present in actual human malignancies. Furthermore, I hypothesize that
the epigenetic and immune landscapes between these 2 etiologically-distinct tumor
microenvironments are profoundly different, regardless of their anatomical origins.
As previously detailed above, HR HPVs cause cancer at multiple distinct anatomical
locations. Regardless of the tissue of origin, most HPV+ cancers show highly upregulated
expression of the p16 product of the CDKN2A gene (Klaes et al., 2001; Sano et al., 1998).
Paradoxically, HPV+ tumor cells require continuous expression of this tumor suppressor
for survival (McLaughlin-Drubin et al., 2013). Thus, restoration of normal p16 regulation
has potential therapeutic value against HPV-induced cancers. Normally, p16 transcription
is tightly controlled at the epigenetic level via polycomb repressive complex-mediated trimethylation of H3K27 (Popov and Gil, 2010). Although a mechanism by which HPV
induces p16 has been previously proposed based on in vitro tissue culture models
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013), it has not been
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extensively validated in actual human tumors. Indeed, these cell culture-based experiments
have allowed for a detailed elucidation of the biological factors involved in HPV-mediated
upregulation of p16; however, an analysis of these HPV-specific epigenetic effects has not
been done in any large cohorts of HPV-induced cancers under the influence of their
respective native heterogenous environments. Therefore, my objective was to determine if
the epigenetic changes involved in p16 upregulation observed in artificial culture systems
were recapitulated in actual primary HPV+ tumors from different anatomical locations.
In Chapter 2, I used genomic and transcriptomic data from over 800 human cervical and
head and neck tumors from The Cancer Genome Atlas to test this model. I sought out to
determine the impact of HPV status on expression from the CDKN2A locus, the adjacent
CDKN2B locus, and transcript levels of key epigenetic regulators of these loci. As
expected, HPV+ tumors from both anatomical sites exhibited high levels of p16.
Furthermore, HPV+ tumors expressed higher levels of KDM6A, which demethylates
H3K27me3. In addition, analysis of CpG methylation also detected two sites in the
CDKN2A locus with consistently altered methylation in HPV+ tumors compared to their
HPV– counterparts. Taken together, this data validates previous tissue culture studies and
identifies remarkable similarities between the effects of HPV on gene expression and DNA
methylation in both cervical and head and neck tumors from large human cohorts.
Moreover, these results support a model whereby HPV-mediated deregulation of CDKN2A
transcription requires KDM6A, a potentially druggable target.
I next wanted to use the same computational methodology to validate another tissue culture
model that proposed an HPV-mediated transcriptional downregulation of the class I major
histocompatibility complex (MHC I) antigen presentation system (Georgopoulos et al.,
2000; Heller et al., 2011; Li et al., 2010). Indeed, this proposed downregulation could
contribute to viral persistence and allow the infected or transformed cells to evade the
adaptive immune response. In Chapter 3, I utilized the same genomic and transcriptomic
data from Chapter 2, to determine the impact of HPV status on the mRNA expression of
all six MHC-I heavy chain genes (HLA-A, -B, -C, -E, -F, and -G), and the β2 microglobulin
light chain in actual HPV-induced carcinomas. Unexpectedly, these genes were all
expressed at high levels in HPV+ cancers compared with normal control tissues. Indeed,
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many of these genes were expressed at significantly enhanced levels in HPV+ tumors.
Similarly, the transcript levels of several other components of the MHC-I peptide-loading
complex were also high in HPV+ cancers. The coordinated expression of high mRNA
levels of the MHC-I antigen presentation apparatus could be a consequence of the higher
intratumoral levels of interferon-gamma (IFNγ) observed in HPV+ carcinomas, which
correlated with signatures of increased infiltration by T- and NK-cells. These data, which
were obtained from both cervical and head and neck carcinomas in large human cohorts,
indicate that HPV oncoproteins do not efficiently suppress the transcription of the MHC-I
antigen presentation system in actual human tumors as proposed by in vitro cell culture
models.
Given the observation of higher levels of intratumoral IFNγ and increased infiltration by
T- and NK-cells into the HPV+ TME, a mechanistic and detailed characterization of
immune cell presence and status between the 2 anatomically-similar, etiologically-different
HNSC types were warranted. In Chapter 4, I utilized an immunogenomic approach on
transcriptomic and clinical data to compare the immune landscape between the TMEs of
HPV+ and HPV– HNSC and their influence on clinical outcomes. I found that HPV+
HNSC exhibited a strong Th1 response characterized by increased infiltration with multiple
types of immune cells—CD4+, CD8+, and regulatory T-cells—and expression of their
effector molecules. HPV+ HNSC also expressed higher levels of CD39 and multiple T-cell
exhaustion markers including LAG3, PD1, TIGIT, and TIM3 compared to their HPV–
counterparts. Importantly, patients with higher expression of these exhaustion markers—
indicative of a T-cell-inflamed tumor—correlated with markedly improved survival in
HPV+, but not HPV–, HNSC. Thus, profound differences exist between the immune
landscape of HPV+ and HPV– HNSC. In addition, these results suggest that immune
checkpoint inhibitor therapy is a promising treatment strategy for HPV+ HNSC, and that
expression of immune checkpoint molecules could also serve as predictive biomarkers of
patient outcome.
In the final data chapter of this thesis, I complete my profiling of the immune landscape
between the TMEs of HPV+ and HPV– HNSC by determining the impact of HPV status
on the expression of class II major histocompatibility complex (MHC-II) genes and related
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genes involved in their regulation, antigen presentation, and T-cell co-stimulation.
Expression of MHC-II is typically restricted to antigen presenting cells (APCs) (van den
Elsen et al., 2004). However, during inflammation, epithelial cells can be induced to
express MHC-II and function as accessory APCs (Boss and Jensen, 2003; Collins et al.,
1984; Kim et al., 2009). As done previously, I utilized RNA-seq data from over 500 HNSC
patients from the TCGA and found that expression of virtually all MHC-II genes was
significantly upregulated in HPV+ carcinomas compared to HPV– or normal control
tissues. Similarly, genes that encode products involved in MHC-II-specific antigen
presentation were also significantly upregulated in the HPV+ cohort. In addition, the
expression of CIITA and RFX5—regulators of MHC-II transcription—were significantly
upregulated in HPV+ tumors. This coordinated upregulation of MHC-II genes was found
to be correlated with higher intratumoral levels of IFNγ in HPV+ carcinomas. Furthermore,
genes that encode for various co-stimulatory molecules involved in T-cell activation and
survival were also significantly upregulated in HPV+ tumors. Collectively, these results
suggest a previously unappreciated role for epithelial cells in antigen presentation that
functionally contributes to the highly immunogenic tumor microenvironment observed in
HPV+ HNSC.
Taken together, these analyses have provided insight into the validity of certain models
proposed from artificial in vitro culture systems, as well as illustrating the profound
differences

in

the

epigenetic

and

immune

landscapes

between

the

tumor

microenvironments of HPV+ and HPV– carcinomas. These studies also identify a
potentially useful therapeutic target in KDM6A and advocate for the use of promising
immunotherapy strategies in the treatment of HPV+ HNSC. Furthermore, I also show that
expression of immune checkpoint molecules could serve as predictive biomarkers of
clinical outcomes that could allow for treatment deintensification. Moreover, the novel
hypotheses that have been generated by this work will feedback into the laboratory and
allow for further exploration in an experimental setting where relevant models can be
generated and biologically manipulated. Lastly, I hope that the accumulated knowledge
gained from these studies will advance the field of tumor virology and have a positive
impact on patients with these devastating HPV-induced malignancies.
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Chapter 2

2

Human Papillomavirus Dysregulates the Cellular
Apparatus Controlling the Methylation Status of H3K27
in Different Human Cancers to Consistently Alter Gene
Expression Regardless of Tissue of Origin

2.1 Introduction
Human papillomaviruses (HPV) that infect mucosal tissues are classified as low- or highrisk based on the frequency with which they are associated with cancer. Although both
types dysregulate normal cell growth, infection by high-risk HPV is a causative agent for
cancers at multiple distinct anatomical subsites (zur Hausen, 1996; zur Hausen, 2002).
HPV was first recognized as the cause of virtually all cervical carcinomas and was then
subsequently found to contribute to other anogenital cancers as well (Alemany et al., 2016;
Crosbie et al., 2013; Guimera et al., 2017; zur Hausen, 2002). More recently, HPV infection
was recognized as the agent responsible for an epidemic of oropharyngeal cancers (Gillison
et al., 2000; Syrjanen, 2005). HPV has also been suggested to cause a subset of lung,
prostate, bladder, and breast cancers (Lawson et al., 2015; The Cancer Genome Atlas
Research Network, 2014; Singh et al., 2015; Zhai et al., 2015). Taken together, HPV
infection is thought to be responsible for at least 5% of human cancers worldwide (Forman
et al., 2012).
HPV encodes two main oncogenes, E6 and E7 (Doorbar et al., 2012). Both are
constitutively expressed in HPV-positive (HPV+) tumors, and suppression of expression
of either of these two viral proteins causes HPV-dependent tumor cells to senesce and die
(Deng et al., 2013; Goodwin and DiMaio, 2000; Goodwin et al., 2000; Jiang and Milner,
2002; Rampias et al., 2009; Sima et al., 2008; zur Hausen, 1996). Both E6 and E7 perform
multiple functions in an infected and/or cancerous cell. These two viral oncoproteins
function by interacting with multiple key cellular regulatory proteins to dysregulate gene
expression and growth (Doorbar et al., 2012). For example, p53 is bound and degraded by
E6, while the retinoblastoma protein (Rb) and family members are important targets of E7
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(Dyson et al., 1992; Kessis et al., 1993). Rb controls exit from the G1 phase of the cell
cycle, and the interaction and subsequent degradation of Rb by E7 induces inappropriate
cell cycle progression in HPV infected cells (Boyer et al., 1996; Brehm et al., 1998). In
high-risk HPV infections, viral oncoproteins function to uncouple cell growth and
differentiation and contribute to the formation of epithelial dysplasia, which may progress
to carcinoma if the infection is not resolved (Doorbar et al., 2012).
The HPV E7 oncoproteins alter the regulation of many host cellular genes and much effort
has been devoted to understanding the mechanisms by which this occurs (Munger et al.,
2001). A subset of the effects of E7 on the cellular transcriptome are mediated by epigenetic
changes (Durzynska et al., 2017). Specifically, E7 expression has been reported to reduce
the global levels of tri-methylated lysine 27 on histone 3 (H3K27me3), a mark of
transcriptionally silenced chromatin (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin
et al., 2008; Schwartz and Pirrotta, 2007). Paradoxically, several cell culture studies have
shown that HPV induces a significant upregulation in the expression level of the enhancer
of zeste homolog 2 (EZH2) component of the polycomb repressive complex 2 (PRC2)
(Holland et al., 2008; Hyland et al., 2011; McLaughlin-Drubin et al., 2011)—which is the
methyltransferase responsible for mono-, di-, and tri-methylation of H3K27 (Popov and
Gil, 2010; Schwartz and Pirrotta, 2007). Both studies also observed an HPV-dependent
increase in lysine demethylase 6A (KDM6A) or lysine demethylase 6B (KDM6B)—the
demethylases that convert H3K27me3 to the di-methylated or mono-methylated forms
(Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Thus, HPV increases expression of
the enzymes responsible for creating and removing H3K27me3, complicating our
understanding of how the global decrease in H3K27me3 is achieved in an HPV infection.
Mechanistic studies of these HPV-dependent changes on epigenetic regulators of gene
expression have focused on altered p16 expression, which is present at high levels in nearly
all HPV-induced tumors (Klaes et al., 2001; Sano et al., 1998). Indeed, p16 was commonly
used as a surrogate marker of HPV status during pathological assessment of tumors, but
this method to determine HPV status has largely been superseded by the implementation
of molecularly-based diagnostics (Burd, 2016; Hoffmann et al., 2010; Klaes et al., 2001).
The p16 and p14 products of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene
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locus normally function as negative regulators of the cell cycle. The p16 tumor suppressor
induces cell cycle arrest and senescence by inhibiting E2F-mediated transcription, whereas
p14 induces cell cycle arrest and apoptosis by facilitating p53 function (Zhang et al., 1998).
Neither of these products inhibit cell cycle progression in HPV-induced cancers, as the p53
and Rb pathways have been abrogated by E6 and E7, respectively (Dyson et al., 1992;
Kessis et al., 1993). However, transcription from the CDKN2A locus is tightly regulated
by epigenetic changes, with PRC2 serving a key role in repressing expression by catalyzing
tri-methylation of H3K27 across this locus. Subsequently, the polycomb repressive
complex 1 (PRC1) is recruited to maintain a transcriptionally repressive chromatin
environment that is typically reflected by a local increase in DNA methylation (Popov and
Gil, 2010). Thus, this well-characterized locus serves as a good model of epigenetic
dysregulation induced by HPV infection (Kanao et al., 2004; Schlecht et al., 2015).
In a detailed series of tissue culture-based experiments, evidence was obtained to suggest
that the HPV-mediated reduction in H3K27me3 and subsequent transcriptional activation
of p16 required E7 to induce expression of the H3K27-specific demethylases KDM6A and
KDM6B (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013). Knockdown
of either KDM6A or KDM6B in HPV+ cervical carcinoma cell lines not only reduced p16
expression, but also induced cell death (McLaughlin-Drubin et al., 2011; McLaughlinDrubin et al., 2013). Subsequent experiments showed that E7 expression in cell lines
induced an acute dependence on KDM6B for growth. E7 expressing cells were similarly
dependent on p16 expression, as treatment with a KDM6 selective small molecule inhibitor
was cytotoxic in multiple cervical carcinoma cell lines (McLaughlin-Drubin et al., 2011;
McLaughlin-Drubin et al., 2013). Thus, HPV E7 expressing cells are uniquely vulnerable
to a targeted agent affecting an epigenetic regulator of cellular gene expression.
While most of this work was done in tissue culture models, similar changes in expression
of H3K27me3 regulators were reported in individual cervical carcinomas (Holland et al.,
2008; Hyland et al., 2011; McLaughlin-Drubin et al., 2011). An analysis of these effects
has not been done in any HPV+ oral cavity tumors or on a large scale for any HPV-induced
tumor site. As such, it remains an open question as to whether these changes in epigenetic
regulators are specific for distinct subsites of HPV-induced tumors, and how frequently
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they occur in clinical samples. This information is clearly relevant, considering that
cancerous cells expressing E7 appear preferentially sensitive to KDM6 inhibition
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013), which could represent
a new therapeutic approach for their treatment.
In this study, we used data from over 800 human cervical (The Cancer Genome Atlas
Research Network, 2017) and head and neck tumors (The Cancer Genome Atlas Research
Network, 2015) from The Cancer Genome Atlas (TCGA) to determine how high-risk HPV
oncogene expression alters expression of H3K27me3 regulators in human tumors. We
assessed the impact of HPV status on the transcript levels of key regulators of H3K27
methylation, including EZH2, KDM6A, and KDM6B. We also examined the effect of HPV
status on gene expression and DNA methylation status across the CDKN2A genomic region
in these two distinct patient cohorts. We found that HPV+ tumors from both anatomical
sites exhibited high levels of p16 and p14. Furthermore, HPV+ tumors also expressed
higher levels of EZH2 and KDM6A. Analysis of CpG methylation also detected two sites
in the CDKN2A locus with consistently altered methylation in HPV+ tumors versus HPVnegative (HPV–) samples. Taken together, this data validates conclusions drawn from
tissue culture studies and identifies remarkable similarities between the effects of HPV on
gene expression and methylation in both cervical and oral tumors in large human cohorts.
These results also provide compelling evidence from human tumors that support the current
model of HPV dysregulation of H3K27 methylation and cognate gene expression via the
upregulation of KDM6A.

2.2 Materials and Methods
2.2.1

RNA expression comparisons and statistical analysis

Level 3 RNA-Seq by Expectation Maximization (RSEM) normalized Illumina HiSeq RNA
expression data for the TCGA head and neck cancer (HNSC) and cervical carcinoma
(CESC) cohorts was downloaded from the Broad Genome Data Analysis Centers Firehose
server (https://gdac.broadinstitute.org/). The use of mRNA expression data that has
undergone RSEM normalization via a uniform pipeline allows comparison of samples
within and between TCGA cohorts (Li and Dewey, 2011). Effectively, these files represent
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tables listing a quantitative RNA-seq read value for each gene or isoform for each TCGA
sample. Although rare HPV+ samples have been identified in the TCGA bladder urothelial
carcinoma (BLCA) and colon adenocarcinoma (COAD) cohorts, they were not present in
sufficient numbers for any useful comparisons. For all genes except p16 and p14, the gene
level Firehose dataset was used. For p16 and p14, the gene isoform level Firehose dataset
was used (uc003zpk.2 and uc003zpl.2, respectively) to adequately discriminate between
these two different products of the CDKN2A gene. Normalized expression data was
extracted into Microsoft Excel and the HPV status was manually curated based on
published datasets (Banister et al., 2017; Bratman et al., 2016; The Cancer Genome Atlas
Research Network, 2015; The Cancer Genome Atlas Research Network, 2017). For each
gene analyzed, primary patient samples with known HPV status were grouped as HPV+,
HPV–, or normal control tissue. Patient samples with unknown HPV status were omitted
from our calculations, as were samples obtained from secondary metastatic lesions. This
resulted in 73 HPV+, 442 HPV–, and 43 normal control samples with data available for
the

HNSC

gene

expression

analysis

and

278

HPV+,

19

HPV–,

and 3 normal control samples available for the CESC gene expression analysis.
Boxplot

comparison

of

gene

expression

was

performed

using

BoxPlotR

(http://shiny.chemgrid.org/boxplotr/) and assembled into final form using CorelDRAW.
For the box plots, center lines show the medians, box limits indicate the 25th and 75th
percentiles as determined by R software and whiskers extend 1.5 times the interquartile
range from the 25th and 75th percentiles. Statistical significance was calculated using
Graphpad Prism v6.01. p-values were assigned using a one-tailed non-parametric MannWhitney U test. Post-hoc power calculations were performed with G*Power software
version 3.1.9.2 (Faul et al., 2007), using post-hoc t-test family calculations, with effect size
selected as 0.8 and α = 0.05. All comparisons achieved a power value > 0.8, or
demonstrated significant differences, unless otherwise noted in the text.

2.2.2

DNA methylation comparisons and statistical analysis

Level 3 Infinium Human Methylation450 BeadChip array data for the TCGA HNSC and
CESC cohorts was downloaded from the Broad Genome Data Analysis Centers Firehose
server (https://gdac.broadinstitute.org/). There were 14 methylation probes identified to be
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present in the CDKN2A and adjacent CDKN2B region: cg00718440, cg02400248,
cg03079681, cg04026675, cg07562918, cg08390209, cg10848754, cg12840719,
cg13601799, cg13926295, cg14069088, cg14430974, cg19133618, cg19481686.
Methylation data for all patient samples for these probes were extracted from the Firehose
files and assembled into a table using Microsoft Excel. HPV status was manually curated
based on published datasets (Banister et al., 2017; Bratman et al., 2016; The Cancer
Genome Atlas Research Network, 2015; The Cancer Genome Atlas Research Network,
2017). For each gene analyzed, primary patient samples with known HPV status were
grouped as HPV+, HPV–, or normal control tissue. Patient samples with unknown HPV
status were omitted from our calculations, as were samples obtained from secondary
metastatic lesions. This resulted in 73 HPV+ tumors, 442 HPV– tumors, and 43 normal
control samples with data available for the HNSC methylation analysis and 278, 19, and 3
samples, respectively, available for the CESC methylation analysis. The average
methylation Beta-value and standard deviation was calculated for each probe for each
sample type in each cohort. Data was plotted using Excel and assembled into final form
using CorelDRAW. For statistical analysis, Beta-values were converted to M-values using
the following equation to improve homoscedasticity of the data:
𝑀" = log ' (

𝐵𝑒𝑡𝑎"
/
1 − 𝐵𝑒𝑡𝑎"

where Mi and Betai are the M-value and Beta-value of the ith interrogated CpG site (Du et
al., 2010). The data was analyzed using Graphpad Prism v6.01. The p-values were assigned
using non-parametric Kruskal-Wallis test and Dunn’s multiple comparisons test.

2.3 Results
2.3.1

Impact of HPV status on CDKN2A and CDKN2B expression
in human tumors

The CDKN2A and adjacent cyclin-dependent kinase inhibitor 2B (CDKN2B) loci encode
three distinct tumor suppressors: p16 INK4A, p14 ARF, and p15 INK4B. This gene cluster
also encodes a long non-coding RNA transcribed in the antisense direction that is referred
to as CDKN2B-AS or antisense non-coding RNA in the INK4 locus (ANRIL) (Figure 2.1).
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Figure 2.1. Organization of the CDKN2A and CDKN2B loci.
The cyclin-dependent kinase inhibitor 2A (CDKN2A) locus encodes two functionally
unrelated protein products named p16 INK4A and p14 ARF. The adjacent CDKN2B locus
encodes p15 INK4B. This gene cluster also encodes a long non-coding RNA transcribed
in the antisense direction named CDKN2B-AS or antisense non-coding RNA in the INK4
locus (ANRIL). The position of transcripts (black lines), exons (black vertical bars), coding
regions (thick black vertical bars), and orientation (direction of arrowheads) of the major
transcripts in this region of chromosome 9 are indicated.
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Figure 2.2. HPV perturbation of expression of the CDKN2A and CDKN2B genes in
human head & neck and cervical carcinomas.
Normalized RNA-Seq data extracted from the TCGA database for the HNSC (A) and
CESC (B) cohorts for HPV+, HPV–, and normal control tissues. Numbers in brackets refer
to the number of samples included in each analysis. * p ≤ 0.05, *** p ≤ 0.001, ns – not
significant.

50

Expression of all three coding genes from this cluster is silenced by PRCs during normal
cell growth (Popov and Gil, 2010). While HPV-induced cancers commonly express high
levels of the p16 product of the CDKN2A locus (Klaes et al., 2001; Sano et al., 1998), the
expression levels of p14, p15, and the non-coding CDKN2B-AS RNA have not been studied
as extensively. We analyzed the TCGA Illumina HiSeq RNA expression data from the
HNSC and CESC cohorts for expression of all four genes (Figure 2.2). As expected, HPV+
samples from both the HNSC and CESC cohorts had greatly increased levels of p16 mRNA
expression compared to HPV– tumors and normal control tissue. Like p16, a similar
upregulation of p14, p15, and CDKN2B-AS was observed in HPV+ cancers with respect to
HPV– cancers (Figure 2.2). These results indicate that PRC-mediated repression is
abrogated across the entire CDKN2A and CDKN2B regions of the INK4 locus by HPV
infection. The only major difference appears to be the high level of p15 expression present
in the normal control samples for the HNSC cohort, which likely reflects some tissue
specific, HPV-independent regulation.

2.3.2

Impact of HPV status on expression of PRC2 components
and BMI1 in human tumors

The H3K27 methyltransferase activity of PRC2 relies on the catalytic subunit EZH2, as
well as the embryonic ectoderm development (EED) and suppressor of zeste 12 (SUZ12)
components. Multiple studies have reported EZH2 upregulation in HPV+ cancer cell lines,
with similarly higher expression reported in small studies of HPV+ cervical carcinomas
(Holland et al., 2008; Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Much less is
known about the effect of HPV status on the other PRC2 core components. Analysis of
TCGA data reveals significantly elevated expression of all three PRC2 core components
compared to normal control tissue in both HNSC and CESC (Figure 2.3). All but SUZ12
in the CESC cohort are similarly elevated as compared to HPV– cancers. Thus, the core
components of the PRC2 methyltransferase are all consistently transcribed at high levels
in HPV+ human tumors. This is in stark contrast to the reported decreases in global
H3K27me3 (Hyland et al., 2011; McLaughlin-Drubin et al., 2011) and the upregulation of
the CDKN2A and CDKN2B loci we observe in HPV+ tumors.
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Figure 2.3. HPV perturbation of expression of polycomb components that may
regulate CDKN2A transcription in human head & neck and cervical carcinomas.
Normalized RNA-Seq data extracted from the TCGA database for the HNSC (A) and
CESC (B) cohorts for HPV+, HPV–, and normal control tissues. Numbers in brackets refer
to the number of samples included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001,
ns – not significant, red bracket indicates a comparison that did not achieve significance
with a power value < 0.8.
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Tri-methylation of H3K27 by PRC2 is proposed to recruit PRC1 via its B lymphoma MoMLV insertion region 1 (BMI1) component to maintain a transcriptionally repressive state
(Schwartz and Pirrotta, 2007). A previous study reported that BMI1 expression was
reduced by transduction of HPV E6 and E7 into human foreskin keratinocytes (HFKs)
(Hyland et al., 2011). A reduction in BMI1 is consistent with a reduction of repression of
the CDKN2A locus by PRC1. BMI1 expression in HPV+ CESC tumors was lower than in
HPV– or normal control tissues (Figure 2.3). However, its expression was generally the
same or higher in HPV+ HNSC tumors compared to the HPV– or normal control tissues
(Figure 2.3). The lack of a consistent reduction in BMI1 expression in HPV+ tumors
suggest that it is not a key factor in HPV activation of CDKN2A and CDKN2B
transcription. This is supported by a smaller independent study that found no correlation
between p16 and BMI1 expression in head and neck cancers (Lundberg et al., 2016).

2.3.3

Impact of HPV status on expression of KDM6A and KDM6B
in human tumors

The KDM6A and KDM6B demethylases convert H3K27me3 to the di-methylated or
mono-methylated forms (Swigut and Wysocka, 2007). Multiple studies have reported that
upregulation of one or both of the KDM6 demethylases occurs in cell lines when HPV E7
is expressed. Furthermore, knockdown of KDM6B or treatment with a small molecule
KDM6 inhibitor reduces p16 expression in these models, suggesting a direct causal
relationship between KDM6 activity and p16 transcription (McLaughlin-Drubin et al.,
2011; McLaughlin-Drubin et al., 2013). Our analysis of the expression of KDM6A reveals
that it is significantly upregulated in HPV+ tumors compared to HPV– tumors in both the
HNSC and CESC cohorts (Figure 2.4). In contrast, KDM6B expression is significantly
reduced in HPV+ cancers compared to HPV– tumors in both the HNSC and CESC tumor
types (Figure 2.4). Significant changes in KDM6A and KDM6B expression were similarly
noted between HPV+ and normal control tissues for the HNSC samples. However, no
significant differences were observed for the CESC samples, which could reflect the
limited number of normal control samples in this cohort. Overall, the increased expression
of KDM6A suggests that it is more likely to play a role in dysregulation of H3K27me3mediated regulation of transcription in HPV+ cancers.
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Figure 2.4. HPV perturbation of expression of the lysine demethylases KDM6A and
KDM6B in human head & neck and cervical carcinomas.
Normalized RNA-Seq data extracted from the TCGA database for the HNSC (A) and
CESC (B) cohorts for HPV+, HPV–, and normal control tissues. Numbers in brackets refer
to the number of samples included in each analysis. * p ≤ 0.05, *** p ≤ 0.001, ns – not
significant, red brackets indicate a comparison that did not achieve significance with a
power value < 0.8.
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2.3.4

Assessment of the DNA methylation status of the CDKN2A
and CDKN2B loci in human tumors

HPV-mediated changes in epigenetic regulation of transcription of the CDKN2A and
CDKN2B genes would be expected to be reflected in methylation status of CpG
dinucleotide sequences in or adjacent to these loci. Indeed, a previous report identified
altered methylation at 4 CpG loci in this genomic region that correlated with HPV status
(Hyland et al., 2011; Schlecht et al., 2015). We analyzed the Infinium
HumanMethylation450 BeadChip array data for the TCGA HNSC and CESC cohorts for
consistent alterations in DNA methylation in this region of the genome (Figure 2.5). A
region of DNA upstream of the p14 transcript (probe cg14069088; see Figure 2.5A for
location) was consistently identified to be hypomethylated in HPV+ tumors in both the
HNSC and CESC cohorts compared to HPV– tumors or normal control tissue. No
differences in methylation were detected in the remainder of the probes across the
transcribed regions of these loci in HPV+ versus HPV– or normal control samples. In
contrast, a hypermethylated region of DNA was identified within the 3’-end of the
CDKN2A locus (probe cg12840719; see Figure 2.5A for location) in HPV+ tumors
regardless of anatomical location. Thus, altered methylation is detected at the CDKN2A
locus in HPV+ tumors, which is consistent with an epigenetic mechanism for
transcriptional activation of this locus by HPV infection.

2.4 Discussion
HPV infection and subsequent expression of the E6 and E7 oncogenes leads to a largescale reprogramming of gene expression. This is likely further exacerbated in high-risk
HPV+ tumor cells, which typically express higher levels of these powerful viral regulatory
proteins compared to levels found in the context of normal infections. Consequently, highrisk HPV transformed cells exhibit many changes in gene expression that contribute to the
acquisition and maintenance of cancerous phenotypes unique to viral transformation
(Doorbar et al., 2012). In particular, dysregulation of H3K27me3 homeostasis by the E7
proteins from high-risk HPVs contributes to increased expression of loci normally
repressed by PRCs, including the CDKN2A locus encoding p16 INK4A (McLaughlin
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Figure 2.5. HPV perturbation of DNA methylation at the CDKN2A and CDKN2B loci
in human head & neck and cervical carcinomas.
HPV+ cancers exhibit markedly altered methylation from HPV– tumors or normal control
tissues at two regions flanking the CDKN2A locus. (A) Location of the transcripts (black
lines), CpG islands, and methylation probes used in this study. Normalized methylation
data was extracted from the TCGA database for the HNSC (B) and CESC (C) cohorts. The
mean methylation levels for HPV+, HPV–, and normal control tissues for all probes located
in the vicinity of the CDKN2A and CDKN2B loci are shown. ** p ≤ 0.01, *** p ≤ 0.001,
**** p ≤ 0.0001.
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Drubin et al., 2011; McLaughlin-Drubin et al., 2008; McLaughlin-Drubin et al., 2013).
Interestingly, while strong p16 expression is a near universal hallmark of high-risk HPV+
carcinomas of the cervix or oral cavity (Hoffmann et al., 2010; Klaes et al., 2001; Sano et
al., 1998), p16 is not expressed in high-risk HPV+ low-grade lesions and variably
expressed in higher grade precancerous lesions (Mills et al., 2015; Woo et al., 2013) or
lesions caused by low-risk HPV types (Geissler et al., 2013; Mooren et al., 2014; Sano et
al., 1998). Thus, expression of high-risk HPV oncogenes alone is not sufficient to activate
high levels of p16 expression, and additional adaptations acquired during tumor
development likely contribute to this process.
While cell culture models have allowed detailed analyses of factors involved in virusmediated activation of p16 gene expression from the CDKN2A locus, far less is known
about how similar these effects are to actual HPV+ tumors. In this study, our goal was to
determine if the changes in H3K27me3 regulators and their target genes observed in cell
culture models of HPV transformation are recapitulated in primary HPV+ tumors from
different anatomical locations.
Using data from over 800 primary human tumors, we provide evidence that HPV+ tumors
from both the head and neck and cervical sites exhibit remarkably similar alterations in
expression of the genes encoded by the CDKN2A locus (Figure 2.2). It is well established
that HPV induces expression of p16 INK4A in both oropharyngeal and cervical carcinomas
(Hoffmann et al., 2010; Klaes et al., 2001). While overexpression of the p14 ARF gene
from this locus has been observed in these cancers (Kanao et al., 2004; Schlecht et al.,
2015), this has not been extensively documented. Our observation that p14 expression, like
that of p16, is similarly elevated in comparison to HPV– tumors or normal control tissue
clearly demonstrates that HPV activates expression of the entire CDKN2A locus.
Furthermore, this activation extends into the adjacent CDKN2B locus, which is also
regulated by PRCs (Popov and Gil, 2010). Indeed, both the long non-coding RNA,
CDKN2B-AS ANRIL, and p15 INK4B are induced in HPV+ cervical carcinomas with
respect to HPV– tumors and normal control tissue; similarly, high levels of both CDKN2B
encoded genes are expressed in HPV+ head and neck cancers (Figure 2.2). Existing

58

literature from independent cohorts confirms that p15 is expressed at lower levels in normal
cervical tissue compared to cervical carcinomas (Feng et al., 2007; Zhang et al., 2014),
supporting our conclusions from the TCGA CESC data. In addition, an independent
analysis of a subset of the TCGA HNSC cohort used in our analysis observed similarly
high, albeit variable, levels of p15 in HPV+ and normal control samples (Salyakina and
Tsinoremas, 2016). Taken together, the similarities between the normalized expression of
all four gene products from the CDKN2A and CDKN2B gene loci in HPV+ tumors from
both the cervix and oropharynx is extraordinary. These results clearly demonstrate the
dominant nature of viral reprogramming of cellular gene expression in these cancers with
respect to normal control tissue and HPV-negative cancers.
A simple mechanism to explain the observed increase of CDKN2A and CDKN2B
expression in HPV+ cells would be a decreased expression of the proteins necessary for
the H3K27 methyltransferase activity of the PRC2. In tissue culture models, expression of
the EZH2 methyltransferase is increased by the presence of HPV oncogenes, and no
significant change is observed for the EED and SUZ12 core proteins also required for
catalytic activity (Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Similarly, in
HPV+ tumors from both anatomical sites, we find that these genes are expressed at levels
equivalent or even higher than normal control tissue and HPV– samples (Figure 2.3).
Furthermore, an analysis of ten biopsies of normal cervical tissue, HPV+ high-grade
precancerous lesions, and HPV+ cervical carcinomas detected similarly elevated levels of
EZH2 protein in the HPV expressing samples (Holland et al., 2008). Thus, there is a
remarkably close agreement between the finding reported from tissue culture models and
what is observed in human tumors, confirming that a reduction in the overall level of PRC2
expression is not likely responsible for CDKN2A and CDKN2B activation.
Silencing of euchromatin by PRC2 is stabilized and maintained by PRC1. Cell culture
experiments suggest that expression of BMI1, a core component of PRC1, is reduced in
E6/E7 transduced HFKs (Hyland et al., 2011) and BMI1 expression is inversely correlated
with HPV viral load in cervical carcinomas (Kim et al., 2016). Our analysis of primary
human cervical carcinomas indicates that BMI1 expression is significantly reduced in
HPV+ tumors with respect to HPV– tumors. However, this is not the case in head and neck
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tumors, where it is modestly upregulated (Figure 2.3). For this reason, it seems unlikely
that the induction of CDKN2A and CDKN2B expression observed in both these cancers is
related to a reduction in expression of the BMI1 component of PRC1. This is further
supported by a study reporting that BMI1 protein expression was lost in less than half of
the 40 p16-positive oropharyngeal tumors tested (Lundberg et al., 2016). Thus, a loss of
BMI1 expression appears unrelated to increased p16 transcription, at least in the context of
oropharyngeal tumors.
An alternative method of activating the CDKN2A and CDKN2B loci could be via the
removal of the repressive H3K27me3 modification catalyzed by the PRC2 complex. This
histone modification is erased by the KDM6A and KDM6B demethylases. Previous work
in tissue culture models established that transduction of HPV E7 into HFKs induced
KDM6A and/or KDM6B mRNA and protein levels (Hyland et al., 2011; McLaughlinDrubin et al., 2011). Mechanistically, induction of KDM6B was independent of the
interaction of E7 with Rb. More importantly, siRNA knockdown of KDM6B antagonized
p16 induction by E7, suggesting that upregulation of these demethylases is the mechanism
by which HPV reduces global H3K27me3 levels and activates p16 expression
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013). Our analysis of
primary human tumors indicates that KDM6A expression is significantly increased in
HPV+ head and neck and cervical carcinoma cells with respect to HPV– tumors and likely
normal control tissue. However, this is not the case for KDM6B, which is significantly
reduced (Figure 2.4). These data fully support the model proposed from tissue culture
experiments, in which enhanced expression of KDM6A, but not KDM6B, by HPV is
related to the dysregulation of H3K27me3 homeostasis and subsequent activation of
CDKN2A and likely CDKN2B transcription in both these cancer types. One small study
reported that expression of both KDM6A and KDM6B is substantially reduced in HPV+
mildly dysplastic lesions; however, stepwise increases were observed for both
demethylases in precancerous lesions and cervical carcinoma, such that the carcinomas
express both demethylases at levels similar to normal control tissues (Iancu et al., 2015).
This pattern of re-expression correlates well with the acquisition of p16 expression
observed during cervical carcinoma progression.
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Accompanying the global reduction in H3K27me3, HPV+ head and neck cancers and
cervical carcinomas exhibit numerous alterations in DNA methylation (Lorincz, 2016; van
Kempen et al., 2014). Indeed, we recently reported a methylation signature that predicts
HPV status in HNSC samples (Papillon-Cavanagh et al., 2017). Our analysis of
methylation data for all the probes across the CDKN2A and CDKN2B loci for the TCGA
HNSC and CESC cohorts revealed that there were two consistent alterations in DNA
methylation relative to methylation levels present in HPV– tumors and normal tissue
(Figure 2.5). A hypomethylated region of DNA was identified on the south shore of the
CpG island located at the start of the p14 transcript in HPV+ tumors in both the HNSC and
CESC cohorts. Genome-wide studies have clearly shown that methylation in the immediate
vicinity of the transcription start site blocks initiation (Jones, 2012). As such, the greatly
reduced methylation in HPV+ samples at this region is fully consistent with enhanced
CDKN2A expression. In addition, we also observed a hypermethylated region of DNA on
the north shore of the CpG island closest to the third exon of the p14 and p16 transcripts.
Hypermethylation at this location has been described in other studies of HPV+ head and
neck and cervical carcinomas using alternative probes (Ben-Dayan et al., 2017; Schlecht
et al., 2015; Wijetunga et al., 2016). These studies have established that p16 and p14
expression in a given tumor sample is strongly correlated with increased methylation at
this position in the CDKN2A locus (Ben-Dayan et al., 2017; Schlecht et al., 2015).
Hypermethylation of gene-bodies has recently been shown to occur during elongation
through a mechanism whereby RNA Polymerase II recruits Su(var)3-9, Enhancer-of-zeste
and Trithorax domain containing 2 (SETD2), a histone methyltransferase, which then trimethylates H3K36. DNA Methyltransferase 3 (DNMT3) recognizes and binds
H3K36me3, leading to the methylation of CpGs (Baubec et al., 2015; Neri et al., 2017).
Thus, along with promoter hypomethylation, gene-body methylation correlates well with
the observed enhanced transcription from the CDKN2A locus, providing further support
for an epigenetic mechanism as the basis for HPV induction of expression from this locus.
Taken together, our analysis of over 350 HPV+ head and neck or cervical carcinomas in
comparison with over 450 HPV– cancers from their respective anatomical sites
demonstrates that HPV consistently activates expression of both the CDKN2A and
CDKN2B loci in these cancers. Interestingly, this extends beyond just p16, with most
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tumors expressing the other gene products from these loci including p14, ANRIL, and p15.
In these cancers, HPV oncogene expression similarly dysregulates expression of key
regulators of H3K27me3, including members of PRC2 and the demethylases KDM6A and
KDM6B. As a likely result of these and other alterations in epigenetic regulation, the levels
of methylation in the center of the CDKN2A and CDKN2B loci are significantly decreased
in cells expressing high-risk HPV oncogenes.
Importantly, epigenetic reprogramming of gene expression induced by HPV should be
reversible and could represent a unique therapeutic target. Paradoxically, cervical
carcinoma cell lines or other tumor cell lines expressing HPV E7 from several high-risk
HPVs appear to require continuous p16 expression for survival. Although p16 normally
serves as a tumor suppressor, for currently unknown reasons, it becomes necessary for
continued growth in cells expressing HPV E7. As HPV+ cells require KDM6 demethylase
activity to maintain p16 expression, they are sensitive to small molecule inhibitors of
KDM6 in cell culture models (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al.,
2013). However, it has not been determined if actual primary HPV+ head and neck or
cervical carcinoma cells will respond similarly. Our analysis of the epigenetic regulators
that control p16 expression finds many commonalities between the hundreds of tumors
making up the TCGA CESC and HNSC cohorts and cell culture models, strongly
suggesting that testing of KDM6 inhibitors should be aggressively pursued as a novel
therapy of HPV+ cancers.
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Chapter 3

3

Analysis of Class I Major Histocompatibility Complex
Gene Transcription in Human Tumors Caused by Human
Papillomavirus Infection

3.1 Introduction
Anti-viral immunity is comprised of multiple levels of defenses that cooperatively block,
control, and eliminate infection. Intrinsic and innate immunity function as pre-existing
defenses against viral infection, and serve as the first levels of response (Takeuchi and
Akira, 2009; Yan and Chen, 2012). In the event that these non-specific immune responses
are not sufficient to eliminate an infection, subsequent antigen-specific adaptive immune
responses develop. As such, the recognition of intracellularly-derived viral peptides in the
context of major histocompatibility complex class I (MHC-I) molecules by cytotoxic T
lymphocytes (CTLs) triggers the elimination of virally infected cells (Tscharke et al.,
2015), while antibodies specific for virion antigens neutralize viral particles, and block the
spread of infection (Dorner and Radbruch, 2007).
Despite the effectiveness of the immune system, many viruses have acquired sophisticated
methods to evade anti-viral defenses, including the adaptive CTL response. For example,
several viral proteins have been identified that block MHC-I antigen presentation by
downregulating the loading of antigen onto MHC-I, the expression of MHC-I itself, and
the transport of MHC-I to the cell surface. Viral proteins have also been found to trigger
MHC-I internalization and/or degradation (Hansen and Bouvier, 2009). Collectively, these
strategies facilitate the evasion of the infected cell from CTL attack, thus allowing the virus
to persist.
Human papillomaviruses (HPV) are small, non-enveloped, double-stranded DNA viruses
that infect mucosal or cutaneous epithelia and induce cellular proliferation (Doorbar et al.,
2015). HPV infections of mucosal tissues are highly prevalent, and infections typically take
one to two years to resolve (Munoz et al., 2009). Mucosal HPVs are classified as low- or
high-risk based on the frequency with which they are associated with cancer. High-risk
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HPVs are causative agents for cancers at multiple distinct anatomical subsites (Doorbar et
al., 2015), including the cervix (Crosbie et al., 2013), other anogenital tissues (Alemany et
al., 2016; De Vuyst et al., 2009; Guimera et al., 2017), and the oropharynx (Gillison et al.,
2000; Mehanna et al., 2013; Syrjanen, 2005). Worldwide, mucosal high-risk HPV infection
is responsible for greater than 5% of all human cancers (Forman et al., 2012).
HPV encodes two main oncogenes, E6 and E7 (Doorbar et al., 2012), which are
constitutively expressed in HPV-positive (HPV+) tumors. The E6 and E7 oncoproteins
perform multiple functions in an infected and/or cancerous cell. They interact with key
cellular regulatory proteins to dysregulate gene expression and cell growth (Doorbar et al.,
2012). For example, E6 binds to and degrades p53, while E7 targets the retinoblastoma
protein (Rb) and its family members (Dyson et al., 1992; Scheffner et al., 1990). These
events contribute to inappropriate cell cycle progression in HPV-infected cells (Boyer et
al., 1996; Brehm et al., 1998). In high-risk HPV infections, viral oncoproteins uncouple
cell growth from differentiation. Consequently, this contributes to the formation of
epithelial dysplasia, which may progress to carcinoma if the infection is not resolved
(Doorbar et al., 2012).
Multiple studies have suggested that HPV oncoproteins contribute to the evasion of the
adaptive immune response, which supports a model by which the establishment of a
persistent HPV infection contributes to the ability of HPV+ cancers to evade anti-tumor
CTL responses (Westrich et al., 2017). Although both E5—a third viral oncoprotein—and
E6 from HPV16 have been reported to block MHC-I expression (Ashrafi et al., 2006; Kim
et al., 2011), the majority of studies in this area focus on the E7-mediated reduction of
MHC-I expression. Specifically, transfection of high-risk HPV E7 into various cell lines
represses MHC-I and/or transporter associated with antigen processing (TAP) expression
(Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 2010). Reciprocal studies have
shown that the knock-down of E7 in some HPV+ cervical cancer cell lines increases MHCI expression (Bottley et al., 2008; Li et al., 2006). In these studies, the repression of MHCI appears to be a specific function of high-risk HPV E7 that is not shared by low-risk HPV
E7 (Georgopoulos et al., 2000; Heller et al., 2011). Mechanistically, the reduction of MHCI and TAP expression in these studies occurs at the transcriptional level (Georgopoulos et
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al., 2000; Heller et al., 2011; Li et al., 2010). The most detailed studies of the HPVmediated repression of MHC-I expression report that E7 associates with the promoter of
the MHC-I HLA-A heavy chain gene, and recruits histone deacetylase activity via residues
70, 80, and 88 of HPV16 E7 (Heller et al., 2011; Li et al., 2006; Li et al., 2009). In addition
to repressing the basal transcription of MHC-I, HPV E7 abrogates the interferon regulatory
factor-1

(IRF-1)

response,

thus

inhibiting

interferon-gamma

(IFNγ)-mediated

transcriptional induction of MHC-I expression, antigen presentation, and CTL-induced cell
death (Park et al., 2000; Perea et al., 2000; Um et al., 2002; Zhou et al., 2013; Zhou et al.,
2011).
While the majority of published studies using tissue culture models indicate that HPV
oncoproteins such as E7 repress the expression of the antigen presentation apparatus,
cognate studies on the effects of HPV in human carcinomas are less consistent. Conflicting
reports suggest that HPV+ carcinomas/dysplastic lesions display increased (Jochmus et al.,
1993; Torres et al., 1993), decreased (Cromme et al., 1993; Keating et al., 1995; Ritz et al.,
2001; van Esch et al., 2014), or the same levels (Djajadiningrat et al., 2015; Ramqvist et
al., 2015) of MHC-I or TAP expression when compared with HPV negative (HPV−)
tumors or normal control tissues. Some of these differences may be related to different
tissue types, stages, and/or grades. The most comprehensive analysis, which examined 109
cervical carcinoma samples, concluded that only about 40% of the samples exhibited
MHC-I downregulation (Mehta et al., 2008). However, many types of tumors that are
HPV− contain a similar subset that are deficient in MHC-I and/or TAP expression (GarciaLora et al., 2003), which suggests that this reduction is not actually virally-mediated. As
such, it remains an open question as to whether the E7-mediated changes in the
transcription of various MHC-I pathway components observed in tissue culture similarly
occur in the context of actual human HPV+ carcinomas. This information is clearly
relevant, considering that the activation of an antigen-dependent clearance of tumor cells
by the immune system is an extraordinarily effective cancer therapy (Gotwals et al., 2017).
In this study, we used data from over 800 human cervical (The Cancer Genome Atlas
Research Network, 2017) and head & neck tumors (The Cancer Genome Atlas Research
Network, 2015) from The Cancer Genome Atlas (TCGA). We set out to determine if high-
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risk HPV oncogene expression alters the expression of MHC-I heavy chain genes, the β2
microglobulin light chain gene, and other components of the antigen-loading apparatus,
which includes: TAP1/2, tapasin, ERp57, calreticulin, calnexin, and ERAP1/2 in human
tumors. We found that HPV+ tumors from both anatomical sites expressed substantial
levels of mRNA for each of these MHC-I pathway components. Indeed, many of these
genes were expressed at significantly higher levels than normal control tissues.
Furthermore, an analysis of mutation frequencies in MHC-I genes indicated that the HPV+
and HPV− cancers exhibit similar frequencies of alteration. This is in contrast to TP53 and
CDKN2A, which are key regulators of pathways known to be targeted by HPV
oncoproteins and are frequently mutated in HPV− but not HPV+ carcinomas. This suggests
that the acquisition of somatic mutations in MHC-I genes as a means of evading the antitumor CTL response occurs similarly in HPV+ and HPV− cancers, which would not be
expected if HPV oncoproteins were effective at repressing MHC-I expression or function.
Taken together, this data does not entirely validate conclusions drawn from previous tissue
culture studies. Specifically, HPV oncoprotein expression does not repress the transcription
of the MHC-I pathway components in cervical carcinomas, although a modest reduction in
MHC-I mRNA levels was observed in HPV+ vs. HPV− head & neck cancers.

3.2 Materials and Methods
3.2.1

RNA expression comparisons and statistical analysis

Level 3 RNA-Seq by Expectation Maximization (RSEM) normalized Illumina HiSeq RNA
expression data for the TCGA head & neck cancer (HNSC) and cervical carcinoma (CESC)
cohorts was downloaded from the Broad Genome Data Analysis Center’s Firehose server
(https://gdac.broadinstitute.org/). For all of the genes, the gene level Firehose dataset was
used. Normalized expression data was extracted into Microsoft Excel, and the HPV status
was manually curated based on published datasets (Banister et al., 2017; Bratman et al.,
2016; The Cancer Genome Atlas Research Network, 2015; The Cancer Genome Atlas
Research Network, 2017). For each gene analyzed, primary patient samples with known
HPV status were grouped as HPV+, HPV−, or normal control tissue. Patient samples with
unknown HPV status were omitted from our calculations, as were samples obtained from
secondary metastatic lesions. This resulted in 73 HPV+, 442 HPV−, and 43 normal control
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samples with data available for the HNSC gene expression analysis and 278 HPV+, 19
HPV−, and 3 normal control samples available for the CESC gene expression analysis.
Boxplot comparison of gene expression was performed using GraphPad Prism v7.0
(Graphpad Software, Inc., San Diego, California, USA) and assembled into final form
using CorelDRAW (Corel, Ottawa, Ontario, Canada). For the boxplots, center lines show
the medians, box limits indicate the 25th and 75th percentiles as determined by Graphpad
Prism, and whiskers extend from the minimum to maximum values. Statistical significance
was calculated using Graphpad Prism. p-values were assigned using a one-tailed nonparametric Mann–Whitney U test. Post-hoc power calculations were performed with
G*Power software version 3.1.9.2 (Faul et al., 2007), using post-hoc t-test family
calculations, with effect size selected as 0.8 and α = 0.05. All comparisons achieved a
power value > 0.8, or demonstrated significant differences, unless otherwise noted in the
text.

3.2.2

Somatic mutation frequency comparisons and statistical
analysis

Somatic mutations present in selected genes of the tumor samples in the TCGA, HNSC,
and CESC cohorts were downloaded as the DNA Mutation Packager Calls
dataset

from

the

Broad

Genome

Data

Analysis

Center’s

Firehose

server

(https://gdac.broadinstitute.org/), and manually annotated for HPV status. This resulted in
67 HPV+ and 431 HPV− samples for the HNSC cohort, and 181 HPV+ and 10 HPV–
samples for the CESC cohort. Differences in the frequencies of DNA mutations in selected
genes were calculated between HPV+ and HPV− samples using the maftools package
(Mayakonda et al., 2018) in R statistical environment (Version 3.4.0). Silent mutations
were excluded from the analysis, and samples with multiple mutations in a gene were
counted as one for the calculations. Statistical significance (p < 0.05) was determined using
Fisher’s exact test.
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3.3 Results
3.3.1

Impact of HPV status on MHC-I heavy chain expression in
human tumors

MHC-I is a heterodimer comprised of a heavy chain encoded by one of three classical
(HLA-A, -B, and -C) or non-classical (HLA-E, -F, and -G) genes and the invariant β2
microglobulin light chain (Hansen and Bouvier, 2009). We analyzed the Illumina HiSeq
RNA expression data from the TCGA head & neck squamous cell carcinoma (HNSC) and
cervical carcinoma (CESC) cohorts for expression of HLA-A, HLA-B, and HLA-C, the three
classical genes (Figure 3.1). Unexpectedly, HPV+ samples from both the HNSC and
CESC cohorts expressed high levels of mRNA for all three genes, as shown by the
normalized RNA-seq absolute read count values, which averaged in the range of 25,000–
50,000. The HPV+ samples from the HNSC cohort expressed significantly elevated levels
of HLA-A, HLA-B, and HLA-C compared with normal control tissue. In the CESC cohort,
although the median RNA-seq values for the HPV+ samples appeared at least as high as
those for normal control samples, there was insufficient power to exclude the possibility
that the expression of HLA-A, HLA-B, or HLA-C was not different. In the HNSC cohort,
levels in HPV+ samples were slightly lower than HPV− samples, whereas HPV+ samples
in the CESC cohort had substantially higher levels of expression versus HPV− samples.
Nevertheless, all tumor subsets expressed high absolute levels of the mRNAs for each of
the classical MHC-I heavy chain genes.
Similarly, higher or comparable levels of expression of the non-classical genes, HLA-E,
HLA-F, and HLA-G, were observed in HPV+ cancers with respect to normal control tissues
in the HNSC cohort (Figure 3.2). Again, a comparison of the HPV+ samples to normal
control samples in the CESC cohort was insufficiently powered to allow us to exclude the
possibility that the expression of HLA-E, HLA-F, or HLA-G was not altered by the presence
of HPV oncogenes. However, HLA-E and HLA-F were expressed at relatively high levels
based on the absolute normalized read values. As noted by others (Cicchini et al., 2017),
HLA-E was expressed at significantly reduced levels in HPV+ samples compared with
HPV− samples in the HNSC cohort. However, this was not a consistent effect in all HPV+
carcinomas, as HLA-E was expressed at much higher levels in the HPV+ samples compared
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Figure 3.1. Expression of classical MHC-I heavy chain genes in head & neck or
cervical carcinomas stratified by HPV status.
Normalized RNA-seq data for the indicated MHC-I heavy chain genes was extracted from
The Cancer Genome Atlas (TCGA) database for the head & neck cancer (HNSC) (A) and
cervical carcinoma (CESC) (B) cohorts for HPV+, HPV−, and normal control tissues.
Numbers in brackets refer to the number of samples included in each analysis. * p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant, red brackets indicate a
comparison that did not achieve significance with a power value < 0.8.
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Figure 3.2. Expression of non-classical MHC-I heavy chain genes in head & neck or
cervical carcinomas stratified by HPV status.
Normalized RNA-seq data for the indicated MHC-I heavy chain genes was extracted from
the TCGA database for the HNSC (A) and CESC (B) cohorts for HPV+, HPV−, and normal
control tissues. Numbers in brackets refer to the number of samples included in each
analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant, red
brackets indicate a comparison that did not achieve significance with a power value < 0.8.
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with the HPV− samples in the CESC cohort. Although HLA-G was expressed at lower
overall levels than the other heavy chain genes, it was also expressed at comparable or
elevated levels in HPV+ samples versus HPV− or normal control samples (Figure 3.2).
Collectively, these results indicate that the expression of HPV oncogenes in actual human
tumors is not correlated with strong repression of the MHC-I loci, in contrast to what is
reported in tissue culture-based models. Indeed, the average expression of the mRNA for
these genes is consistently higher or equivalent in HPV+ samples versus the normal
control.

3.3.2

Impact of HPV status on the expression of other components
of the antigen presentation apparatus in human tumors

The MHC-I heavy chain folds and assembles with the β2 microglobulin light chain within
the endoplasmic reticulum, in a process dependent on binding to a peptide antigen (Hansen
and Bouvier, 2009). The MHC-I peptide-loading complex consists of MHC-I, the peptide
transporter TAP, the bridging factor tapasin, the endoplasmic reticulum aminopeptidase
(ERAP), and the chaperones: calreticulin, calnexin, and ERp57. Several studies have
reported the downregulation of TAP in HPV+ cancer cell lines (Georgopoulos et al., 2000;
Li et al., 2010). Much less is known about the effect of HPV status on the expression of
the other components necessary for MHC-I antigen presentation, so we examined the
impact of HPV status on all mRNA expression for all components of the MHC-I peptideloading complex. Analysis of TCGA data revealed high levels of transcripts for the B2M
gene encoding β2 microglobulin, the TAP1 and TAP2 genes encoding the TAP
heterodimer, and the genes encoding ERAP, tapasin, calreticulin, calnexin, and ERp57
(ERAP1/2, TAPBP, CALR, CANX, and PDIA3 respectively) in HPV+ samples in head &
neck (Figure 3.3) and cervical (Figure 3.4) carcinomas. All genes were expressed at higher
levels in HPV+ samples with respect to normal control tissue in the HNSC cohort, with the
sole exception of CANX, which was expressed at a comparable level. There were no
consistent differences in expression with respect to HPV+ and HPV− samples in the HNSC
cohort. B2M and TAP1 were expressed at equivalent levels; TAP2, CANX, CALR, and
PDIA3 were reduced; while TAPBP, ERAP1, and ERAP2 were increased (Figure 3.3). In
the CESC cohort, nearly all of these genes were expressed at elevated or comparable levels
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Figure 3.3. Expression of the MHC-I light chain and other genes involved in MHC-Idependent antigen presentation in head & neck carcinomas stratified by HPV status.
Normalized RNA-seq data for the indicated genes involved in MHC-I-dependent antigen
presentation was extracted from the TCGA database for the HNSC cohort for HPV+,
HPV−, and normal control tissues. Numbers in brackets refer to the number of samples
included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not
significant.

77

Figure 3.4. Expression of the MHC-I light chain and other genes involved in MHC-Idependent antigen presentation in cervical carcinomas stratified by HPV status.
Normalized RNA-seq data for the indicated genes involved in MHC-I-dependent antigen
presentation was extracted from the TCGA database for the CESC cohort for HPV+,
HPV−, and normal control tissues. Numbers in brackets refer to the number of samples
included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not
significant, red brackets indicate a comparison that did not achieve significance with a
power value < 0.8.
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to normal control tissue or HPV− samples, although some comparisons were limited based
on insufficient sample numbers. The sole exception was CANX, which was expressed at a
lower level in HPV+ versus HPV− samples (Figure 3.4). Thus, most components of the
MHC-I loading complex were transcribed in HPV+ human tumors at levels that appear
similar or significantly higher than normal control tissue. This again contrasts with the
reported decreases in TAP transcription reported in tissue culture models.

3.3.3

Higher levels of lymphocytes and interferon γ are present in
HPV+ human tumors

IFNγ, the product of the IFNG locus, can coordinately induce higher levels of transcription
in many of the genes involved in antigen processing and presentation by MHC-I, and
provides enhanced immune surveillance under inflammatory conditions (Boehm et al.,
1997). Given our observation that mRNA levels of all MHC-I loading and presentation
genes were expressed at higher or at least similar levels in HPV+ tumors compared with
HPV− and normal control tissues, we hypothesized that infiltrating lymphocytes producing
IFNγ could be present at higher levels in HPV+ tumors versus HPV− tumors or normal
control tissues.
We first assessed the relative proportion of T- and NK-cells in these samples, which are
the primary producers of IFNγ. Similarly to what has been done by others (Becht et al.,
2016), we analyzed the mRNA expression levels of the genes encoding CD3 (CD3D,
CD3E, and CD3G) and CD16a (FCGR3A), as surrogate markers for T- and NK-cells,
respectively (Figure 3.5). HPV+ samples from both the HNSC and CESC cohorts showed
significantly increased expression of all three genes encoding subunits of CD3 versus
HPV− samples. For the HNSC cohort, CD3 expression in HPV+ samples were also
consistently higher than normal control tissues. No significant differences in CD3 levels
were observed between HPV+ samples and normal control tissues in the CESC cohort, but
this comparison was not powered sufficiently to confirm this result. For the NK-cell marker
CD16a, expression of FCGR3A was readily detected and significantly higher in HPV+
cells versus normal control tissue from both the HNSC and CESC cohorts. No difference
in FCGR3A levels were apparent between HPV+ and HPV− samples from either cohort,
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Figure 3.5. Detection of tumor infiltrating T-cells and NK-cells in head & neck and
cervical carcinomas stratified by HPV status.
Normalized RNA-seq data for genes indicative of tumor-infiltrating T-cells (CD3D, CD3E,
and CD3G) or NK-cells (FCGR3A) was extracted from the TCGA database for the HNSC
(A) and CESC (B) cohorts for HPV+, HPV−, and normal control tissues. Numbers in
brackets refer to the number of samples included in each analysis. * p ≤ 0.05, *** p ≤ 0.001,
**** p ≤ 0.0001, ns – not significant, red brackets indicate a comparison that did not
achieve significance with a power value < 0.8.
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which indicated that infiltration by NK-cells is similar in both HPV+ and HPV− samples.
Taken together, these results suggest that there is significant infiltration of both cervical
and head & neck tumors with T-cells and likely NK-cells, which could be stimulating the
tumor cells to upregulate MHC-I. Notably, the absolute normalized RNA-seq read levels
for genes derived from these infiltrating lymphocytes were much lower than any of the
other genes we analyzed, with the exception of the weakly expressed HLA-G. This was as
expected, as the lymphocytes are expected to represent only a fraction of the tumor mass
(Aran et al., 2015).
We next looked for IFNγ mRNA to determine whether these lymphocytes were producing
this proinflammatory cytokine (Figure 3.6). Although the expression of IFNγ mRNA in
these samples was low, it was detectable, and significantly higher in HPV+ samples versus
HPV− or normal control tissues in both the HNSC and CESC cohorts (Figure 3.6). Taken
together, these results indicate that HPV+ carcinomas have a significant level of infiltrating
lymphocytes that appear to be producing some IFNγ. Thus, the upregulated expression of
the MHC-I loading and presentation genes observed in these carcinomas may be a
consequence of exposure to IFNγ.

3.3.4

Genes encoding components of the antigen presentation
apparatus are frequently mutated in HPV+ human tumors

Precancerous cells undergo strong selection for properties that are advantageous for growth
and survival, leading to clonal evolution and cancer formation. As such, tumor cells
frequently acquire somatic mutations that activate oncogenes or inactivate growth
inhibitory genes. In HPV-dependent cancers, the expression of virally-derived oncogenes
should eliminate the need for somatic mutations in the key cellular regulatory pathways
they target. Thus, if high-risk HPV E7 repressed MHC-I expression and function, the
frequency of mutations in MHC-I that would allow tumor escape from the immune system
should be reduced in HPV+ versus HPV− carcinomas.
To validate this concept, we first analyzed the frequency of mutations in TP53 and
CDKN2A (Figures 3.7A, B, left panels). TP53 encodes the p53 tumor suppressor protein,
which is targeted by the E6 oncoproteins of high-risk HPVs. CDKN2A encodes the p16
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Figure 3.6. Detection of IFNγ mRNA in head & neck and cervical carcinomas
stratified by HPV status.
Normalized RNA-seq data for the IFNγ gene produced by tumor-infiltrating lymphocytes
was extracted from the TCGA database for the HNSC (A) and CESC (B) cohorts for
HPV+, HPV−, and normal control tissues. Numbers in brackets refer to the number of
samples included in each analysis. ** p ≤ 0.01, **** p ≤ 0.0001.
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tumor suppressor, a key regulator of the Rb pathway targeted by the E7 oncoprotein of
high-risk HPVs (Boyer et al., 1996; Sherr and McCormick, 2002). There were dramatic
differences in the frequency of somatic mutations in TP53 and CDKN2A in HPV+ versus
HPV− samples from both the TCGA HNSC and CESC cohorts, although the frequencies
in the CESC cohort were not statistically different due to a smaller sample size. The
mutation load for TP53 was much higher in HPV− samples, with a 55-fold (HNSC) and
5.2-fold (CESC) increase compared with their HPV+ counterparts. For CDKN2A, a fold
increase could not be calculated for the HNSC cohort, as no mutations were present in the
HPV+ samples. However, 26% of HPV− HNSC samples contained CDKN2A mutations.
In the CESC cohort, there was an 18-fold increase in CDKN2A mutations in HPV−
compared with HPV+, respectively. These observations were expected, as high-risk HPV
E6 targets p53 for degradation, while high-risk HPV E7 targets Rb. Thus, these viral
oncoproteins functionally inactivate these critical anti-cancer pathways without the need
for the somatic mutations acquired by HPV− carcinomas during tumor evolution.
We next compared the frequency of somatic mutations in all of the genes encoding MHCI and the antigen-loading complex in HPV+ samples versus HPV− samples in the TCGA
HNSC and CESC cohorts (Figures 3.7A, B, right panels). As noted by others (The Cancer
Genome Atlas Research Network, 2015; The Cancer Genome Atlas Research Network,
2017), mutations in the genes encoding MHC-I heavy chains were the most frequent.
However, mutations in B2M, TAP1/2, or other components of the MHC-I loading complex
were also present at lower frequencies. To simplify this analysis, we compared the mutation
frequency in both classical and non-classical MHC-I genes as a group, as well as all of the
components of the MHC-I and associated loading complex, collectively. This second
comparison should be valid, as the inactivation of any single component of this pathway
could be sufficient to impair antigen presentation (Hansen and Bouvier, 2009). Indeed, one
comprehensive study in a small cohort of cervical carcinomas found that 15 out of 16
tumors exhibited an impaired expression of at least one component of the MHC-I antigen
presentation apparatus (Ritz et al., 2001). Our inspection of the TCGA data reveals that
both HPV+ and HPV− carcinomas in the HNSC or CESC cohorts acquire relatively
frequent somatic mutations in the components of the MHC-I antigen presentation pathway,
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Figure 3.7. Comparison of the somatic mutation frequency in genes involved in MHCI-dependent antigen presentation in head & neck and cervical carcinomas stratified
by HPV status.
The presence or absence of somatic mutations in selected genes of the tumor samples in
the TCGA HNSC and CESC cohorts was obtained from the Broad Genome Data Analysis
Center’s Firehose server. The frequency of mutations in individual genes or groups of
genes in HPV+ versus HPV− samples was calculated to determine whether they were
influenced by HPV status. Analysis of TP53 and CDKN2A (left panels) revealed a
significantly reduced frequency of somatic mutations in HPV+ versus HPV− samples in
both the TCGA HNSC (A) and CESC (B) cohorts. No significant decrease was observed
for somatic mutation frequency in the MHC-I heavy chain genes, or a collective grouping
of all genes involved in MHC-I-dependent antigen presentation between HPV+ and HPV−
samples in either the TCGA HNSC (A) or CESC (B) cohorts. Numbers in brackets refer to
the number of samples included in each analysis. * p ≤ 0.05, ns – not significant.
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presumably as a means of immune escape. There was no difference in the frequency of
somatic mutations in genes encoding MHC-I or the antigen-loading apparatus between
HPV+ and HPV− samples in either cohort (Figures 3.7A, B, right panels). Thus, the
presence of HPV oncogenes has no impact on the frequency of somatic mutations in genes
related to MHC-I antigen presentation. This is consistent with the conclusion that HPV
oncogenes do not effectively reduce antigen presentation by MHC-I, which would have
eliminated the need for HPV+ carcinomas to acquire mutations in this pathway.

3.4 Discussion
The stable surface expression of MHC-I requires loading of the heavy chain/light chain
dimer with an antigenic peptide in the endoplasmic reticulum. The loading complex
consists of multiple essential factors, including the peptide transporter TAP, the bridging
factor tapasin, and the chaperones: calreticulin, calnexin, and ERp57. Reduced expression
or mutation of any of these components can compromise MHC-I-dependent antigen
presentation, and allow the infected or cancerous cell to escape T-cell recognition and
clearance (Hansen and Bouvier, 2009).
HPV infection and subsequent expression of the viral oncoproteins leads to a large-scale
reprogramming of gene expression. Multiple studies have reported that the high-risk HPV
E7 oncoprotein contributes to the evasion of the adaptive immune response; this process
occurs through transcriptional downregulation of the MHC-I heavy chain genes or other
components necessary for antigen loading and presentation (Georgopoulos et al., 2000;
Heller et al., 2011; Li et al., 2010). This mechanism has been proposed to support the
establishment of persistent HPV infection and contribute to the ability of HPV+ cancers to
evade anti-tumor CTL responses. Additional downregulation of MHC-I is mediated by the
high-risk HPV E5 oncoprotein. This occurs via a non-transcriptional mechanism in which
the classical heavy chains are trapped in the Golgi apparatus and not transported to the cell
surface (Ashrafi et al., 2006).
While cell culture models have allowed detailed studies on the mechanism of E7-mediated
transcriptional downregulation of components in the MHC-I antigen presentation
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apparatus, far less is known about how similar these effects are to actual HPV+ tumors. In
this study, our goal was to determine whether the transcriptional reduction in MHC-I
components mediated by E7 is recapitulated in primary HPV+ tumors from different
anatomical locations.
Using data from over 800 primary human tumors, we provide evidence that HPV+ tumors
from both the head & neck and cervical sites display high mRNA levels for MHC-I
components, including heavy and light chains, as well as all factors required for MHC-I
loading. Indeed, HPV+ head & neck carcinomas exhibit significant increases, rather than
decreases, in mRNA levels for many MHC-I components compared with normal control
tissue, and this trend continues in the cervical carcinoma cohort (Figures 3.1–3.4). These
unexpected results contradict the existing paradigm of virally-mediated immune evasion
and suggest that in the context of an in vivo tumor setting, the presence of HPV may
actually result in enhanced expression of mRNA encoding MHC-I-dependent antigen
presentation components.
As our results specifically addressed the question of whether HPV oncoproteins repress
expression of the MHC-I genes at the transcriptional level, they do not eliminate the
possibility that other post-transcriptional mechanisms, such as those mediated by high-risk
HPV E5, can reduce antigen presentation. However, a comprehensive analysis of MHC-I
protein expression by immunohistochemical detection indicated that only a subset of about
40% of HPV+ cervical carcinomas have reduced expression of one or more components at
the protein level (Mehta et al., 2008). As only a minority of carcinomas have reduced
antigen presentation apparatus, it appears that the HPV-mediated reduction of MHC-I is
not absolutely necessary for tumorigenesis.
Our results also do not rule out the possibility that E7 could mediate a reduction in MHCI transcription in non-cancerous or pre-cancerous lesions, as all samples in this study are
carcinomas. However, a purpose for the reacquisition of expression of MHC-I during the
progression of a non-neoplastic lesion to a carcinoma is difficult to reconcile with current
models of tumorigenesis.
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Further evidence supporting our conclusion that HPV oncoproteins are unable to
functionally antagonize MHC-I-dependent antigen presentation in human carcinomas is
provided by our comparison of somatic mutation frequencies between HPV+ and HPV−
samples (Figure 3.7). The anticipated sharp reduction in the occurrence of mutations in
genes encoding MHC-I or antigen-loading complex components was not observed in
HPV+ samples. This is in stark contrast to what was observed for TP53, which encodes
p53, a known target of the high-risk HPV E6 oncoproteins (Scheffner et al., 1990) or
CDKN2A, which encodes the p16 component of the Rb pathway targeted by high-risk HPV
E7 oncoproteins (Boyer et al., 1996).
Furthermore, HPV utilizes multiple other strategies to evade the adaptive immune
response, which suggests that a simple reduction in MHC-I transcription is unlikely to be
sufficient to escape surveillance by the immune system. These include the ability of E5 to
block MHC-I transport to the cell surface (Ashrafi et al., 2006), the preferential utilization
of low-abundance codons to ensure minimal translation of viral antigens (Zhao and Chen,
2011), and the induction of the ERAP1 protease to partially degrade and attenuate the
presentation of viral antigenic epitopes (Steinbach et al., 2017).
A simple mechanism to explain the lack of MHC-I repression would be a failure of these
tumors to express the HPV E7 oncogene, which has been reported to be necessary and
sufficient for the downregulation of transcription from at least some of these genes (Bottley
et al., 2008; Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 2006; Li et al., 2009;
Li et al., 2010). This is clearly not the case, as all HPV+ samples were reported to express
detectable levels of E6 and E7 mRNAs (The Cancer Genome Atlas Research Network,
2015; The Cancer Genome Atlas Research Network, 2017). In addition, a lack of E7 would
not be expected to lead to the observed increase in MHC-I expression, but rather cause
equivalent expression to that of HPV− cervical carcinoma samples.
An alternative method of activating expression of MHC-I and components of the antigenloading complex could be via the activation of the JAK/STAT/IRF-1 signal transduction
pathway by exposure to IFNγ. However, multiple studies done in tissue culture models
have shown that HPV E7 abrogates the IRF-1 response, thus inhibiting the IFNγ induction

88

of MHC-I expression, antigen presentation, and CTL-induced cell death (Park et al., 2000;
Perea et al., 2000; Um et al., 2002; Zhou et al., 2013; Zhou et al., 2011). Our analysis
reveals low but detectable levels of mRNA for IFNγ in HPV+ samples, which are higher
than HPV− samples or normal control tissue in both TCGA cohorts (Figure 3.6). In
addition, we searched for the presence of mRNAs that should be unique to infiltrating
lymphocytes that can express IFNγ (Figure 3.5). Using these surrogate markers, we found
evidence for significant infiltration by T-cells and NK-cells in both HPV+ and HPV−
carcinomas. Indeed, the levels of infiltrating lymphocytes were significantly higher in
HPV+ vs. HPV− samples for both TCGA cohorts, which could have resulted from
detection of foreign virally-derived antigens. Taken together, the high absolute levels of
mRNAs encoding MHC-I components expressed in HPV+ head & neck and cervical
carcinomas provide good evidence that high-risk HPV E7 is unable to efficiently block the
IFNγ induction of transcription of these genes in actual human tumors. Although this
contrasts with the results of the studies listed above, our work agrees with other studies
showing that various cervical cancer cell lines upregulate MHC-I in response to IFNγ
(Bornstein et al., 1997; Evans et al., 2001; Mora-Garcia Mde et al., 2006), and the treatment
of HPV+ pre-cancerous cervical lesions in patients increased expression of at least HLAB in a majority of cases (Sikorski et al., 2004). It should be noted that the levels of MHCI heavy chain mRNAs are statistically lower in HPV+ vs HPV− samples in the HNSC
cohort (Figure 3.1), despite the increased levels of IFNγ (Figure 3.6). This may indicate
that HPV is able to modestly impact IFNγ activation in these tissues, but this was not
observed in the CESC cohort.
Our analysis of over 350 HPV+ head & neck or cervical carcinomas in comparison with
over 450 HPV− cancers demonstrates subtle differences in the effect of HPV on MHC-I
transcription between the two anatomical sites. Specifically, HPV does not repress the
transcription of MHC-I heavy chain genes in cervical carcinomas, which exhibit high levels
with respect to both HPV− carcinomas and normal control tissue. In contrast, a statistically
significant but modest reduction in MHC-I heavy chain mRNA levels was observed in
HPV+ vs HPV− head & neck cancers. However, transcription of these genes was
nevertheless substantially elevated with respect to normal control tissues. Interestingly, our
observations with the MHC-I heavy chain genes extend to many of the other genes
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involved in MHC-I loading. These results are in sharp contrast to much of the existing
literature derived from tissue culture-based experiments, possibly because of the complex
interplay between the MHC-I antigen presentation apparatus and cytokines produced by
infiltrating lymphocytes present in actual tumors. This differs markedly from our previous
study on the effects of HPV on numerous regulators of H3K27 methylation and the
expression of multiple downstream targets of these regulators, in which we showed that
tissue culture models faithfully recapitulate what is observed in human tumors (Gameiro
et al., 2017).
Importantly, MHC-I-dependent antigen presentation is critical for CD8+ T-cell responses,
which are essential for the control and clearance of virally-infected or cancerous cells. This
is particularly important as recent advances in cancer immunotherapy using immune
checkpoint blockades rely on reactivating antigen-dependent clearance of tumor cells
(Postow et al., 2015). Although we detect high levels of MHC-I mRNA in HPV+ tumors,
this may not necessarily translate into high levels of expression of these proteins. In
addition, a functional defect in any component of the MHC-I antigen presentation
apparatus could compromise the detection and clearance of HPV+ carcinomas by the
adaptive immune system (Hansen and Bouvier, 2009). Thus, the utility of immune
checkpoint blockade therapy in HPV-dependent cancers remains to be determined.
Nevertheless, it is intriguing to speculate that the expression of non-self-derived viral
antigens, combined with intact MHC-I presentation and increased levels of infiltrating Tcells, may contribute to the well-established observation that patient outcomes using
conventional therapies are markedly better for HPV+ versus HPV− carcinomas in both the
head & neck and cervix (Ang et al., 2010; Gotwals et al., 2017).

3.5 References
Alemany L, Cubilla A, Halec G, et al. (2016) Role of Human Papillomavirus in Penile
Carcinomas Worldwide. Eur Urol 69: 953-961.
Ang KK, Harris J, Wheeler R, et al. (2010) Human papillomavirus and survival of patients
with oropharyngeal cancer. N Engl J Med 363: 24-35.
Aran D, Sirota M and Butte AJ. (2015) Systematic pan-cancer analysis of tumour purity.
Nat Commun 6: 8971.

90

Ashrafi GH, Haghshenas M, Marchetti B, et al. (2006) E5 protein of human papillomavirus
16 downregulates HLA class I and interacts with the heavy chain via its first
hydrophobic domain. Int J Cancer 119: 2105-2112.
Banister CE, Liu C, Pirisi L, et al. (2017) Identification and characterization of HPVindependent cervical cancers. Oncotarget 8: 13375-13386.
Becht E, Giraldo NA, Lacroix L, et al. (2016) Estimating the population abundance of
tissue-infiltrating immune and stromal cell populations using gene expression.
Genome Biol 17: 218.
Boehm U, Klamp T, Groot M, et al. (1997) Cellular responses to interferon-gamma. Annu
Rev Immunol 15: 749-795.
Bornstein J, Lahat N, Kinarty A, et al. (1997) Interferon-beta and -gamma, but not tumor
necrosis factor-alpha, demonstrate immunoregulatory effects on carcinoma cell
lines infected with human papillomavirus. Cancer 79: 924-934.
Bottley G, Watherston OG, Hiew YL, et al. (2008) High-risk human papillomavirus E7
expression reduces cell-surface MHC class I molecules and increases susceptibility
to natural killer cells. Oncogene 27: 1794-1799.
Boyer SN, Wazer DE and Band V. (1996) E7 protein of human papilloma virus-16 induces
degradation of retinoblastoma protein through the ubiquitin-proteasome pathway.
Cancer Res 56: 4620-4624.
Bratman SV, Bruce JP, O'Sullivan B, et al. (2016) Human Papillomavirus Genotype
Association With Survival in Head and Neck Squamous Cell Carcinoma. JAMA
Oncol 2: 823-826.
Brehm A, Miska EA, McCance DJ, et al. (1998) Retinoblastoma protein recruits histone
deacetylase to repress transcription. Nature 391: 597-601.
Cicchini L, Blumhagen RZ, Westrich JA, et al. (2017) High-Risk Human Papillomavirus
E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human
Keratinocytes. Sci Rep 7: 3633.
Cromme FV, Meijer CJ, Snijders PJ, et al. (1993) Analysis of MHC class I and II
expression in relation to presence of HPV genotypes in premalignant and malignant
cervical lesions. Br J Cancer 67: 1372-1380.
Crosbie EJ, Einstein MH, Franceschi S, et al. (2013) Human papillomavirus and cervical
cancer. Lancet 382: 889-899.
De Vuyst H, Clifford GM, Nascimento MC, et al. (2009) Prevalence and type distribution
of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva,
vagina and anus: a meta-analysis. Int J Cancer 124: 1626-1636.

91

Djajadiningrat RS, Horenblas S, Heideman DA, et al. (2015) Classic and nonclassic HLA
class I expression in penile cancer and relation to HPV status and clinical outcome.
J Urol 193: 1245-1251.
Doorbar J, Egawa N, Griffin H, et al. (2015) Human papillomavirus molecular biology and
disease association. Rev Med Virol 25 Suppl 1: 2-23.
Doorbar J, Quint W, Banks L, et al. (2012) The biology and life-cycle of human
papillomaviruses. Vaccine 30 Suppl 5: F55-70.
Dorner T and Radbruch A. (2007) Antibodies and B cell memory in viral immunity.
Immunity 27: 384-392.
Dyson N, Guida P, Munger K, et al. (1992) Homologous sequences in adenovirus E1A and
human papillomavirus E7 proteins mediate interaction with the same set of cellular
proteins. J Virol 66: 6893-6902.
Evans M, Borysiewicz LK, Evans AS, et al. (2001) Antigen processing defects in cervical
carcinomas limit the presentation of a CTL epitope from human papillomavirus 16
E6. J Immunol 167: 5420-5428.
Faul F, Erdfelder E, Lang AG, et al. (2007) G*Power 3: a flexible statistical power analysis
program for the social, behavioral, and biomedical sciences. Behav Res Methods
39: 175-191.
Forman D, de Martel C, Lacey CJ, et al. (2012) Global burden of human papillomavirus
and related diseases. Vaccine 30 Suppl 5: F12-23.
Gameiro SF, Kolendowski B, Zhang A, et al. (2017) Human papillomavirus dysregulates
the cellular apparatus controlling the methylation status of H3K27 in different
human cancers to consistently alter gene expression regardless of tissue of origin.
Oncotarget 8: 72564-72576.
Garcia-Lora A, Algarra I and Garrido F. (2003) MHC class I antigens, immune
surveillance, and tumor immune escape. J Cell Physiol 195: 346-355.
Georgopoulos NT, Proffitt JL and Blair GE. (2000) Transcriptional regulation of the major
histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by
the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene
19: 4930-4935.
Gillison ML, Koch WM, Capone RB, et al. (2000) Evidence for a causal association
between human papillomavirus and a subset of head and neck cancers. J Natl
Cancer Inst 92: 709-720.
Gotwals P, Cameron S, Cipolletta D, et al. (2017) Prospects for combining targeted and
conventional cancer therapy with immunotherapy. Nat Rev Cancer 17: 286-301.

92

Guimera N, Alemany L, Halec G, et al. (2017) Human papillomavirus 16 is an aetiological
factor of scrotal cancer. Br J Cancer 116: 1218-1222.
Hansen TH and Bouvier M. (2009) MHC class I antigen presentation: learning from viral
evasion strategies. Nat Rev Immunol 9: 503-513.
Heller C, Weisser T, Mueller-Schickert A, et al. (2011) Identification of key amino acid
residues that determine the ability of high risk HPV16-E7 to dysregulate major
histocompatibility complex class I expression. J Biol Chem 286: 10983-10997.
Jochmus I, Durst M, Reid R, et al. (1993) Major histocompatibility complex and human
papillomavirus type 16 E7 expression in high-grade vulvar lesions. Hum Pathol 24:
519-524.
Keating PJ, Cromme FV, Duggan-Keen M, et al. (1995) Frequency of down-regulation of
individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1
expression. Br J Cancer 72: 405-411.
Kim DH, Kim EM, Lee EH, et al. (2011) Human papillomavirus 16E6 suppresses major
histocompatibility complex class I by upregulating lymphotoxin expression in
human cervical cancer cells. Biochem Biophys Res Commun 409: 792-798.
Li H, Ou X, Xiong J, et al. (2006) HPV16E7 mediates HADC chromatin repression and
downregulation of MHC class I genes in HPV16 tumorigenic cells through
interaction with an MHC class I promoter. Biochem Biophys Res Commun 349:
1315-1321.
Li H, Zhan T, Li C, et al. (2009) Repression of MHC class I transcription by HPV16E7
through interaction with a putative RXRbeta motif and NF-kappaB cytoplasmic
sequestration. Biochem Biophys Res Commun 388: 383-388.
Li W, Deng XM, Wang CX, et al. (2010) Down-regulation of HLA class I antigen in human
papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1
expression. Int J Gynecol Cancer 20: 227-232.
Mayakonda A, Lin DC, Assenov Y, et al. (2018) Maftools: efficient and comprehensive
analysis of somatic variants in cancer. Genome Res 28: 1747-1756.
Mehanna H, Beech T, Nicholson T, et al. (2013) Prevalence of human papillomavirus in
oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and
meta-analysis of trends by time and region. Head Neck 35: 747-755.
Mehta AM, Jordanova ES, Kenter GG, et al. (2008) Association of antigen processing
machinery and HLA class I defects with clinicopathological outcome in cervical
carcinoma. Cancer Immunol Immunother 57: 197-206.
Mora-Garcia Mde L, Duenas-Gonzalez A, Hernandez-Montes J, et al. (2006) Upregulation of HLA class-I antigen expression and antigen-specific CTL response in

93

cervical cancer cells by the demethylating agent hydralazine and the histone
deacetylase inhibitor valproic acid. J Transl Med 4: 55.
Munoz N, Hernandez-Suarez G, Mendez F, et al. (2009) Persistence of HPV infection and
risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian
women. Br J Cancer 100: 1184-1190.
Network TCGAR. (2015) Comprehensive genomic characterization of head and neck
squamous cell carcinomas. Nature 517: 576-582.
Network TCGAR. (2017) Integrated genomic and molecular characterization of cervical
cancer. Nature 543: 378-384.
Park JS, Kim EJ, Kwon HJ, et al. (2000) Inactivation of interferon regulatory factor-1
tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated
immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275: 67646769.
Perea SE, Massimi P and Banks L. (2000) Human papillomavirus type 16 E7 impairs the
activation of the interferon regulatory factor-1. Int J Mol Med 5: 661-666.
Postow MA, Callahan MK and Wolchok JD. (2015) Immune Checkpoint Blockade in
Cancer Therapy. J Clin Oncol 33: 1974-1982.
Ramqvist T, Mints M, Tertipis N, et al. (2015) Studies on human papillomavirus (HPV)
16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in
relation to clinical outcome and immunological parameters. Oral Oncol 51: 11261131.
Ritz U, Momburg F, Pilch H, et al. (2001) Deficient expression of components of the MHC
class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19:
1211-1220.
Scheffner M, Werness BA, Huibregtse JM, et al. (1990) The E6 oncoprotein encoded by
human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:
1129-1136.
Sherr CJ and McCormick F. (2002) The RB and p53 pathways in cancer. Cancer cell 2:
103-112.
Sikorski M, Bobek M, Zrubek H, et al. (2004) Dynamics of selected MHC class I and II
molecule expression in the course of HPV positive CIN treatment with the use of
human recombinant IFN-gamma. Acta Obstet Gynecol Scand 83: 299-307.
Steinbach A, Winter J, Reuschenbach M, et al. (2017) ERAP1 overexpression in HPVinduced malignancies: A possible novel immune evasion mechanism.
Oncoimmunology 6: e1336594.

94

Syrjanen S. (2005) Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32
Suppl 1: S59-66.
Takeuchi O and Akira S. (2009) Innate immunity to virus infection. Immunol Rev 227: 7586.
Torres LM, Cabrera T, Concha A, et al. (1993) HLA class I expression and HPV-16
sequences in premalignant and malignant lesions of the cervix. Tissue Antigens 41:
65-71.
Tscharke DC, Croft NP, Doherty PC, et al. (2015) Sizing up the key determinants of the
CD8(+) T cell response. Nat Rev Immunol 15: 705-716.
Um SJ, Rhyu JW, Kim EJ, et al. (2002) Abrogation of IRF-1 response by high-risk HPV
E7 protein in vivo. Cancer Lett 179: 205-212.
van Esch EM, Tummers B, Baartmans V, et al. (2014) Alterations in classical and
nonclassical HLA expression in recurrent and progressive HPV-induced usual
vulvar intraepithelial neoplasia and implications for immunotherapy. Int J Cancer
135: 830-842.
Westrich JA, Warren CJ and Pyeon D. (2017) Evasion of host immune defenses by human
papillomavirus. Virus Res 231: 21-33.
Yan N and Chen ZJ. (2012) Intrinsic antiviral immunity. Nat Immunol 13: 214-222.
Zhao KN and Chen J. (2011) Codon usage roles in human papillomavirus. Rev Med Virol
21: 397-411.
Zhou F, Chen J and Zhao KN. (2013) Human papillomavirus 16-encoded E7 protein
inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced
lysis by blocking IRF-1 expression in mouse keratinocytes. J Gen Virol 94: 25042514.
Zhou F, Leggatt GR and Frazer IH. (2011) Human papillomavirus 16 E7 protein inhibits
interferon-gamma-mediated enhancement of keratinocyte antigen processing and
T-cell lysis. FEBS J 278: 955-963.

95

Chapter 4

4

Treatment-naïve HPV+ Head and Neck Cancers Display
a T-cell-inflamed Phenotype Distinct from their HPV–
Counterparts that has Implications for Immunotherapy

4.1 Introduction
Recent advances in understanding the basics of tumor immunology have paved the way for
development of therapies that can induce effective anti-tumor immune responses. Many of
these are based on immune checkpoint inhibition, in which normal negative regulatory
mechanisms, which keep immune responses in check, are overcome (Pardoll, 2012;
Topalian et al., 2015). Current immuno-oncology therapies can demonstrate tremendous
efficacy and induce long-term remission in patients (Del Paggio, 2018). However,
responses to immunotherapy are often restricted to a subset of cancers, for reasons that are
not entirely understood.
Head and neck squamous cell carcinomas (HNSC) represent the 6th most common human
cancer type (Ferlay et al., 2010) and are often characterized by aggressive local invasion
and overall poor prognosis (Baxi et al., 2012). In addition to mortality, both the disease and
its treatment often result in significant patient morbidity. Indeed, treatments for HNSC
often impact the most personal characteristics of an individual, including facial appearance
and the ability to eat and speak.
Infection with human papillomavirus (HPV) is a major etiological factor for tumors located
in the oropharynx. Indeed, HPV-positive (HPV+) HNSC is increasing at an epidemic pace
(Marur et al., 2010; Nichols et al., 2013). Importantly, HPV-negative (HPV–) and HPV+
HNSC are molecularly distinct, with a different spectrum of mutations (The Cancer
Genome Atlas Research Network, 2015). HPV+ HNSC also constitutively express viral
oncogenes that deregulate cell growth and gene expression (Mittal and Banks, 2017). In
addition, clinical outcomes for HPV+ HNSC are far superior to those in HPV– cases (Ang
et al., 2010; Fakhry et al., 2008).
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Both HPV+ and HPV– HNSC display a comparable frequency of somatic mutations, a
major source of tumor specific neoantigens that can be recognized and targeted by antitumor immunity (The Cancer Genome Atlas Research Network, 2015). However, HPV+,
but not HPV–, HNSC express exogenous antigenic viral proteins that may be the source of
a key difference in the tumor immune landscape between these two types of HNSC and
may contribute to the superior clinical outcomes associated with HPV+ HNSC. Several
studies have compared various immunological parameters between HPV+ and HPV–
HNSC and have commonly concluded that HPV+ HNSC are immune “hot” tumors, with
markedly more immune infiltration and higher levels of CD8+ T-cell activation than HPV–
HNSC (Mandal et al., 2016; Solomon et al., 2018). These and other studies suggest that a
detailed comparison of the immunological differences between HPV+ and HPV– HNSC
provides an opportunity to identify immunological determinants that contribute to
successful treatment in HNSC that may be broadly applicable to cancer treatment in general
(Feng et al., 2017; Lyford-Pike et al., 2013; Montler et al., 2016).
In this study, we used RNA-sequencing data from over 500 HNSC samples from The
Cancer Genome Atlas (TCGA) to compare the immune landscape between HPV+, HPV–,
and normal-adjacent control tissue. Importantly, these samples were treatment-naïve prior
to surgical resection, avoiding any confounding effects of exposure to chemotherapy or
radiation on the immune-status of these tumors. Such analysis can provide scientific
rationale for treating HNSC patients with immune checkpoint inhibitors (ICIs) as first-line
therapy.
We determined that HPV+ HNSC tumors exhibit a strong Th1 response, characterized by
increased infiltration with dendritic cells (DCs), CD4+ and CD8+ T-cells. HPV+ HNSC
also expressed higher levels of CD39 and multiple T-cell exhaustion markers including
LAG3, PD1, TIGIT, and TIM3 compared to HPV– HNSC. This gene expression profile is
consistent with a “T-cell-inflamed” phenotype, one that is dominated by T-cell markers
and chemokines associated with effector T-cell recruitment (Gajewski et al., 2013).
Importantly, higher expression of these T-cell exhaustion genes correlated with markedly
improved patient survival in HPV+, but not HPV–, HNSC. These results illustrate the
profound differences between the immune landscape of HPV+ and HPV– HNSC tumors
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and its association with patient outcome. Furthermore, the presence of high expression
levels of multiple immune inhibitory genes in HPV+ HNSC suggests that these cancers
will exhibit strong beneficial responses to immunotherapy, providing a strong rationale for
using ICIs as single treatment or combination therapies in first-line treatment of HPV+
HNSC. This would save patients from disfiguring surgery, or the toxicities associated with
conventional chemotherapy or radiation treatment.

4.2 Materials and Methods
4.2.1

Data collection

Patient data from The Cancer Genome Atlas (TCGA), including Merged Clinical data
(build 2016012800) and Level 3 RSEM-normalized Illumina HiSeq RNA expression data
(build 2016012800) for the HNSC cohort, was downloaded from the Broad Genome Data
Analysis Centers Firehose server (https://gdac.broadinstitute.org/). Written informed
consents were obtained from the patients (or their families) by the TCGA project.
CIBERSORT immune fraction data (TCGA.Kallisto.fullIDs.cibersort.relative.tsv) and
Leukocyte Fraction (TCGA_all_leuk_estimate.masked.20170107.tsv) data from the PanCancer Atlas was downloaded from the National Cancer Institute Cancer Genome
Commons (https://gdc.cancer.gov/about-data/publications/panimmune).

4.2.2

RNA expression comparisons

RNA-Seq by Expectation Maximization (RSEM)-normalized expression data was
extracted into Microsoft Excel and the HPV status was manually curated based on
published datasets as described (Gameiro et al., 2017a). Primary patient samples with
known HPV status were grouped as HPV+, HPV–, or normal control tissue. This
classification agrees completely with work done by others (Chakravarthy et al., 2016), with
the exception of sample TCGA-BB-7862‐01A. That sample had minimal reads aligning to
the HPV genome, none of which aligned to the HPV16 E6 or E7 oncogenes, and we
classified this sample as HPV– rather than HPV+. Patient samples with unknown HPV
status were omitted from our calculations, as were samples obtained from secondary
metastatic lesions. This resulted in 73 HPV+, 442 HPV–, and 43 normal control samples
with data available for the HNSC gene expression analysis. This surgically managed cohort
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was considered treatment-naïve, as only 9 patients received neoadjuvant radiation or
chemotherapy treatment (2 HPV+, 7 HPV–). Boxplot comparison of gene expression was
performed using GraphPad Prism v7.0 (Graphpad Software, Inc., San Diego, California,
USA) and assembled into final form using Adobe Illustrator. For the boxplots, center lines
show the medians, box limits indicate the 25th and 75th percentiles as determined by
Graphpad Prism, and whiskers extend 1.5 times the interquartile range from the 25th and
75th percentiles. Statistical significance was calculated using Graphpad Prism. p-values
were assigned using a one-tailed non-parametric Mann-Whitney U test. Selected genes
were compared in a pairwise fashion and concordance calculated using Spearman’s Rho
analysis. Differences were considered to be statistically significant for p < 0.05.

4.2.3

Immune fraction estimates

The relative fractions of 22 leukocyte types as calculated using CIBERSORT (Newman et
al., 2015) was previously reported for all TCGA samples as part of the Pan-Cancer Atlas
(Thorsson et al., 2018). Only those HNSC samples with a CIBERSORT p < 0.01 were
included in our analysis, which resulted in 28 HPV+, 209 HPV–, and 17 normal control
samples used in this analysis. The total leukocyte fraction was also previously reported for
all TCGA samples as part of the Pan-Cancer Atlas. The HNSC values were extracted from
this data and annotated for HPV status as described above.

4.2.4

Survival analysis

Five-year overall survival outcomes and disease-free progression were compared in both
HPV+ and HPV– subsets of patients as dichotomized by median expression of LAG3, PD1,
TIGIT, TIM3, or CD39. A second set of survival outcomes were done to compare tumors
expressing high levels of each combination of two of these markers. Log-rank statistical pvalues were calculated for each Cox survival model. Univariate survival analysis was done
through R statistical environment (version 3.4.0) based on a Cox Proportional Hazard
Model using survival package (version 2.41-3). Stepwise bidirectional multivariate
analysis was then carried out with clinical variables (sex, age, smoking history, subsite, T
stage, N stage, Overall stage, and HPV type), LAG3, PD1, TIGIT, TIM3, and CD39
expression. The p-values derived from the Wald test on survival coefficients were reported
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for investigated variables. The derived log-rank p-values for all tested genes (Table 4.1)
were assessed for significance after correcting for false discovery rate (FDR) using the
Benjamini–Hochberg method, and an FDR threshold of 0.1 was set for significance.

4.3 Results
4.3.1

HPV+ and HPV– head & neck carcinomas exhibit differences
in some leukocyte populations

To identify and understand differences in the immune landscape between HPV+ and HPV–
HNSC, we conducted a preliminary analysis using the CIBERSORT deconvolution
algorithm in order to elucidate the immune cell populations present in each sample
(Newman et al., 2015). This computational method is based on the differential expression
of 547 genes to estimate the relative fraction of 22 leukocyte populations in each of the
samples for the TCGA HNSC cohort (Figure 4.1). Our comparison of the HPV+ and HPV–
samples revealed a number of differences, including an increased percentage of CD8+ Tcells and CD4+ T-regulatory cells (Tregs) in HPV+ samples compared to HPV– samples.
HPV+ samples were also estimated to contain a greatly decreased level of uncommitted
(M0) and anti-inflammatory (M2) macrophages as compared to HPV– samples. Increased
levels of follicular helper CD4+ T-cells, but not other types of CD4+ T-cells, were present
in HPV+ versus HPV– HNSC samples, as well increased levels of naïve and memory Bcells, but not plasma cells. These data indicate a difference between the immune landscape
of HPV+ and HPV– HNSC tumors that requires further investigation.
Given the observed differences in the various leukocyte populations, we also compared the
total leukocyte fraction between the HPV+ and HPV– samples in the TCGA HNSC cohort
using a previously defined DNA methylation signature that is highly specific for leukocytes
(Hoadley et al., 2018). However, no significant differences were detected between the
overall leukocyte fraction of HPV+ versus HPV– HNSC (Figure 4.2).

4.3.2

HPV+ head & neck carcinomas exhibited a Th1 CD4+ helper
T-cell phenotype

CIBERSORT identified a number of differences between HPV+ and HPV– HNSC samples
for multiple classes of T-cells, however, cancer-induced dysregulations and immune
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Table 4.1. Analysis of significance between gene expression and survival (overall and
disease-free) after correcting for false discovery rate (FDR).
Gene
CD8A
CD8B
FOXP3
TBX21
CD6
CD3D
CD3E
CD3G
SH2D1A
TRAT1
XCL1
XCL2
NCR1
KIR2DL3
KIR3DL1
KIR3DL2
IL21R
FPR1
NCAM1
MS4A2
CD84
LAG3
CD19
CD103
ITGB7
KLRB1
CD4
TIM3
PDCD1
GATA3
STAT6
XCR1
CD141
IRF8
CD137
FCGR3A
IL6R
IL10RB
IL12A
IL12B
CD11A
CD11B
CD11C
IDO1
BIN1
IFNG
TNF
RORC
RORA

All HNSC
Overall
Disease-free
Survival
Survival
p
p
FDR
FDR
value
value
0.031
0.091 0.620 0.730
0.118
0.208 0.426 0.566
0.014
0.052 0.007 0.093
0.277
0.367 0.927 0.927
0.002
0.014 0.204 0.403
0.015
0.052 0.488 0.623
0.001
0.014 0.091 0.269
0.002
0.014 0.264 0.463
0.010
0.043 0.202 0.403
0.028
0.087 0.055 0.210
0.755
0.805 0.659 0.752
2.4e-04 0.005 0.278 0.463
0.008
0.037 0.144 0.325
0.091
0.169 0.078 0.263
0.005
0.026 0.009 0.093
0.025
0.082 0.042 0.171
0.032
0.091 0.013 0.093
0.726
0.786 0.067 0.241
0.005
0.026 0.178 0.385
0.002
0.014 0.017 0.113
0.357
0.446 0.095 0.269
0.245
0.346 0.227 0.433
2.1e-05 0.001 0.042 0.171
0.693
0.763 0.008 0.093
0.015
0.052 0.314 0.495
1.2e-04 0.004 0.028 0.139
0.057
0.126 0.007 0.093
0.875
0.903 0.081 0.263
0.076
0.160 0.818 0.872
0.496
0.608 0.367 0.508
0.561
0.663 0.114 0.296
0.085
0.167 0.001 0.048
0.258
0.357 0.577 0.708
0.316
0.402 0.140 0.325
0.088
0.168 0.012 0.093
0.952
0.964 0.272 0.463
0.238
0.346 0.243 0.450
0.244
0.346 0.351 0.495
0.192
0.297 0.489 0.623
0.042
0.104 0.703 0.788
0.034
0.092 0.205 0.403
0.646
0.737 0.093 0.269
0.124
0.212 0.398 0.539
0.040
0.104 0.122 0.304
0.820
0.860 0.629 0.730
0.047
0.112 0.787 0.855
0.079
0.160 0.789 0.855
0.102
0.185 0.102 0.275
0.148
0.247 0.009 0.093

HPV+ HNSC
Overall
Disease-free
Survival
Survival
p
p
FDR
FDR
value
value
0.023 0.087 0.821 0.937
0.009 0.058 0.614 0.912
0.039 0.115 0.380 0.912
0.004 0.047 0.814 0.937
0.027 0.090 0.647 0.912
0.069 0.164 0.711 0.912
0.005 0.047 0.576 0.912
0.076 0.165 0.582 0.912
0.035 0.107 0.603 0.912
0.003 0.047 0.383 0.912
0.271 0.385 0.423 0.912
0.073 0.164 0.432 0.912
0.095 0.175 0.694 0.912
0.498 0.589 0.044 0.912
0.258 0.381 0.923 0.968
0.020 0.083 0.385 0.912
0.049 0.127 0.365 0.912
0.690 0.729 0.068 0.912
0.701 0.729 0.364 0.912
0.405 0.510 0.734 0.912
0.004 0.047 0.569 0.912
0.047 0.127 0.343 0.912
0.134 0.229 0.630 0.912
0.257 0.381 0.219 0.912
0.028 0.090 0.277 0.912
0.006 0.048 0.847 0.947
0.073 0.164 0.598 0.912
0.019 0.083 0.151 0.912
0.013 0.075 0.265 0.912
0.305 0.421 0.744 0.912
0.397 0.510 0.525 0.912
0.512 0.594 0.530 0.912
0.415 0.510 0.472 0.912
0.097 0.175 0.621 0.912
0.416 0.510 0.422 0.912
0.134 0.229 0.100 0.912
0.082 0.172 0.953 0.968
0.706 0.729 0.729 0.912
0.898 0.898 0.996 0.996
0.272 0.385 0.289 0.912
0.016 0.081 0.701 0.912
0.089 0.175 0.081 0.912
0.345 0.458 0.335 0.912
0.664 0.729 0.233 0.912
0.340 0.458 0.441 0.912
0.095 0.175 0.930 0.968
0.015 0.079 0.807 0.937
0.554 0.632 0.111 0.912
0.694 0.729 0.107 0.912

HPV– HNSC
Overall
Disease-free
Survival
Survival
p
p
FDR
FDR
value
value
0.481 0.795 0.955 0.955
0.538 0.795 0.653 0.912
0.154 0.454 0.016 0.209
0.280 0.634 0.777 0.935
0.011 0.200 0.696 0.912
0.136 0.449 0.917 0.955
0.042 0.343 0.429 0.846
0.091 0.449 0.881 0.954
0.145 0.449 0.726 0.912
0.517 0.795 0.724 0.912
0.536 0.795 0.499 0.854
0.021 0.267 0.484 0.854
0.111 0.449 0.186 0.626
0.336 0.693 0.158 0.626
0.049 0.357 0.261 0.678
0.979 0.982 0.671 0.912
0.283 0.634 0.239 0.675
0.804 0.886 0.291 0.701
0.034 0.316 0.179 0.626
0.004 0.200 0.009 0.203
0.888 0.962 0.036 0.293
0.706 0.846 0.927 0.955
0.012 0.200 0.405 0.823
0.622 0.843 0.009 0.203
0.025 0.271 0.156 0.626
0.012 0.200 0.322 0.720
0.500 0.795 0.033 0.293
0.582 0.822 0.498 0.854
0.399 0.740 0.816 0.936
0.691 0.846 0.330 0.720
0.763 0.885 0.186 0.626
0.132 0.449 0.003 0.163
0.798 0.886 0.291 0.701
0.716 0.846 0.254 0.678
0.778 0.886 0.090 0.534
0.635 0.843 0.484 0.854
0.454 0.795 0.353 0.741
0.161 0.455 0.196 0.626
0.510 0.795 0.744 0.912
0.532 0.795 0.870 0.954
0.662 0.846 0.689 0.912
0.958 0.982 0.090 0.534
0.177 0.472 0.736 0.912
0.524 0.795 0.946 0.955
0.697 0.846 0.707 0.912
0.141 0.449 0.801 0.936
0.182 0.472 0.675 0.912
0.070 0.449 0.036 0.293
0.338 0.693 0.015 0.209
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Table 4.1. (continued). Analysis of significance between gene expression and survival
(overall and disease-free) after correcting for false discovery rate (FDR).
Gene
CXCR3
STAT4
CCR5
CCL3
CCL4
CXCL1
CXCR6
CXCL2
TIGIT
CD39
GZMA
GZMB
PRF1
PDL1
IL23A
EBI3

All HNSC
Overall
Disease-free
Survival
Survival
p
p
FDR
FDR
value
value
0.002
0.014 0.011 0.093
0.658
0.738 0.342 0.495
0.058
0.126 0.145 0.325
0.532
0.641 0.312 0.495
0.964
0.964 0.845 0.885
0.182
0.288 0.332 0.495
0.001
0.014 0.267 0.463
0.200
0.303 0.022 0.127
0.005
0.026 0.351 0.495
0.011
0.043 0.038 0.171
0.157
0.255 0.913 0.927
0.306
0.398 0.624 0.730
0.052
0.120 0.538 0.672
0.591
0.686 0.862 0.890
0.005
0.026 0.027 0.139
0.266
0.360 0.330 0.495

HPV+ HNSC
Overall
Disease-free
Survival
Survival
p
p
FDR
FDR
value
value
0.005 0.047 0.664 0.912
0.685 0.729 0.254 0.912
0.002 0.047 0.720 0.912
0.189 0.313 0.395 0.912
0.043 0.122 0.097 0.912
0.096 0.175 0.546 0.912
0.007 0.048 0.950 0.968
0.020 0.083 0.537 0.912
0.027 0.090 0.581 0.912
0.001 0.047 0.649 0.912
0.218 0.346 0.860 0.947
0.237 0.366 0.245 0.912
0.192 0.313 0.909 0.968
0.430 0.518 0.355 0.912
0.051 0.127 0.390 0.912
0.813 0.826 0.800 0.937

HPV– HNSC
Overall
Disease-free
Survival
Survival
p
p
FDR
FDR
value
value
0.215 0.537 0.143 0.626
0.692 0.846 0.202 0.626
0.579 0.822 0.709 0.912
0.610 0.843 0.126 0.626
0.930 0.975 0.556 0.912
0.397 0.740 0.332 0.720
0.093 0.449 0.955 0.955
0.923 0.975 0.112 0.606
0.127 0.449 0.726 0.912
0.100 0.449 0.078 0.534
0.366 0.720 0.821 0.936
0.135 0.449 0.737 0.912
0.260 0.625 0.626 0.912
0.341 0.693 0.457 0.854
0.097 0.449 0.230 0.675
0.982 0.982 0.845 0.947
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Figure 4.1. The relative fraction of immune cell populations in head & neck
carcinomas stratified by HPV status.
The relative population of 22 leukocyte types present in the tumor microenvironment was
determined by the CIBERSORT algorithm and compared between HPV+, HPV–, and
normal control samples. Four leukocyte types (neutrophils, eosinophils, naïve CD4+ Tcells, and gamma delta T-cells) are not shown, as they were undetectable in this cohort.
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant.
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Figure 4.2. No differences in total leukocyte fraction were detected between HPV+
and HPV– HNSC samples.
Total leukocyte fraction as estimated by a DNA methylation signature was extracted for
all HNSC samples in the TCGA dataset and annotated for HPV status. Numbers in brackets
refer to the number of samples included in each analysis. ns – not significant.
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cell phenotypic plasticity can limit the ability of CIBERSORT to accurately characterize
immune components of the tumor microenvironment (Newman et al., 2015). Therefore,
we began a detailed and mechanistically oriented comparison of the immune responses in
HPV+ versus HPV– HNSC. CD4+ helper T-cells are instrumental in establishing the type
of response triggered by immune activation, whether it be a cell-mediated Th1 response, a
humorally-biased Th2 response, or the proinflammatory Th17 response necessary to
maintain the immunological integrity of mucosal barriers (Mucida and Salek-Ardakani,
2009). Each of the CD4+ subsets are characterized by a distinct transcriptional program
regulated by specific master regulatory transcription factors (Fang and Zhu, 2017). To
examine the tumor immune landscape of HPV+ and HPV– HNSC, we analyzed the TCGA
Illumina HiSeq RNA expression data from the HNSC cohort for expression of TBX21
(Th1), GATA3 and STAT6 (Th2), and RORA and RORC (Th17) (Figure 4.3). As expected,
a strong Th17 signature was observed in normal control samples, and that signature
expression profile was markedly reduced in HPV+ and HPV– carcinomas (Figure 4.3A).
HPV+ samples had significantly increased levels of TBX21 as compared to HPV– and
normal control samples, indicative of a polarization toward a Th1 response (Figure 4.3B).
A modest increase in GATA3 accompanied by a reduction in STAT6 was observed in HPV+
samples versus normal control samples (Figure 4.3C). Taken together, these results
indicate that a strong shift in the normal Th17 bias towards Th1 occurred in HNSC, with a
significantly accentuated Th1 signature in HPV+ versus HPV– carcinomas.

4.3.3

Higher levels of CD4+ and CD8+ T-cells were present in HPV+
head & neck carcinomas

We next assessed the relative proportion of CD4+ and CD8+ T-cells in these samples, based
on relative expression of the lineage defining CD4 and CD8A/CD8B marker genes,
respectively (Figures 4.4A and B). HPV+ samples showed significantly increased
expression of all three genes versus HPV– HNSC or normal control samples, confirming
that enhanced T-cell infiltration is a common feature of HPV+ HNSC. We also observed
significantly higher FOXP3 expression in HPV+ HNSC compared to HPV– HNSC and
normal control samples. FOXP3 is associated with Tregs infiltrating into these tumor
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Figure 4.3. Expression of marker genes indicating CD4+ helper T-cell subsets present
in head & neck carcinomas stratified by HPV status.
Normalized RNA-seq data for RORA and RORC (Th17) (A), TBX21 (Th1) (B), and GATA3
and STAT6 (Th2) (C) was extracted from The Cancer Genome Atlas (TCGA) database for
the head & neck cancer (HNSC) cohort for HPV+, HPV−, and normal control tissues.
Numbers in brackets refer to the number of samples included in each analysis. * p ≤ 0.05,
** p ≤ 0.01, **** p ≤ 0.0001, ns – not significant.
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(Figure 4.4C). Furthermore, analysis of the expression of CD137 (4-1BB), an activationinduced costimulatory molecule present primarily on CD8+ T-cells, detected significantly
higher levels in HPV+ versus HPV– or normal control samples, suggesting a higher overall
level of T-cell activation and effector function in HPV+ disease (Figure 4.4D).
Activated cytotoxic CD8+ T-cells produce various effector molecules, including IFNγ and
TNF. Although expression of IFNγ mRNA (IFNG) in these samples was low, it was
detectable at significantly higher levels in HPV+ samples versus HPV– HNSC or normal
control tissues. No significant difference was observed for TNF (Figure 4.4E). HPV+
HNSC tumors also expressed significantly higher levels of cytotoxic mediators, including
granzyme A (GRZA), granzyme B (GRZB), and perforin (PRF1) compared to both HPV–
HNSC or normal control tissues (Figure 4.5A). Taken together, these results indicate CD8+
T-cells are not only present at higher levels in HPV+ HNSC, but are concomitantly more
active and producing effector molecules such as IFNγ, granzyme A, granzyme B, and
perforin, but not TNF. We also observed low—but significantly higher than in HPV–
HNSC or normal control tissues—expression levels of genes associated with natural killer
(NK)-cells (SH2D1A, XCL2, NCR1, KIR2DL3, KIR3DL1, and KIR3DL2) and B-cells
(IL21R and CD19) in HPV+ tumors indicating higher infiltration of these immune cells
into HPV+ HNSC (Figures 4.5B and C, respectively). While many of these observations
agree with the CIBERSORT estimations (Figure 4.1), there are some differences. In some
cases, this may be related to the use of different marker genes, or to the fact that
CIBERSORT divides some classes of leukocytes into multiple subcategories based on a
gene signature that can be affected by disease dysregulation.

4.3.4

Interferon γ-induced immunomodulatory genes are expressed
at higher levels in HPV+ head & neck carcinomas

An expected consequence of higher levels of infiltrating CD8+ T-cells producing IFNγ
would be induction of expression of interferon response genes in tumor cells in close
proximity to the infiltrating T-cells. Indeed, we previously reported that multiple interferon
responsive components of the MHC-I antigen presentation apparatus were upregulated in
HPV+ HNSC (Gameiro et al., 2017b). We extended those studies to PDL1 and IDO1, two
immunomodulatory genes known to be expressed by tumor cells in response to IFNγ
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Figure 4.4. Detection of tumor infiltrating T-cells and their activation status in head
& neck carcinomas stratified by HPV status.
Normalized RNA-seq data for genes indicative of tumor infiltrating CD4+ (CD4) (A),
CD8+ (CD8A and CD8B) (B), or regulatory (C) T-cells and their activation status (CD137,
IFNG, and TNF) (D, E) was extracted from the TCGA database for the HNSC cohort for
HPV+, HPV–, and normal control tissues. Numbers in brackets refer to the number of
samples included in each analysis. **** p ≤ 0.0001, ns – not significant.

108

Figure 4.5. Detection of immune effector molecules and tumor-infiltrating NK-cells
and B-cells in head & neck carcinomas stratified by HPV status.
Normalized RNA-seq data for genes indicative of tumor infiltrating: Effector molecules
(GZMA, GZMB, and PRF1) (A), NK-cells (SH2D1A, XCL2, NCR1, KIR2DL3, KIR3DL1,
and KIR3DL2) (B), and B-cells (IL21R and CD19) (C) was extracted from the TCGA
database for the HNSC cohort for HPV+, HPV–, and normal control tissues. Numbers in
brackets refer to the number of samples included in each analysis. **** p ≤ 0.0001.
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(Figure 4.6). Both PDL1 and IDO1 were significantly upregulated in HPV+ HNSC
compared to normal control samples. While IDO1 was also significantly upregulated
compared to HPV– HNSC, no significant difference was observed between PDL1
expression in HPV+ versus HPV– carcinomas. Interestingly, BIN1 expression was
significantly downregulated in HPV+ compared to both HPV– HNSC and normal control
samples (Figure 4.6). As BIN1 is a negative regulator of IDO expression and deletion of
BIN1 increases IFNγ stimulation of IDO1 gene expression, these results are consistent with
the higher levels of IDO1 observed in both HPV+ and HPV– HNSC (Muller et al., 2005).
Taken together, these data (Figures 4.4–4.6) indicate that HPV+ HNSC, in treatment-naïve
patients, shows a T-cell-inflamed phenotype (Gajewski et al., 2013).

4.3.5

Dendritic cell signatures are elevated in HPV+ head & neck
carcinomas

Because HPV+ HNSC displayed a T-cell-inflamed phenotype and DCs play a key role as
professional antigen-presenting cells to stimulate T-cell function, we performed an analysis
of DC signatures in these tumors. Using the expression of mRNA encoding CD103 and
CD11C to detect DCs in tumor samples, we found that both genes are expressed at higher
levels in HPV+ HNSC compared to normal control samples (Figure 4.7A). While CD103
was expressed at significantly higher levels in HPV+ versus HPV– carcinomas, CD11C
was not. We also determined that there was a modest but significant correlation between
CD103 and CD11C in individual tumors (Figure 4.7A; r = 0.56, p = 2.6e-07). This
suggested that these markers tended to be coordinately expressed, although the link was
not strong enough to lead to increased CD11C expression in HPV+ carcinomas in accord
with increased CD103.
A key anti-tumor role for DCs is to express effector cytokines such as IL12 and IL23 that
mediate CD8+ T-cell activation and IFNγ production. While IL12A mRNA levels in HPV+
samples were not significantly induced versus normal control tissue, they were elevated
compared to HPV– HNSC (Figure 4.7B). IL12 activates STAT4 signaling, which is
critical for anti-tumor immunity (Lund et al., 2004). Notably, STAT4 expression levels
were higher in HPV+ HNSC tumors (Figure 4.7B). Activated DCs also produce IL23—
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Figure 4.6. Transcript levels of tumor-derived IFNg-responsive immunomodulatory
genes in head & neck carcinomas stratified by HPV status.
Normalized RNA-seq data for genes associated with tumor cell mediated immunemodulation including IDO1, its negative regulator BIN1, and PDL1 was extracted from the
TCGA database for the HNSC cohort for HPV+, HPV–, and normal control tissues.
Numbers in brackets refer to the number of samples included in each analysis. ** p ≤ 0.01,
**** p ≤ 0.0001, ns – not significant.
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Figure 4.7. Detection of dendritic cells and their effector cytokines in head & neck
carcinomas stratified by HPV status.
Normalized RNA-seq data for genes indicative of tumor infiltrating dendritic cells (CD103
and CD11C) (A) and genes encoding cytokines indicative of dendritic cell activation status
(IL12A, STAT4, IL23A, and EBI3) (B) was extracted from the TCGA database for the
HNSC cohort for HPV+, HPV–, and normal control tissues. Numbers in brackets refer to
the number of samples included in each analysis. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤
0.0001, ns – not significant.
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a proinflammatory cytokine—that induces IFNγ secretion from activated CD4+ T-cells
(Shi et al., 2015). IL23A levels were higher in HPV+ HNSC than HPV– tumors and normal
control samples (Figure 4.7B). Moreover, Epstein-Barr virus-induced gene 3 (EBI3)
transcripts that encode a component of IL27—a cytokine that synergizes with IL12 and
induces IFNγ production by naïve CD4+ T-cells (Pflanz et al., 2002)—were significantly
higher in HPV+ than HPV– tumors and normal control samples (Figure 4.7B). We were
not able to analyze the other two genes within the IL12 family of cytokines—IL12B and
IL27A—because their RNA transcripts were not detectable in the majority of tumor and
normal control samples. Finally, we looked at a number of inflammatory chemokines and
chemokine receptors that are crucial for DC and T-cell recruitment to tumors (Castellino
et al., 2006; Chen et al., 2018a; Mikucki et al., 2016; Mitchell et al., 2015). CCR5, CCL4,
and CXCR3 were highly expressed in HPV+ HNSC compared to HPV– tumors and normal
control samples, while CCL3 expression was elevated in HPV+ HNSC compared to normal
control samples (Figure 4.8). Overall, these results indicate a higher level of DC
involvement in HPV+ than in HPV– HNSC, with higher levels of effector cytokines that
could be responsible for the elevated levels of T-cell infiltration of these samples.

4.3.6

HPV+ head & neck carcinomas expressed high levels of
multiple T-cell exhaustion markers

Once activated, T-cells upregulate expression of multiple cell surface receptors that
negatively regulate their proliferation and moderate their level of activation. These socalled “exhaustion markers” include LAG3, PD1, TIGIT, and TIM3 (Anderson et al.,
2016). They are important targets for immune checkpoint blockade therapies that are
approved or under development. Notably, all four of these checkpoint genes were
significantly upregulated in HPV+ compared with HPV– HNSC or normal control samples
(Figure 4.9). We also determined that individual tumors expressing high levels of any one
of these T-cell inhibitory genes generally co-expressed high levels of the other exhaustion
markers (r values ranging from 0.78 to 0.9), suggesting that these genes are coordinately
expressed (Figure 4.10). We also examined the expression of the immunosuppressive
molecule CD39 (Jie et al., 2013) in this cohort of patients. CD39 was recently shown to be
exclusively expressed on tumor antigen-specific CD8+ T-cells and not bystander CD8+
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Figure 4.8. Detection of dendritic cell-associated chemokines and receptors in head &
neck carcinomas stratified by HPV status.
Normalized RNA-seq data for genes indicative of dendritic cell-associated chemokines and
receptors (CCR5, CCL3, CCL4, and CXCR3) was extracted from the TCGA database for
the HNSC cohort for HPV+, HPV–, and normal control tissues. Numbers in brackets refer
to the number of samples included in each analysis. *** p ≤ 0.001, **** p ≤ 0.0001, ns –
not significant.
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Figure 4.9. Transcript levels of T-cell exhaustion marker genes and CD39 in head &
neck carcinomas stratified by HPV status.
Normalized RNA-seq data for genes associated with T-cell exhaustion (LAG3, PD1,
TIGIT, and TIM3) and CD39 was extracted from the TCGA database for the HNSC cohort
for HPV+, HPV–, and normal control tissues. Numbers in brackets refer to the number of
samples included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.
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Figure 4.10. HPV+ head & neck carcinomas concordantly express multiple markers
of T-cell exhaustion.
Normalized RNA-seq data for LAG3, PD1, TIGIT, and TIM3 was compared in a pairwise
fashion in HPV+ HNSC samples and concordance calculated by Spearman’s Rho analysis.
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T-cells in colorectal and lung tumors (Simoni et al., 2018). Notably, CD39 showed
significantly higher RNA expression levels in HPV+ HNSC tumors compared to HPV–
HNSC samples (Figure 4.9). Interestingly, individual tumors expressing high levels of
CD39 also co-expressed high levels of the four exhaustion markers (r values ranging from
0.37 to 0.62), suggesting that these genes are coordinately expressed (Figure 4.11). Taken
together, HPV+ HNSC display a markedly different immune signature from HPV– HNSC,
indicative of sustained CD8+ T-cell activation in HPV+ HNSC.

4.3.7

High levels of T-cell exhaustion markers correlated with
improved survival of HPV+ head & neck carcinomas

High CD8+ T-cell infiltration into HNSC tumors has been previously linked to better
patient outcome (de Ruiter et al., 2017). Moreover, expression of checkpoint molecules
such as PD1 on circulating CD8+ T-cells is a biomarker of tumor antigen specificity (Gros
et al., 2016). We therefore dichotomized the HPV+ HNSC data set based on median LAG3,
PD1, TIGIT, or TIM3 expression and calculated the impact of high versus low expression
on overall patient survival (Figure 4.12, black and red curves). Higher than median
expression of any of these genes predicted markedly improved survival in HPV+ HNSC
over those patients with tumors expressing these markers at levels below the median. This
sharp overall increase in clinical outcome was also statistically significant following
correction for multiple testing in all the assessed genes, with the exception of LAG3 (Table
4.1). In contrast, a similar analysis did not reveal any survival advantage for HPV– samples
expressing higher levels of LAG3, PD1, TIGIT, or TIM3 (Figure 4.12, green and purple
curves).
Given our observation that HPV+ tumors expressing high levels of LAG3, PD1, TIGIT, or
TIM3 transcripts generally displayed higher levels of at least one more of these exhaustion
markers (Figure 4.10), we repeated the survival analysis by comparing HPV+ HNSC
samples that were above the median expression for each combination of two markers to
those below the median for both markers (Figure 4.13, black and red curves).
Remarkably, overall survival for patients with high expression of any combination of two
of the T-cell exhaustion markers identified individuals with a virtual certainty of long-term
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Figure 4.11. HPV+ head & neck carcinomas express CD39 concordantly with multiple
markers of T-cell exhaustion.
Normalized RNA-seq data for CD39 was compared in a pairwise fashion to LAG3, PD1,
TIGIT, and TIM3 in HPV+ HNSC samples. Concordance was calculated by Spearman’s
Rho analysis.
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Figure 4.12. High LAG3, PD1, TIGIT, or TIM3 gene transcript levels are strongly
associated with improved survival in treatment naïve patients with HPV+ but not
HPV– head & neck carcinomas.
Overall survival of patients within the HPV+ cohort dichotomized by median expression
of LAG3, PD1, TIGIT, or TIM3. Comparison between groups was made by the 2-sided logrank test. Red = low expression of the indicated gene in HPV+ samples, Black = high
expression of the indicated gene in HPV+ samples, Purple = low expression of the indicated
gene in HPV– samples, Green = high expression of the indicated gene in HPV– samples.

119

Figure 4.13. Concordant levels of multiple markers of T-cell exhaustion is strongly
associated with survival in patients with HPV+ head & neck carcinomas.
Overall survival of patients within the HPV+ cohort dichotomized by median transcript
levels of the indicated pairs of T-cell exhaustion markers. Comparison between groups was
made by the 2-sided log-rank test. Red = low expression of the indicated gene in HPV+
samples, Black = high expression of the indicated gene in HPV + samples, Purple = low
expression of the indicated gene in HPV– samples, Green = high expression of the
indicated gene in HPV– samples.
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survival. No improvement was seen when a similar analysis was performed using the
HPV– HNSC cohort (Figure 4.13, green and purple curves). These results suggest that
the co-expression of high levels of LAG3, PD1, TIGIT, and TIM3 in HPV+ HNSC reflect
the successful development of T-cell-based anti-tumor immunity and a T-cell-inflamed
phenotype, which contributed to long-term remission. This immune signature could be
used as a predictive biomarker of HPV+ HNSC patient outcome after surgery.

4.3.8

High levels of CD39 correlated with improved survival of
HPV+ head & neck carcinomas

We also dichotomized the HPV+ and HPV– HNSC data set based on median CD39
expression and calculated the impact of high versus low expression on overall patient
survival (Figure 4.14). Higher than median expression of CD39 predicted markedly
improved survival in HPV+ HNSC over those patients with tumors expressing this marker
at levels below the median. This sharp overall increase in clinical outcome was also
statistically significant. Similar to our previous analysis (Figure 4.13), a combination of
CD39 and any of the T-cell exhaustion markers identified long-term survivors in HPV+
HNSC (Figure 4.14).
We next applied the Cox Proportional Hazards model to identify clinical variables and
immunological markers predictive of overall survival (Table 4.2). By univariate analysis
high expression of TIGIT, TIM3, PD1, and CD39 were correlated with favorable prognosis
(HzR = 0.29, 0.24, 0.22, and 0.15 respectively, p < 0.05), while an HPV type other than
HPV16 was associated with a markedly poorer survival (HzR = 3.22, p = 0.03). Oral cavity
tumors had significantly worse survival compared those in the oropharyngeal subsite (HzR
= 3.05, p = 0.03). There was a trend towards improved outcome with high expression of
LAG3 (HzR = 0.32, p = 0.06). Stepwise regression analysis was used to identify the best
multivariate model of survival, and the final model included N stage, HPV type, and CD39.
Notably, CD39 (HzR = 0.07, p = 0.0007), and HPV type (HzR = 9.23, p = 0.001) remained
as significant predictors of survival in the multivariate model.
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Figure 4.14. High CD39 gene transcript level is strongly associated with improved
survival in treatment naïve patients with HPV+ head & neck carcinomas.
Overall survival of patients within the HPV+ and HPV– cohorts were dichotomized by
median expression of CD39 (A). Concordant levels of CD39 and multiple markers of Tcell exhaustion was strongly associated with survival in patients with HPV+ head & neck
carcinomas (B). Overall survival of patients within the HPV+ cohort dichotomized by
median transcript levels of the indicated pairs of T-cell exhaustion markers with CD39.
Comparison between groups was made by the 2-sided log-rank test. Red = low expression
of the indicated gene in HPV+ samples, Black = high expression of the indicated gene in
HPV+ samples, Purple = low expression of the indicated gene in HPV– samples, Green =
high expression of the indicated gene in HPV– samples.
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Table 4.2. Univariate and multivariate analysis of the association of clinical
characteristics and LAG3, PD1, TIGIT, TIM3, and CD39 expression and overall
survival in HPV+ HNSC.
Univariate Analysis
Variables
Sex
Age
Smoking
Subsite
T Stage
N Stage
Overall Stage
HPV Type
LAG3
PD1
TIGIT
TIM3
CD39

Male vs Female
per every additional year
Light vs Non-Smoker
Heavy vs Non-Smoker
Oral cavity vs Oropharynx
Larynx vs Oropharynx
Hypopharynx vs Oropharynx
T3-4 vs T1-2
N2b-N3 vs N0-N2a
IV vs I-III
Other vs 16
High vs Low Expression
High vs Low Expression
High vs Low Expression
High vs Low Expression
High vs Low Expression

HzR (95% CI)
0.95 (0.21 – 4.29)
0.99 (0.94 – 1.05)
0.84 (0.16 – 4.39)
1.99 (0.54 – 7.38)
3.05 (1.09 – 8.49)
1.46e-08 (0 – Inf)
1.57e-08 (0 – Inf)
1.06 (0.37 – 2.99)
0.35 (0.12 – 1.05)
0.80 (0.27 – 2.36)
3.22 (1.10 – 9.45)
0.32 (0.10 – 1.04)
0.22 (0.06 – 0.81)
0.29 (0.09 – 0.93)
0.24 (0.07 – 0.87)
0.15 (0.04 – 0.56)

p
value
0.95
0.77
0.84
0.30
0.03
Inf
Inf
0.92
0.06
0.69
0.03
0.06
0.02
0.04
0.03
0.004

Multivariate Analysis
HzR (95% CI)

p
value

0.24 (0.08 – 0.81)

0.02

9.23 (2.45 – 34.7)

0.001

0.07 (0.02 – 0.34)

0.0007
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4.4 Discussion
Although evading anticancer immunity is one of the hallmarks of cancer,
immunotherapy—also referred to as immuno-oncology—harnesses the power of the
immune system to destroy cancer cells. Durable responses to immunotherapy among
cancer patients are what sets immunotherapy apart from conventional oncology therapies,
including chemotherapy, radiotherapy, and targeted therapy. Cancer immunotherapy is
now widely recognized as having the potential to revolutionize cancer treatment. Despite
the recent “tsunami of immunotherapy in oncology” and many reports of immunotherapy
treatment resulting in near-miraculous cures in cases of highly refractory cancers, in
general only a subset of patients respond to these treatments. The underlying reasons for
response, or lack thereof, remain an intense area of investigation (Routy et al., 2018).
Based on their somatic mutation prevalence (Sadelain et al., 2017), tumors can be
categorized as immunologically “cold” or immunologically “hot”. Immunologically hot
tumors such as melanoma and smoking-induced lung cancer, often respond more favorably
to immune checkpoint inhibition therapy than cold tumors. Therefore, a partial explanation
for immune checkpoint inhibitor response appears to be related to high mutation burden,
which leads to higher levels of tumor-derived neoantigens. Indeed, a significant correlation
exists between immune checkpoint inhibitor response and mutational load across cancer
sites (Yarchoan et al., 2017).
A variety of studies have compared various immunological parameters between HPV+ and
HPV– HNSC and generally concluded that HPV+ HNSC are immune “hot” tumors, with
markedly more immune infiltration and higher levels of CD8+ T-cell activation than HPV–
HNSC (Chen et al., 2018b; Keck et al., 2015; Mandal et al., 2016; Solomon et al., 2018).
Although this is thought to contribute to the improved prognosis of HPV+ HNSC, the
mutational loads in HPV+ and HPV– HNSC are similar therefore the immune hot and cold
model cannot explain the survival differences observed among HNSC patients. However,
HPV+, but not HPV–, HNSC express exogenous antigenic viral oncoproteins that may
represent a key difference in the tumor immune landscape between these two types of
HNSC, giving HPV+ HNSC a T-cell-inflamed phenotype that can at least partially explain
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the better patient outcome in HPV+ HNSC compared to HPV– HNSC. Furthermore, HPV+
HNSC tumors are different from HPV– HNSC tumors at the epigenetic and genomic levels,
but viral etiology alone may not be sufficient to confer favorable outcome in HNSC
(Chakravarthy et al., 2016). Therefore, the substantial differences observed in anti-tumor
immunity between HPV+ and HPV– cancers could be the major source of improved
prognosis in HPV+ tumors.
In this study, for the first time, we report the detailed immune characteristics of T-cellinflamed HPV+ HNSC compared to non-T-cell-inflamed HPV– HNSC. We performed a
mechanistic analysis of the tumor immune landscape in treatment-naïve HNSC using the
TCGA cohort, which allows a detailed and direct comparison between HPV+ and HPV–
HNSC and normal-adjacent control tissue. However, examination of only the RNA
expression levels limits the ability to accurately confirm expression levels on each cell
type. To address this limitation, we primarily used immune lineage-specific markers or
examined co-expression correlations for markers that are expressed by more than one cell
type. We found that HPV+ HNSC has a predominant Th1 immune phenotype (Figure 4.3)
with a significant increase in CD8+ and CD4+ T-cell infiltration compared to HPV– HNSC
(Figure 4.4). Interestingly, higher T-cell infiltration into HPV+ tumors was accompanied
with greater T-cell activation, as shown by high CD137 (4-1BB) gene transcript levels.
Mononuclear cells isolated from patients with advanced head and neck cancer have been
reported to be defective in IFNγ production in vitro (Conti-Freitas et al., 2012). Given the
high CD137 RNA levels in HPV+ HNSC samples, we expected higher effector cytokine
production by T-cells in these samples. Indeed, HPV+ HNSC expressed significantly
higher levels of IFNγ, granzyme A, granzyme B, and perforin compared to HPV– HNSC
or normal control samples, indicating that there remains some T-cell effector functionality
in these tumors. Moreover, the higher levels of CD137 and multiple effector molecules in
HPV+ HNSC could be a consequence of higher infiltration of these tumors with antigenspecific tumor-infiltrating lymphocytes (TILs). In contrast, we did not observe differences
in TNF transcript levels—a critical cytokine for anti-tumor immunity (Calzascia et al.,
2007)—between HPV+ and HPV– HNSC, indicating T-cell dysfunction in these samples.
Given the role of IFNγ in inducing MHC-I expression in tumor cells, these findings explain
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our previous observation that HPV+ HNSC tumors had significantly higher levels of
expression of MHC-I apparatus (Gameiro et al., 2017b). Furthermore, high IFNγ transcript
levels in HPV+ HNSC were associated with significantly higher levels of IFN-responsive
gene transcripts, including IDO and PD-L1 (Figure 4.6). These observations provide a
scientific rationale for combining immunotherapy of HPV+ HNSC with ICIs and IDO
inhibitors in treatment-naïve patients. Currently the only phase II study of such a
combination (NCT03325465) has been canceled in light of the recent failure of combined
IDO inhibition and pembrolizumab in showing advantage in progression-free survival over
pembrolizumab monotherapy in melanoma patients. However, that study (NCT03325465)
was not focused specifically on HPV+ HNSC, which we show here express higher levels
of IDO compared to HPV– HNSC.
The observed increased numbers of CD8+ and CD4+ T-cells in HPV+ HNSC can likely be
explained by the ability of DCs to migrate to these tumors, pick up antigens, and present
those antigens to T-cells (Spranger et al., 2015). Indeed, we observed not only high levels
of transcripts from DC-associated genes, but also molecules expressed by activated DCs,
including chemokines that attract DCs and T-cells into tumors (Figure 4.7 and Figure
4.8). We also observed less M2 macrophages in HPV+ HNSC samples (Figure 4.1)
indicative of less immunosuppressive activity in these tumors compared to HPV– HNSC.
These observations provide a mechanistic insight into the processes that shape the immune
structure of HPV+ HNSC as a T-cell-inflamed tumor.
T-cell-inflamed tumors show high levels of immune regulatory genes including IDO and
PD-L1, and high infiltration of FoxP3+ Tregs (Gajewski et al., 2017), secondary to
cytotoxic T-cell infiltration into those tumors. The presence of these immunosuppressive
events in a T-cell-inflamed microenvironment is often accompanied by increased levels of
multiple T-cell immune checkpoint molecules and T-cell anergy (Gajewski et al., 2017).
Our findings show that HPV+ HNSC, but not HPV– HNSC, have similarly high levels of
multiple immune checkpoint molecules (LAG3, TIM3, PD1, and TIGIT; Figure 4.9),
suggesting that combined immunotherapy with drugs that target more than one of these
inhibitory molecules can be effective in overcoming resistance to anti-tumor immunity in
HPV+ HNSC tumors. There are no such trials currently under way, but these findings
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strongly indicate that initiation of such clinical studies is justified. CD39 is an
immunosuppressive molecule that can be expressed on intratumoral Tregs (Jie et al., 2013)
and tumor-specific CD8+ TILs, but not bystander CD8+ T-cells (Simoni et al., 2018). CD39
RNA expression was higher in both HPV+ and HPV– HNSC tumors compared to normal
control samples (Figure 4.9). Of note, CD39 expression in HPV+ HNSC was significantly
higher than HPV– tumors. CD39 alone or in combination with any of the T-cell exhaustion
markers analyzed above was also a predictive biomarker of survival in HPV+ HNSC
(Figure 4.14). Therefore, CD39 may represent a useful biomarker of survival in HPV+
HNSC. Our findings warrant the initiation of prospective trials in determining the
predictive value of this gene as a potential genomic biomarker correlated with improved
overall survival in HPV+ HNSC.
High T-cell infiltration into HNSC, regardless of HPV status, has been reported as a
positive prognostic factor (Nguyen et al., 2016). We observed that high levels of transcripts
from one or any combination of two genes expressing immune checkpoint molecules (PD1,
TIM3, TIGIT, LAG3) in HPV+, but not HPV–, HNSC can predict patient survival after
surgery. These findings require confirmation by prospective clinical studies to—we
anticipate—pave the way for the development of immune-predictive biomarkers for HPV+
HNSC patients that will ultimately lead to treatment deintensification in this patient
population.
Taken together, this study provides clear evidence, for the first time, that the immune
landscape of HPV+ HNSC represents a T-cell-inflamed phenotype that is very different
from HPV– HNSC. Of prime importance, we demonstrate that multiple mechanisms that
negatively regulate the anti-tumor immune response are significantly upregulated in the
majority of HPV+ HNSC cases, that is secondary to CD8+ T-cell infiltration and IFNγ
production in HPV+ HNSC. Therefore, high levels of such gene transcripts—PD1, TIM3,
LAG3, and TIGIT—correlate strongly with improved clinical outcome. Crucially, many of
these negative regulators of the immune response are targets of clinically-approved
immune checkpoint inhibitors or inhibitors under investigation in current clinical trials.
Thus, HPV+ HNSC has many immunological features that suggest that it would be highly
amenable to immune checkpoint inhibition therapy. Based on these data, we propose that
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HPV+ HNSC is a T-cell-inflamed disease and should be treated differently in the clinic
than HPV– HNSC, specifically with combinations of immune checkpoint inhibitors.
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Chapter 5

5

High Level Expression of MHC-II in HPV+ Head and
Neck Cancers Suggests that Tumor Epithelial Cells
Serve an Important Role as Accessory Antigen
Presenting Cells

5.1 Introduction
High-risk human papillomaviruses (HPVs) are small, non-enveloped, double-stranded
DNA viruses that are responsible for an estimated 5% of all human cancers (Doorbar et al.,
2015; Forman et al., 2012). These biological carcinogens are the causative agents of
virtually all cervical cancers and a subset of head and neck squamous cell carcinomas
(HNSC) (Doorbar et al., 2015). HNSC are a heterogenous group of malignancies caused
by multiple distinct etiologies. Infection with high-risk HPVs is responsible for
approximately 85,000 of the 600,000 global annual cases of HNSC, making it the second
most common cause of HPV-induced cancers (Gillison et al., 2014; Gillison et al., 2000;
Syrjanen, 2005). HPV-positive (HPV+) tumors are distinct from their HPV-negative
(HPV−) counterparts from a molecular perspective, with distinct genetic, epigenetic, and
protein expression profiles (Gameiro et al., 2018; Gameiro et al., 2017a; Gameiro et al.,
2017b; Seiwert et al., 2015; Sepiashvili et al., 2015; Worsham et al., 2013). Interestingly,
patients with HPV+ HNSC tumors have markedly better clinical outcomes compared to
those with HPV− tumors, leading to the recognition of HPV+ HNSC as unique clinical
entities (Ang et al., 2010; Fakhry et al., 2008; Psyrri et al., 2014).
We and others have noted significant differences in the immune landscape between the
tumor microenvironments of HPV+ and HPV− HNSC (Baruah et al., 2019; Chen et al.,
2018; Gameiro et al., 2018; Gameiro et al., 2017b; Mandal et al., 2016; Nguyen et al.,
2016; Solomon et al., 2018). Specifically, HPV+ tumors express higher levels of class I
major histocompatibility complex (MHC-I) compared to their HPV− counterparts, which
could be a consequence of the higher intratumoral levels of interferon-gamma (IFNg)
observed in the tumors of the HPV+ cohort (Gameiro et al., 2017b). Utilizing an
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immunogenomic approach, we have also shown that HPV+ HNSC tumors exhibited a
strong Th1 response characterized by increased infiltration with multiple types of T-cells—
CD4+, CD8+, and regulatory T-cells—and expression of their effector molecules (Gameiro
et al., 2018). In addition, HPV+ HNSC also expressed higher levels of CD39 and multiple
T-cell exhaustion markers including LAG3, PD1, TIGIT, and TIM3 compared to HPV−
HNSC. Importantly, patients with higher expression of these exhaustion markers—
indicative of a T-cell-inflamed tumor—exhibited markedly improved survival in HPV+,
but not HPV−, HNSC (Gameiro et al., 2018).
In order for an effective T-cell-specific anti-tumor response to occur, a tumor associated
antigen must be presented in either the context of MHC-I or class II MHC (MHC-II) (Rock
et al., 2016). This process is dependent on the initial acquisition of specific antigenic
peptides by surveilling antigen presenting cells (APCs). APCs present these exogenous
peptides on their cell surface in the context of major histocompatibility complex-II (MHCII) to activate cognate CD4+ helper T-cells in an antigen-specific fashion (Roche and
Furuta, 2015). This crosslinking of T-cell receptor (TCR) with its cognate antigen-MHCII complex is the initial step in the activation of T-cells. The next step is the crosslinking
of co-stimulatory molecules between T-cell and APCs that will provide the appropriate
signals to initiate T-cell proliferation and survival (Chen and Flies, 2013). Once activated,
CD4+ T-cells then stimulate the proliferation of CD8+ cytotoxic T-cells (CTLs) that
recognize and respond to the initial antigenic peptide. CTLs subsequently target tumor cells
for lysis based on presentation of the cognate endogenously derived antigenic peptides on
the tumor cell surface in the context of MHC-I (Luckheeram et al., 2012; Zhang and Bevan,
2011).
Although the ability of HPV to suppress MHC-I expression in cell culture systems is well
known (Ferris, 2015; Heller et al., 2011), this is not likely the case in actual human tumors.
Indeed, we previously reported that HPV+ head and neck cancers express higher levels of
MHC-I than HPV− tumors (Gameiro et al., 2017b). Thus, HPV+ tumor cells may be more
effective at displaying endogenously derived viral or neo-antigenic peptides, making them
more easily targeted for CTL lysis. Expression of MHC-II molecules is typically restricted
to professional APCs, such as dendritic cells (DCs), macrophages, and B-cells (van den
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Elsen et al., 2004). However, epithelial cells can be stimulated by proinflammatory
cytokines—specifically IFNg—to express MHC-II and function as accessory APCs to
stimulate T-cell responses (Boss and Jensen, 2003; Collins et al., 1984; Kim et al., 2009).
As mentioned above, MHC-II proteins play a key role in presenting exogenously-derived
peptide antigens that ultimately lead to an effective CTL response, and it is likely that the
induced tumor-specific MHC-II expression on epithelial cells may accentuate this process.
Indeed, the role of tumor cell-derived MHC-II in anti-tumor immunity has become
increasingly appreciated (Axelrod et al., 2019), with accumulating evidence suggesting
that tumor-specific MHC-II expression is correlated with favorable outcomes in
melanoma, classic Hodgkin’s lymphoma, breast cancer, and oropharyngeal cancers
(Axelrod et al., 2019; Cioni et al., 2019; Forero et al., 2016; Johnson et al., 2016; Roemer
et al., 2018).
In this study, we used RNA-seq data from over 500 human head and neck tumors from The
Cancer Genome Atlas (TCGA) to determine if the presence of oncogenic HPV is associated
with altered expression of all classical MHC-II genes and other key genes involved in their
regulation, antigen presentation, and T-cell co-stimulation. We found that expression of
virtually all classical MHC-II genes was significantly upregulated in HPV+ tumors
compared to their HPV− counterparts or normal control tissue. Similarly, genes that encode
products that are fundamental to proper antigen loading and presentation were also
significantly upregulated in HPV+ tumors. Importantly, the relative level of expression of
these inducible MHC-II genes was far beyond those genes associated with professional
APCs. Furthermore, the expression of class II major histocompatibility complex
transactivator (CIITA) and regulatory factor X5 (RFX5)—essential master regulators of
the MHC-II transcriptional control system—were significantly upregulated in the HPV+
cohort. This coordinated upregulation of the mRNA levels of genes involved in the MHCII antigen presentation pathway and their regulation were correlated with the higher
intratumoral levels of IFNg observed in HPV+ carcinomas. In addition, genes that encode
various T-cell co-stimulatory molecules involved in T-cell activation and survival were
found to be significantly upregulated in HPV+ tumors compared to HPV− tumors and
normal control tissue. Taken together, these results suggest a previously unappreciated role
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for epithelial cells in antigen presentation that functionally contributes to the highly
immunogenic tumor microenvironment observed in HPV+ HNSC. This further illustrates
the profound differences in the immune landscape between the tumor microenvironments
of HPV+ and HPV− HNSC and may in part contribute to the superior clinical outcomes
that are associated with HPV+ HNSC.

5.2 Materials and Methods
5.2.1

TCGA RNA-seq boxplot comparisons

Level 3 RNA-Seq by Expectation Maximization (RSEM)-normalized Illumina HiSeq
RNA expression data for the TCGA head and neck cancer (HNSC) cohort was
downloaded from the Broad Genome Data Analysis Centers Firehose server
(https://gdac.broadinstitute.org/). The normalized, gene level Firehose dataset was utilized
for all the genes analyzed. RSEM-normalized RNA-Seq data was extracted into Microsoft
Excel and the HPV status was determined based on published datasets (Banister et al.,
2017; Bratman et al., 2016; The Cancer Genome Atlas Research Network, 2015; The
Cancer Genome Atlas Research Network, 2017). For all genes analyzed in this study,
patient samples from primary tumors with known HPV status were grouped as HPV+,
HPV−, or normal control samples. Patient samples with undetermined HPV status or
samples from secondary metastatic lesions were omitted from our calculations. This
resulted in 73 HPV+, 442 HPV−, and 43 normal control samples with RNA-Seq data
available for gene expression analysis. Oropharynx-only gene reanalysis was performed
by utilizing patient samples that were isolated from the tissues of the oropharynx (tonsils,
base of tongue, or oropharynx) for both HPV+ and HPV− samples. This resulted in 53
HPV+ and 26 HPV− samples with RNA-Seq data available for gene expression analysis.
Graphpad Prism v7.0 (Graphpad Software, Inc., San Diego, California, USA) was used to
generate boxplot comparisons of gene expression between the indicated HPV+, HPV−, and
normal control samples as well as the oropharynx-only reanalysis between HPV+ and
HPV− samples. For each boxplot, the center line indicates the median, the lower and upper
box limits represent Q1 (25th percentile) and Q3 (75th percentile), respectively, and the
whiskers extend 1.5 times the interquartile range (IQR) from Q1 (lower whisker) and Q3
(upper whisker). An unpaired, two-tailed non-parametric Mann–Whitney U test was

137

utilized to assign p-values. G*Power Software version 3.1.9.2 (Faul et al., 2007) was used
to perform post-hoc power calculations, with effect size selected as 0.8 and α = 0.05. All
boxplot comparisons achieved a power value > 0.8. Figures were assembled into final form
using Adobe Illustrator CS6.

5.2.2

Correlation matrix

Level 3 RSEM-normalized RNA-seq data for the genes listed above were extracted from
the TCGA database and processed as detailed above. For the HPV+ (upper triangle) and
HPV− samples (lower triangle), pairwise spearman correlation was performed for each
gene involved in the MHC-II transcriptional control system. Hierarchical clustering was
utilized to group genes based on strength of correlation. Correlations and clustering were
performed using R statistical environment (version 3.4.0) utilizing packages ggplot2 and
reshape2. Correlation matrix figure was assembled into final form using Adobe Illustrator.

5.3 Results
5.3.1

Classical MHC class II α- and β-chain genes are expressed at
higher levels in HPV+ head & neck carcinomas

Constitutive expression of classical MHC-II molecules is typically restricted to
professional antigen presenting cells—DCs, macrophages, and B-cells (van den Elsen et
al., 2004). However, in non-immune cells that lack constitutive expression, such as those
of the epithelia, their expression can be induced through exposure to proinflammatory
cytokines (Boss and Jensen, 2003; Collins et al., 1984; Steimle et al., 1994). In humans,
the genes that encode the three classical polymorphic MHC-II molecules HLA-DP, HLADQ, and HLA-DR are expressed as α- and β-chains that form heterodimers on the cell
surface (van den Elsen et al., 2004). We began by analyzing the Illumina HiSeq RNA
expression data from the TCGA HNSC cohort for expression of HLA-DPA1, -DPB1, DQA1, -DQA2, -DQB1, -DQB2, -DRA, -DRB1, -DRB5, and -DRB6 genes, encoding the
various α- and β-chains for all three classical isotypes (Figure 5.1). Uniformly, all HPV+
patient samples expressed significantly higher levels of mRNA for all 10 MHC-II genes
analyzed compared to HPV− patient samples and virtually all normal control tissues—with
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Figure 5.1. Expression of classical MHC-II α- and β-chain genes in head & neck
squamous cell carcinomas stratified by high-risk HPV status.
RSEM-normalized RNA-seq data for the indicated MHC-II genes was extracted from the
TCGA database for the HNSC cohort for HPV+, HPV–, and normal control tissues.
Numbers in brackets refer to the number of samples included in each analysis. Statistical
analysis was performed using a two-tailed non-parametric Mann–Whitney U test. ** p ≤
0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant.
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the exception of HLA-DQB2 (HPV+ versus Normal). As the majority of the HPV+ samples
are from the oropharynx subsite, we repeated this analysis with HPV+ and HPV− samples
that occur only in the oropharynx. Similarly, to the analysis including all subsites, HPV+
oropharyngeal tumors expressed significantly higher levels of MHC-II α- and β-chain
genes compared to their HPV− oropharyngeal tumor counterparts (Figure 5.2).
Collectively, these results indicate that HPV+ head and neck tumors express high levels of
the mRNAs encoding the α- and β-chain heterodimers of the classical MHC-II molecules
versus HPV− tumors or normal control tissues. It is noteworthy that based on the
normalized read levels, all of these genes are expressed at levels several orders of
magnitude above any markers of professional APCs, such as CD19 (B-cells) (Wang et al.,
2012), CCL13 (DCs) (Danaher et al., 2017), and CD84 (macrophages) (Zaiss et al., 2003)
(Figure 5.3A). However, these normalized read levels are comparable to that of an
established epithelial cell marker, E-cadherin (CDH1) (Gall and Frampton, 2013) (Figure
5.3B). Thus, it is likely that these genes are being expressed by epithelial cells within the
actual tumor.

5.3.2

Genes encoding key components of the MHC-II antigen
presentation pathway are expressed at higher levels in HPV+
head & neck carcinomas

In the endoplasmic reticulum, newly synthesized MHC-II α- and β-chains form a trimeric
complex with a non-polymorphic protein called the invariant chain (Ii), which is encoded
by the HLA-DR antigens-associated invariant chain or Cluster of Differentiation 74
(CD74) gene (Cresswell, 1996). This association with the Ii chain prevents premature
peptide loading and also dictates the trafficking of the Ii-MHC-II complex to the
endosomal-lysosomal antigen-processing compartments, which contain the antigenic
peptides (Roche and Cresswell, 1990; Roche and Furuta, 2015). Once in this compartment,
Ii is proteolytically cleaved, leaving only a small fragment in the peptide-binding groove
called the class II-associated invariant chain peptide (CLIP). Similarly, to the genes
encoding the classical MHC-II α- and β-chains, CD74 was found to be significantly
upregulated in HPV+ HNSC compared to their HPV− counterparts or normal control
tissues (Figure 5.4).
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Figure 5.2. Gene expression reanalysis in the oropharynx.
RSEM-normalized RNA-seq data for tumors occurring in the oropharynx was extracted
from the TCGA database for the HNSC cohort for HPV+ (53) and HPV– (26) samples.
Statistical analysis was performed using a two-tailed non-parametric Mann-Whitney U
test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant.
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Figure 5.3. Expression of markers associated with APCs or epithelia.
RSEM-normalized RNA-seq data for genes associated with APCs (A) or epithelia (B) was
extracted from the TCGA database for the HNSC cohort for HPV+, HPV–, and normal
control tissues. Statistical analysis was performed using a two-tailed non-parametric MannWhitney U test. Numbers in brackets refer to the number of samples included in each
analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant.
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Figure 5.4. Expression of the invariant chain and MHC class II-like genes in head &
neck carcinomas stratified by HPV status.
RSEM-normalized RNA-seq data for the indicated genes involved in MHC-II-dependent
antigen processing and presentation was extracted from the TCGA database for the HNSC
cohort for HPV+, HPV–, and normal control tissues. Numbers in brackets refer to the
number of samples included in each analysis. Statistical analysis was performed using a
two-tailed non-parametric Mann–Whitney U test. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤
0.0001.
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In order for antigenic peptide-binding to occur, CLIP must be removed from the peptidebinding groove (Cresswell, 1996; Roche and Furuta, 2015). The enzymatic removal of
CLIP is mediated by the MHC class II-like heterodimer, HLA-DM. After HLA-DMmediated removal of CLIP, the class II molecules can now bind lysosomally generated
antigenic peptides (Busch et al., 2005; Roche, 1995). The binding of antigenic peptides is
influenced by another MHC class II-like heterodimer, HLA-DO, which regulates the
MHC-II peptide repertoire by modulating the activity of HLA-DM (Denzin et al., 2005;
Poluektov et al., 2013). The α- and β-chains of these dimeric class II-like molecules are
encoded by the HLA-DMA, HLA-DMB, HLA-DOA, and HLA-DOB genes. Like the
classical MHC-II genes, all four genes encoding the class II-like MHC molecules are
similarly upregulated in HPV+ HNSC versus HPV− tumors or normal control tissues
(Figure 5.4).
When repeated only considering the oropharynx subsite, HPV+ oropharyngeal tumors
expressed significantly higher levels of the invariant chain and MHC-II-like genes
compared to their HPV− oropharyngeal tumor counterparts (Figure 5.2). Taken together,
the upregulation of the genes encoding the MHC-II invariant chain and class II-like genes,
suggests that key components of the MHC-II antigen presentation pathway are transcribed
in HPV+ HNSC at levels that are significantly higher than observed in HPV− tumors or
normal control tissues. Furthermore, these genes are also expressed at very high levels,
with the exception of HLA-DOB, that are indicative of being expressed by epithelial cells
within the actual tumor.

5.3.3

Impact of HPV status on the expression of transcriptional
regulators of MHC-II gene expression

Transcriptional control of MHC-II genes and the related genes that encode key components
of the MHC-II antigen presentation pathway is among one of the best understood systems
in mammals. It is a complex transcriptional system with a unique method of regulation that
is completely dependent on the master transcriptional regulator CIITA (Boss and Jensen,
2003; van den Elsen, 2011). In agreement with the high levels of MHC-II genes and related
genes, analysis of the TCGA data reveals significantly higher levels of CIITA in HPV+
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samples compared to HPV− or normal control tissues (Figure 5.5). In addition, RFX5—
another important transcriptional regulator of MHC-II genes (Boss and Jensen, 2003)—
was similarly expressed at significantly higher levels in HPV+ samples with respect to
HPV− tumors or normal control tissues (Figure 5.5). Again, these differences were also
observed when only considering the expression of these genes in the oropharynx (Figure
5.2).
Expression of MHC-II genes and related genes are restricted to APCs, however nonhematopoietic cells such as fibroblasts, endothelial cells, and epithelial cells can be
stimulated by IFNγ to express MHC-II molecules and related proteins involved in the
antigen presentation pathway (Boss and Jensen, 2003; Collins et al., 1984; Steimle et al.,
1994). We analyzed the expression level of the IFNγ gene (IFNG) (Figure 5.5). As
expected, the relative level of IFNG expression was similar in magnitude to that of other
leukocyte specific genes (Figure 5.3A). However, IFNG was expressed at significantly
higher levels in HPV+ tumors compared to its HPV– counterpart or normal control tissues
(Figure 5.5). In addition, when only considering the oropharynx, the expression of the
IFNγ gene was significantly higher in HPV+ samples compared to HPV− oropharyngeal
tumors (Figure 5.2).
To further illustrate the IFNγ-specific coordinated upregulation of MHC-II genes and
related genes that encode products essential for antigen processing and presentation, we
generated a correlation matrix for both HPV+ (Figure 5.6: upper triangle) and HPV−
samples (Figure 5.6: lower triangle). As expected, regardless of HPV status, we found
that expression of all MHC-II antigen presentation-specific genes were correlated in a
pairwise fashion in each patient sample.
Thus, the upregulated expression of CIITA, RFX5, and subsequent expression of all the
classical MHC-II genes and related genes required for antigen loading and presentation
observed in HPV+ head and neck carcinomas are likely a consequence of IFNγ exposure.
Furthermore, the correlation matrix illustrates the unique simultaneous coordination of the
MHC-II transcriptional control system that has been shown to be dictated by the master
transcriptional regulator CIITA (Boss and Jensen, 2003; van den Elsen, 2011).

145

Figure 5.5. Expression of CIITA, RFX5, and IFNG mRNA in head & neck carcinomas
stratified by HPV status.
RSEM-normalized RNA-seq data for the CIITA, RFX5, and IFNG genes were extracted
from the TCGA database for the HNSC cohort for HPV+, HPV−, and normal control
tissues. Numbers in brackets refer to the number of samples included in each analysis.
Statistical analysis was performed using a two-tailed non-parametric Mann–Whitney U
test. **** p ≤ 0.0001.
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Figure 5.6. Correlation matrix of genes involved in the MHC-II antigen presentation
pathway in head & neck carcinomas stratified by HPV status.
RSEM-normalized RNA-seq data for the genes listed above were extracted from the TCGA
database for the HNSC cohort for HPV+ (upper triangle) and HPV− samples (lower
triangle). Pairwise spearman correlation was performed followed by hierarchical clustering
to group based on correlation. Number in boxes indicate Spearman’s rank correlation
coefficient of analyzed gene pairs.
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5.3.4

Impact of HPV status on the expression of T-cell costimulatory molecules in HPV+ head & neck carcinomas

Co-stimulation of T-cells occurs through the interaction of its constitutively expressed
CD28 receptor with either CD80 or CD86 on APCs (Chen and Flies, 2013). Utilizing RNA
expression data for the levels of each of these co-stimulatory molecules, we found higher
levels of CD28 in HPV+ tumors compared to HPV− or normal control tissues (Figure 5.7).
While the levels of both CD80 and CD86 in HPV+ tumors were not significantly different
compared to their HPV− counterparts, they were significantly higher compared to normal
control tissues (Figure 5.7). In addition, we found that the mRNA levels of CD152, which
encodes for CTLA-4, a marker of T-cell activation (Rudd et al., 2009), was significantly
upregulated in HPV+ tumors compared to HPV− and normal control tissues (Figure 5.7).
Again, these differences were also observed when only considering the expression of these
genes in the oropharynx (Figure 5.2). These results suggest that, like the MHC-II genes
and the genes involved in antigen loading and presentation, co-stimulatory molecules are
similarly present at higher levels in HPV+ tumors and this is correlated with a higher level
of T-cell activation.

5.3.5

Impact of HPV status on the expression of inducible T-cell
survival signal molecules in HPV+ head & neck carcinomas

Utilizing the RNA-seq HNSC dataset from the TCGA, we looked at genes that encode for
inducible, T-cell activation-dependent, survival signal molecules and their respective
ligands (Beier et al., 2007; Chen and Flies, 2013). We found that CD137 (4-1BB,
TNFRSF9) was significantly upregulated in HPV+ tumors compared to HPV− or normal
control tissues (Figure 5.8). However, its ligand TNFSF9 (CD137L, 4-1BBL) was found
to be significantly downregulated in HPV+ tumors compared to HPV− and not
significantly different compared to normal control tissues (Figure 5.8). Next, we looked at
the genes that encode for the inducible T-cell co-stimulator (ICOS) and its ligand ICOSLG
and found that both were significantly upregulated in HPV+ tumors compared to HPV−,
but only ICOS was significantly upregulated in comparison to normal control tissues
(Figure 5.8). Finally, we looked at OX40 (TNFRSF4, CD134) and its ligand OX40L
(TNFSF4, CD252) and found that both genes were significantly upregulated in HPV+
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Figure 5.7. Expression of genes that encode for T-cell co-stimulatory molecules in
head & neck carcinomas stratified by HPV status.
RSEM-normalized RNA-seq data for genes that encode T-cell specific co-stimulatory
molecules was extracted from the TCGA database for the HNSC cohort for HPV+,
HPV–, and normal control tissues. Statistical analysis was performed using a two-tailed
non-parametric Mann–Whitney U test. Numbers in brackets refer to the number of samples
included in each analysis. **** p ≤ 0.0001, ns – not significant.
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Figure 5.8. Expression of inducible T-cell survival signal molecules in head & neck
carcinomas stratified by HPV status.
RSEM-normalized RNA-seq data for inducible genes that encode for T-cell survival
molecules was extracted from the TCGA database for the HNSC cohort for HPV+, HPV−,
and normal control tissues. Statistical analysis was performed using a two-tailed nonparametric Mann–Whitney U test. Numbers in brackets refer to the number of samples
included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, ns – not significant.
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tumors compared to their HPV− counterparts and normal control tissues (Figure 5.8).
Again, these differences were also observed when only considering the expression of these
genes in the oropharynx with the exception of TNFSF4 (Figure 5.2). Taken together, these
results suggest that T-cells are activated and proliferating within the HPV+ tumor
microenvironment via the observation of an increase in expression of genes that encode for
survival signal molecules that are only induced following TCR-mediated antigen-specific
T-cell activation and/or CD28 co-stimulation (Beier et al., 2007; Chen and Flies, 2013).

5.4 Discussion
Expression of MHC-II is typically associated with professional APCs, which are
considered essential for the initiation of the adaptive immune response. They function by
sampling their local environment via phagocytosis, acquiring particles and processing them
internally in order to present them on their cell surface to CD4+ T-cells in the context of an
antigen-MHC-II complex (Roche and Furuta, 2015). The crosslinking of the CD4+ TCR
and antigen-MHC-II complex initiates the T-cell activation protocol that, in conjunction
with co-stimulatory signals, can ultimately lead to an effective adaptive immune response
against a threat of internal or external origin, such as cancerous cells or bacteria and viruses,
respectively (Chen and Flies, 2013).
In non-hematopoietic cells, such as epithelia, MHC-II expression can be induced through
exposure to the proinflammatory cytokine IFNγ (Boss and Jensen, 2003; Collins et al.,
1984; Steimle et al., 1994). This induction of MHC-II on epithelial cells bestows on them
the ability to act as accessory APCs, and this can accentuate the presentation of antigens to
CD4+ T-cells (Kim et al., 2009). However, the ability of epithelial cells to function as
accessory APCs is generally underappreciated, with most existing information related to
the gastrointestinal and respiratory tracts (Wosen et al., 2018). Interestingly, cancerous
tissues can retain tumor-specific MHC-II expression, and this has the potential to increase
recognition of a tumor by the immune system (Axelrod et al., 2019). Indeed, tumor specific
MHC-II expression has been associated with superior prognosis and/or improved response
to immune checkpoint inhibitor therapy in several human cancers, as well as increased
tumor rejection in murine models (Axelrod et al., 2019; Cioni et al., 2019; Forero et al.,
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2016; Johnson et al., 2016; Roemer et al., 2018). The importance of the immune response
for successful resolution of cancers cannot be understated. Indeed, mouse models have
shown that neither chemotherapy nor radiation treatment functioned effectively in the
absence of a functional immune system, at least in HPV+ HNSC (Spanos et al., 2009).
While MHC-II expression has been reported in head and neck tumors (Cioni et al., 2019),
existing studies have been limited to individual classical isotypes, such as HLA-DR, based
on limitations in available antibodies (Johnson et al., 2018). Cell culture models based on
established head and neck cancer lines have also demonstrated MHC-II expression, often
in response to IFNγ, or following transfection with CIITA—master regulator of MHC-II
transcription (Arosarena et al., 1999; Meissner et al., 2009). However, no existing studies
have comprehensively assessed the transcriptional status of the entire MHC-II antigen
presentation system in head and neck cancers. In this study, our goal was to determine if
MHC-II components were widely expressed in human head and neck cancers and whether
expression was influenced by HPV status.
Using data from over 500 primary human head and neck tumors, we provide evidence that
HPV+ head and neck carcinomas display high mRNA levels for virtually all MHC-II
genes, including the classical and non-classical α- and β-chains, the invariant γ chain, as
well as factors required for MHC-II loading and trafficking (Figures 5.1 and 5.4).
Increased expression of these genes was observed whether the comparison included all
head and neck cancer subsites or was restricted to just the oropharynx, where the majority
of HPV+ head and neck cancers arise (Figure 5.2). These results are in good agreement
with the concurrent detection of high levels of expression of CIITA and RFX5, important
global regulators of MHC-II transcription (Boss and Jensen, 2003; van den Elsen, 2011),
in HPV+ tumors. HPV+ head and neck carcinomas express significantly higher levels of
these genes as compared to normal control tissues, and these levels are generally higher
than in HPV– carcinomas (Figure 5.5). This likely reflects the T-cell inflamed nature of
HPV+ cancers (Gameiro et al., 2018), and specifically the higher levels of IFNγ expressed
in these tumors (Figure 5.5). This IFNγ-dependent coordinated upregulation of MHC-II
genes and related genes involved in antigen processing and presentation was further
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illustrated in Figure 5.6, where we observed a strong global correlation with all genes
analyzed in the MHC-II transcriptional control system.
After generation and programming in the thymus, CD8+ and CD4+ T-cells circulate in the
body until they encounter their specific antigen presented on either class I or class II MHC
molecules, respectively (Luckheeram et al., 2012; Pennock et al., 2013; Zhang and Bevan,
2011). This interaction between TCR and antigen-loaded MHC complex represents signal
1, which triggers the activation of T-cells. However, in order for the activated T-cell to
fully respond to the presented threat, and not enter a state of unresponsiveness, it requires
a secondary signal through co-stimulatory molecules (Chen and Flies, 2013). We found
higher levels of CD28 in HPV+ tumors compared to their HPV− counterparts and normal
control tissues (Figure 5.7). The binding of CD28 with either CD80 or CD86 leads to
clonal expansion of the T-cell pool that is specific to the recognized antigen (Beier et al.,
2007; Chen and Flies, 2013). In order to attenuate this response, the aforementioned
interaction leads to the induction of the co-inhibitory molecule CTLA-4, which is encoded
by the gene CD152. This co-inhibitory molecule will compete with CD28 for binding to
either CD80 or CD86 to attenuate the T-cell response (Chen and Flies, 2013; Rudd et al.,
2009). We found that CD152 was significantly upregulated in the HPV+ cohort (Figure
5.7). Collectively, this data indirectly illustrates the higher number of infiltrating T-cells
within the tumor microenvironments of HPV+ HNSC through the identification of
significantly higher levels of the constitutively expressed T-cell-specific CD28 marker. In
addition, it provides good evidence that the interaction of co-stimulatory molecules in
HPV+ HNSC is effective, given that we detected significantly higher levels of expression
of CD152 mRNA, which encodes for the inducible co-inhibitory molecule CTLA-4.
In order for proliferating T-cells to persist and survive after antigen-recognition and
subsequent stimulation with co-stimulatory molecules, they require survival signals that
are delivered through the cross-linking of various molecules (Beier et al., 2007; Chen and
Flies, 2013). Interestingly, unlike other co-stimulatory molecules—such as CD28—that
can be found constitutively expressed on T-cells, the molecules that convey these survival
signals are encoded by genes that are only expressed following TCR-mediated antigenspecific T-cell activation and/or CD28 co-stimulation (Beier et al., 2007; Chen and Flies,
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2013). We found that all inducible T-cell survival genes analyzed, with the exception of
TNFSF9, were expressed at significantly higher levels in HPV+ tumors compared to HPV−
and normal control tissues (Figure 5.8). TNFSF9 was significantly downregulated in
HPV+ tumors compared to its HPV− counterpart (Figure 5.8). This downregulation of
TNFSF9 is indicative of a mechanistic response to excessive CD137-mediated signaling
(Eun et al., 2015; Ho et al., 2013; Kwon, 2015). This data indirectly illustrates that the
HPV+ tumor microenvironment contains increased levels of activated and proliferating Tcells via the observation of an increase in expression of genes that encode for survival
signal molecules that are induced following TCR-mediated antigen-specific T-cell
activation and/or CD28 co-stimulation. These results agree well with previous reports by
our group and others that HPV+ tumors contain more T-cells (Chen et al., 2018; Gameiro
et al., 2018; Mandal et al., 2016; Nguyen et al., 2016; Solomon et al., 2018), but goes
further in that it indirectly provides evidence of productive MHC-II-dependent tumorantigen recognition.
HPV+ HNSC tumors are remarkably different from their HPV− counterparts in that they
express high levels of all components of the MHC-II antigen presentation apparatus.
Importantly, while some of this signal can be attributed to professional APCs, the
extremely high relative level of expression supports a model whereby the T-cell inflamed
environment in HPV+ HNSC induces a functionally effective MHC-II presentation system
based on tumor epithelial cells. As MHC-II-dependent antigen presentation is critical for
CD4+ help in CD8+ T-cell responses, which are essential for the control and clearance of
cancerous cells, it is likely that the expression of non-self-derived viral antigens or tumorderived neoantigens, combined with intact MHC-II presentation and appropriate costimulation, contributes to the markedly better patient outcomes for HPV+ versus HPV–
head and neck carcinomas. As immune checkpoint inhibition therapy in other cancers has
been reported to be most effective for tumors with high MHC-II levels, suggesting that
stratification based on MHC-II levels may help predict those likely to respond to
checkpoint inhibition therapy.
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Chapter 6

6

General Discussion

6.1 Thesis Summary
Much of the existing literature that encompasses the foundation for this body of work
utilizes relatively artificial in vitro model systems. These earlier and current approaches
attempt to phenocopy complex malignancies under conditions that can be manipulated, to
gain insight into mechanistic processes. Indeed, these approaches have several advantages
such as infinite growth, amenability to high-throughput screening, and formation of
xenograft tumors for in vivo testing. However, their lack of heterogeneity, tumor
microenvironment, and infiltrating immune cells severely limit their ability to recapitulate
actual human cancers (Namekawa et al., 2019). Therefore, my thesis research capitalizes
on genomic and transcriptomic “big” data acquired through next-generation “-omics”
technologies from actual human tumors. This in silico approach allows for an insightful
elucidation of mechanistic processes under the influence of a native heterogeneous
environment. Utilizing computational methods, I explored and profiled the epigenetic and
immune landscapes between the tumor microenvironments of HPV-positive (HPV+) and
HPV-negative (HPV–) carcinomas present in actual human malignancies. True to my
proposed hypothesis, my studies have identified strikingly profound differences in the
epigenetic and immune landscapes of the tumor microenvironments (TMEs) of these 2
etiologically-distinct carcinomas, regardless of their tissue of origin. Furthermore, they
also provided insight into the validity of 2 important models of HR HPV-mediated sabotage
of intracellular epigenetic and immune networks that were previously proposed from
artificial in vitro culture studies. In addition, these studies identified potentially useful
therapeutic targets and advocated for the utility of novel immunotherapy treatment
modalities. Notably, the expression of immune checkpoint molecules was shown, in HPV+
head and neck patients, to be potentially predictive biomarkers of clinical outcomes that
could have implications for treatment deintensification.
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6.2 Epigenetic Landscape of HPV+ Tumor Microenvironments
The E7 oncoprotein from HR HPVs have been shown to mediate global changes on the
epigenome of the infected host cell (Durzynska et al., 2017). One prime example of an E7mediated epigenetic change is the global reduction in the levels of tri-methylated lysine 27
on histone 3 (H3K27me3), which is a universal mark of transcriptionally silenced
chromatin. (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2008; Schwartz
and Pirrotta, 2007). Furthermore, HPV has also been shown to increase the expression of
the catalytic enzymes responsible for creating and removing methyl groups on lysine 27 of
histone 3. Indeed, these in vitro studies have shown that HPV induces an increase in the
expression level of the EZH2 core component of the PRC2 methyltransferase (Popov and
Gil, 2010; Schwartz and Pirrotta, 2007), and the lysine demethylases 6A (KDM6A) and
6B (KDM6B) (Hyland et al., 2011; McLaughlin-Drubin et al., 2011).
Mechanistic studies of HPV-dependent effects on epigenetic regulators have primarily
focused on altered expression of the p16 product of the CDKN2A locus, which is commonly
found to be upregulated in HPV+ carcinomas (Klaes et al., 2001; Sano et al., 1998). Indeed,
this HPV-specific upregulation of p16 is a clinically important surrogate marker of HPV
status (Burd, 2016; Hoffmann et al., 2010; Klaes et al., 2001). The CDKN2A locus encodes
for p16 and p14 which are negative regulators of the cell cycle (Zhang et al., 1998).
Importantly, transcription from this locus is tightly regulated at the epigenetic level, with
the methyltransferase PRC2 serving a key role in its repression by catalyzing the trimethylation (me3) of H3K27 across the entire genomic region. This is followed by the
subsequent recruitment of another methyltransferase, PRC1, that maintains the chromatin
in a transcriptionally repressive state by increasing local DNA methylation (Popov and Gil,
2010). Therefore, this well-characterized locus serves as an important model of HPVinduced epigenetic dysregulation (Kanao et al., 2004; Schlecht et al., 2015).
As indicated above, the detailed series of experiments that have mechanistically unraveled
the epigenetic changes induced by HPV E7 on the tightly regulated CDKN2A and adjacent
CDKN2B loci have been elucidated in 2-dimensional in vitro culture systems (McLaughlinDrubin et al., 2011; McLaughlin-Drubin et al., 2013). While these cell culture-based
experiments have allowed for a detailed elucidation of the biological factors involved in
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HPV-mediated upregulation of p16, an analysis of these HPV-specific epigenetic effects
has not been done in any HPV+ head and neck carcinomas or on large cohorts of any HPVinduced cancers. Therefore, my objective was to determine if the epigenetic changes
involved in p16 upregulation observed in artificial culture systems were recapitulated in
actual primary HPV+ tumors from different anatomical locations.
I began this work by developing an initial database of genomic and transcriptomic data that
would serve as the basis for this and subsequent studies presented within my thesis. I
downloaded normalized RNA expression data for the TCGA head and neck cancer (HNSC)
and cervical carcinoma (CESC) cohorts from the Broad Genome Data Analysis Centers
Firehose server. Importantly, HPV status was manually curated based on published datasets
(Banister et al., 2017; Bratman et al., 2016; The Cancer Genome Atlas Research Network,
2015; The Cancer Genome Atlas Research Network, 2017). Primary patient samples with
known HPV status were grouped as HPV+, HPV–, or normal-adjacent control tissue.
Patient samples with unknown HPV status were omitted from my calculations, as were
samples obtained from secondary metastatic lesions. This resulted in 73 HPV+, 442
HPV–, and 43 normal-adjacent control samples for the HNSC cohort and 278 HPV+, 19
HPV–, and 3 normal-adjacent control samples for the CESC cohort. For all genes analyzed
in this thesis, with the exception of p16 and p14, the gene level Firehose dataset was used.
For p16 and p14, the gene isoform level Firehose dataset was used to discriminate between
these two different products of the CDKN2A locus.
In Chapter 2, I began by analyzing the entire CDKN2A and adjacent CDKN2B loci that
encode for the tumor suppressors p16, p14, p15, and the non-coding RNA CDKN2B-AS.
During normal cell growth and development, expression of genes from this cluster are
silenced by PRCs through their catalyzation of methyl groups on lysine 27 of histone 3
(Popov and Gil, 2010). As mentioned above, HPV-induced cancers commonly express
high levels of p16 (Klaes et al., 2001; Sano et al., 1998). In contrast, the expression levels
of the other products of this locus, and the adjacent CDKN2B locus—p14, p15, and the
non-coding CDKN2B-AS—have not been studied as extensively. I therefore utilized my
curated database of transcriptomic data from the TCGA to analyze the expression of the 4
genes from the aforementioned loci in both the HNSC and CESC cohorts. As expected,
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HPV+ samples from both cohorts had greatly increased levels of p16 mRNA expression
compared to HPV– tumors and normal control tissue. Like p16, a similar upregulation of
p14, p15, and CDKN2B-AS was observed in HPV+ cancers with respect to their HPV–
counterparts. These results led me to conclude that PRC-mediated repression was
abrogated across the entire CDKN2A and adjacent CDKN2B genomic regions as a result of
infection by HPV.
Based on the above observations, I wanted to analyze the impact of HPV oncogene
expression on the core components of the methyltransferases, PRC2 and PRC1. A
straightforward mechanistic explanation of the observed increase of expression from the
CDKN2A and CDKN2B loci in HPV+ cells would be a decreased expression of the core
proteins necessary for mediating the methyltransferase activity of PRC2 and PRC1 on
H3K27. Interestingly, tissue culture experiments have shown that expression of EZH2 to
be increased by the presence of HPV oncogenes, while no significant changes were
observed for the EED and SUZ12 core component proteins (Hyland et al., 2011;
McLaughlin-Drubin et al., 2011). Furthermore, other cell culture experiments have shown
that BMI1, a core component of PRC1, is reduced in human foreskin keratinocytes (HFKs)
transduced with E6 and E7. My analysis revealed that all 4 core components of both PRC2
and PRC1 were expressed at levels higher or equivalent to HPV– samples or normal control
tissues, with the exception of BMI1 in the CESC cohort. These results led me to conclude
that the increased expression observed in the HPV+ cohorts from the CDKN2A and
CDKN2B loci were not due to a reduction in the overall levels of the core components that
form the PRC2 and PRC1 methyltransferases, respectively.
I next looked for an alternative method of activating the CDKN2A and CDKN2B loci. Since
I previously looked at the enzymes responsible for catalyzing the repressive methyl groups
onto lysine 27 of histone 3, I therefore wanted to look at the enzymes responsible for the
removal of the repressive H3K27me3 modification catalyzed by PRCs. Indeed, these
histone modifications are erased by the KDM6A and KDM6B demethylases (Dawson and
Kouzarides, 2012). Previous work in tissue culture models established that transduction of
HPV E7 into HFKs induced increases in the levels of KDM6A and/or KDM6B mRNA and
protein (Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Importantly, siRNA
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knockdown of KDM6B antagonized p16 induction by E7, suggesting that upregulation of
these demethylases is the mechanism by which HPV reduces global H3K27me3 levels and
activates p16 expression (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al.,
2013). My analysis concluded that KDM6A expression was significantly increased in
HPV+ samples from both the HNSC and CESC cohorts with respect to their HPV–
counterparts and normal control samples. However, this was not the case for KDM6B,
which was found to be reduced in HPV+ samples compared to HPV– and normal control
tissues from both cohorts. These results support the model proposed from tissue culture
experiments, in which enhanced expression of KDM6A, but not KDM6B, by HPV is
correlated with the dysregulation of H3K27me3 homeostasis and subsequent activation of
transcription from the CDKN2A and CDKN2B loci in both these cancer types.
Since HPV-mediated changes in epigenetic regulation of transcription of genes encoded
by CDKN2A and CDKN2B would be reflected in the methylation-status of CpG
dinucleotide sequences in or adjacent to these loci. I therefore sought to analyze the
Infinium Human Methylation450 BeadChip array data for the TCGA HNSC and CESC
cohorts for consistent alterations in DNA methylation in this region of the genome. My
analysis of methylation data revealed that there were two consistent alterations in DNA
methylation relative to methylation levels present in HPV– tumors and normal control
tissues. Specifically, a region of DNA upstream of the p14 transcript was consistently
identified to be hypomethylated in HPV+ carcinomas of both cohorts. Importantly,
genome-wide studies have clearly indicated that methylation in the immediate vicinity of
the transcription start site blocks initiation (Jones, 2012). As such, the greatly reduced
methylation in HPV+ samples at this region is fully consistent with enhanced CDKN2A
expression. In contrast, I also observed a hypermethylated region of DNA within the 3’end of the CDKN2A locus in HPV+ tumors regardless of their anatomical origins. Indeed,
hypermethylation at this location has been described in other studies of HPV+ head and
neck and cervical carcinomas using alternative probes (Ben-Dayan et al., 2017; Schlecht
et al., 2015; Wijetunga et al., 2016). These studies have established that p16 and p14
expression in a given tumor sample is strongly correlated with increased methylation at
this position in the CDKN2A locus (Ben-Dayan et al., 2017; Schlecht et al., 2015).
Therefore, along with promoter hypomethylation, gene-body methylation correlates well
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with the observed enhanced transcription from the CDKN2A locus, providing further
support for an epigenetic mechanism as the basis for HPV-mediated induction of
expression from this locus.
Epigenetic reprogramming induced by HPV should be reversible and could represent a
unique and useful therapeutic target. Indeed, cervical carcinoma cell lines or other tumor
cell lines expressing HPV E7 from HR HPVs appear to require continuous p16 expression
for survival (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013). Although
p16 normally serves as a tumor suppressor, it becomes necessary for continued growth in
cells expressing E7. Since HPV+ cells require KDM6 demethylase activity to maintain p16
expression, therefore they are sensitive to small molecule inhibitors of KDM6 in cell
culture models (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013).
Notably, it has not been determined if actual primary HPV+ head and neck or cervical
carcinomas will respond similarly. My analysis of the epigenetic regulators that control
p16 expression finds many commonalities between the hundreds of tumors making up the
TCGA HNSC and CESC cohorts compared to in vitro cell culture models. Therefore, these
observations strongly suggest that testing of KDM6 inhibitors should be aggressively
pursued as a novel therapy against HPV+ cancers.
Taken together, my analysis of over 350 HPV+ head and neck or cervical carcinomas in
comparison with over 450 HPV– cancers from their respective anatomical sites validates
conclusions drawn from artificial 2-dimensional in vitro culture models and identifies
remarkable similarities between the effects of HPV on gene expression and methylation in
large human cohorts from two anatomically distinct regions. Furthermore, these results
also showcase the profound differences in the epigenetic landscape between the tumor
microenvironments of HPV+ and HPV− carcinomas. In addition, the findings in this study
strongly advocate for the testing of KDM6 inhibitors in actual human malignancies caused
by infection with HPV.
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6.3 Immune Landscape of HPV+ Tumor Microenvironments
6.3.1

Impact of HPV on the MHC-I antigen presentation network

In Chapter 3, I wanted to use the same computational methodology utilized in Chapter 2 to
validate another important model of HPV-mediated sabotage that was proposed from
artificial in vitro tissue culture studies. Indeed, multiple studies have suggested that HPV
oncoproteins contribute to the evasion of the adaptive immune response, which supports a
model by which the establishment of a persistent HPV infection contributes to the ability
of HPV+ cancers to evade antitumor immune responses (Westrich et al., 2017).
Specifically, transfection of HR HPV E7 into various cell lines has been shown to repress
MHC-I and/or TAP expression (Georgopoulos et al., 2000; Heller et al., 2011; Li et al.,
2010). Furthermore, reciprocal studies have also shown that the knockdown of E7 in some
HPV+ cervical cancer cell lines increases MHC-I expression (Bottley et al., 2008; Li et al.,
2006). Mechanistically, these in vitro studies proposed that the reduction of MHC-I and
TAP occur at the transcriptional level (Georgopoulos et al., 2000; Heller et al., 2011; Li et
al., 2010).
While the majority of published studies using tissue culture models indicate that HPV E7
represses the expression of MHC-I, related studies on the effects of HPV in actual human
carcinomas are less consistent. Indeed, conflicting reports have suggested that HPV+
carcinomas and/or precancerous lesions display increased, decreased, or the same levels of
MHC-I or TAP when compared to their HPV− counterparts or normal control tissues.
(Cromme et al., 1993; Djajadiningrat et al., 2015; Jochmus et al., 1993; Keating et al.,
1995; Ramqvist et al., 2015; Ritz et al., 2001; Torres et al., 1993; van Esch et al., 2014). I
therefore utilized my curated database of transcriptomic data from over 800 human cervical
and head and neck carcinomas, to assess the impact of HPV status on the expression of
MHC-I heavy chain genes, the β2 microglobulin light chain gene, and other components
of the MHC-I antigen presentation network.
I began by analyzing the expression of both the classical (HLA-A, -B, and -C) and nonclassical (HLA-E, -F, and -G) heavy chain genes, as well as the invariant β2 microglobulin
light chain (B2M) that comprises the MHC-I heterodimer (Hansen and Bouvier, 2009).
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Unexpectedly, the expression levels of the 3 classical heavy chain genes were significantly
higher compared to normal control tissues in the HNSC cohort. However, those levels were
significantly lower than those observed in the HPV– samples. Furthermore, the expression
levels of the non-classical heavy chain genes were higher or comparable to normal control
tissues. As noted by others (Cicchini et al., 2017), HLA-E was expressed at significantly
reduced levels in HPV+ samples compared with HPV− samples in the HNSC cohort only.
Moreover, the classical and non-classical heavy chain genes in the CESC cohort were
expressed at levels significantly higher in HPV+ samples compared to their HPV–
counterparts. However, the comparison between HPV+ and normal control samples in the
CESC cohort were insufficiently powered to allow for proper conclusions. In addition, the
B2M light chain gene in both cohorts was expressed in HPV+ carcinomas at levels higher
or comparable to HPV– samples. Collectively, these results indicate that the expression of
HPV oncogenes in actual human tumors is not correlated with strong repression of genes
encoded by the MHC-I loci, which is in stark contrast to what has been reported in tissue
culture-based models. Indeed, the average expression of the mRNA for these genes was
consistently higher or equivalent in HPV+ samples versus their respective controls.
Next, I wanted to analyze the expression of key components involved in MHC-I-specific
antigen loading and presentation that includes the heterodimer peptide transporter TAP
(TAP1/2), the bridging factor tapasin (TAPBP), the endoplasmic reticulum aminopeptidase
(ERAP1/2), and the chaperones: calreticulin (CALR), calnexin (CANX), and ERp57
(PDIA3). As mentioned above, several studies have reported the downregulation of TAP
in HPV+ cancer cell lines (Georgopoulos et al., 2000; Li et al., 2010). However, much less
is known about the effect of HPV on the expression of these other components. In the
HNSC cohort, all genes were expressed at higher levels in HPV+ samples with respect to
normal control tissues, with the exception of CANX. In the CESC cohort, nearly all of these
genes were expressed at elevated or comparable levels to HPV– or normal control tissues,
although some comparisons were limited due to being insufficiently powered. Therefore,
most components of the MHC-I antigen loading and presentation complex were transcribed
in HPV+ human tumors at levels that appear similar or significantly higher than normal
control tissues. This again contrasts with the reported decreases in TAP transcription
reported in tissue culture models.
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These unexpected results contradict the existing paradigm of HPV-mediated immune
evasion and suggest that in the context of an actual human tumor setting, the presence of
HPV may actually result in enhanced expression of mRNA encoding MHC-I-specific
antigen loading and presentation components. Notably, these results illustrate the
limitations of utilizing tissue culture systems to infer on complex networks. The use of in
vitro 2-dimensional approaches are useful as a launching point into many hypothesisdriven research initiatives; however, their utility in tumor virology—as exposed in this
study—can be limited, primarily due to the platforms lack of cellular heterogeneity. Indeed,
this cellular heterogeneity that exemplifies tumor microenvironments is a fundamental
characteristic of actual human cancers and plays a significant role in influencing the
complex interacting biochemical systems of these malignant cells. Specifically, expression
of MHC-I and related genes can be induced by proinflammatory mediators that are
produced by infiltrating immune cells that create an inflammatory state within the tumor
microenvironment (Boehm et al., 1997). However, this would never be recapitulated in
studies that simply transfect cell lines with HR HPV oncogenes without exposing them to
proinflammatory mediators (Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 2010).
Given my observation that mRNA levels of all MHC-I antigen loading and presentation
genes were expressed at higher or at least similar levels in HPV+ tumors compared with
HPV− and normal control tissues, I hypothesized that infiltrating lymphocytes producing
IFNγ—a proinflammatory cytokine—could be present at higher levels in HPV+ tumors
compared to HPV− tumors or normal control tissues. Utilizing an immunogenomic
approach with surrogate markers, I found evidence for significant infiltration by T- and
NK-cells in both HPV+ and HPV− carcinomas. Indeed, the levels of infiltrating T-cells
were significantly higher in HPV+ compared to their HPV– counterparts in both cohorts.
In addition, my analysis also revealed significantly higher levels of IFNγ in HPV+ samples
in both the HNSC and CESC cohorts. Taken together, these results indicate that HPV+
carcinomas have a significant level of infiltrating lymphocytes that appear to be producing
IFNγ, which may explain the upregulated expression of the genes involved in MHC-I
antigen loading and presentation observed in these carcinomas.
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Taken together, the high absolute levels of mRNAs encoding MHC-I components
expressed in HPV+ head & neck and cervical carcinomas provide good evidence that HR
HPV E7 is unable to efficiently block the IFNγ induction of transcription of these genes in
actual human tumors. Although this contrasts with the results of the studies listed above,
my work agrees with other studies showing that various cervical cancer cell lines
upregulate MHC-I in response to IFNγ (Bornstein et al., 1997; Evans et al., 2001; MoraGarcia Mde et al., 2006). Importantly, it should be noted that the levels of MHC-I heavy
chain mRNAs are statistically lower in HPV+ compared to HPV− samples in the HNSC
cohort, despite the increased levels of IFNγ. This may indicate that HPV is able to modestly
impact IFNγ activation in these tissues, but this was not observed in the CESC cohort. In
addition, this work differs markedly from my previous study in Chapter 2, in which I
showed that tissue culture models faithfully recapitulate what is observed in actual human
tumors. This may be due to the intrinsic nature of the pathways analyzed, with the MHC-I
network being amenable to influence by immune cells infiltrating into the local
environment.

6.3.2

Impact of HPV on the immune status of head and neck tumor
microenvironments

Given the observation in Chapter 3 of higher levels of intratumoral IFNγ and increased
infiltration by T- and NK-cells into the HPV+ TME, a mechanistic and detailed
characterization of immune cell presence and status between the 2 anatomically-similar,
etiologically-different head and neck cancer types were warranted. In Chapter 4, I used
transcriptional data from my curated dataset of over 500 HNSC samples from the TCGA
to compare the immune landscape between HPV+ and HPV– samples. Importantly, the
corresponding analysis could not be done in the TCGA CESC cohort because of limitations
in the number of HPV– and normal control samples in this dataset. In addition, these
samples were treatment-naïve prior to surgical resection, avoiding any confounding effects
of exposure to chemotherapy or radiation on the immune-status of these tumors.
Both HPV+ and HPV– HNSC display a similar frequency of somatic mutations, a major
source of tumor specific neoantigens that can be recognized and targeted by antitumor
immunity (The Cancer Genome Atlas Research Network, 2015). However, unlike HPV–
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HNSC, HPV+ carcinomas express exogenous antigenic viral proteins that may contribute
to the initial differences observed in Chapter 3 in the levels of infiltrating immune cells
between these 2 types of HNSC. Indeed, several studies have compared various
immunological parameters between HPV+ and HPV– HNSC and have commonly
concluded that HPV+ HNSC are immune “hot” tumors, with markedly more immune
infiltration and higher levels of CD8+ T-cell activation than HPV– HNSC (Mandal et al.,
2016; Solomon et al., 2018). Importantly, these and other studies suggest that a detailed
comparison of the immunological differences between HPV+ and HPV– HNSC provides
an opportunity to identify immunological determinants that contribute to successful
treatment in HNSC that may be broadly applicable to cancer treatment in general (Feng et
al., 2017; Lyford-Pike et al., 2013; Montler et al., 2016).
I began my investigation by comparing the type of immune response generated in HPV+
HNSC compared to its HPV– counterpart. Specifically, CD4+ helper T-cells are
instrumental in establishing the type of response triggered by immune activation, whether
it be a cell-mediated Th1 response, a humorally-biased Th2 response, or the
proinflammatory Th17 response necessary to maintain the immunological integrity of
mucosal barriers (Mucida and Salek-Ardakani, 2009). Each of the CD4+ subsets is
characterized by a distinct transcriptional program regulated by specific master regulatory
transcription factors (Fang and Zhu, 2017). Therefore, I analyzed my HNSC cohort from
the TCGA for the expression of the following master regulatory transcription factors and
the immune response they dictate: TBX21 (Th1), GATA3 and STAT6 (Th2), and RORA and
RORC (Th17). I found that HPV+ samples had significantly increased levels of TBX21
compared to HPV– and normal control tissues, which was indicative of a predominant Th1
immune phenotype.
Based on the observation that the HPV+ HNSC tumor microenvironment was
characterized by a predominant Th1 cellular-mediated response and the observation in
Chapter 3 of increased infiltration by T-cells into the HPV+ TME, I wanted to assess the
relative proportion of CD4+ and CD8+ T-cells in these samples. Utilizing an
immunogenomic approach, I analyzed the lineage-defining markers CD4 and
CD8A/CD8B. As expected, HPV+ samples showed significantly increased expression of
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all 3 genes compared to HPV– or normal control samples, confirming that enhanced T-cell
infiltration is a common feature of HPV+ HNSC. Furthermore, I also observed
significantly higher FOXP3 expression—associated with regulatory T-cells (Tregs)—in
HPV+ HNSC. Moreover, analysis of the expression of CD137 (4-1BB), an activationinduced costimulatory molecule present primarily on CD8+ T-cells, detected significantly
higher levels in HPV+ compared to their HPV– counterparts or normal control samples,
suggesting a higher overall level of T-cell activation and effector function in HPV+
malignancies. In addition, given the high levels of CD137 RNA in HPV+ HNSC samples,
I expected higher effector cytokine production by T-cells in these samples. Indeed, as
previously shown in Chapter 3, HPV+ HNSC expressed significantly higher levels of IFNγ.
Furthermore, HPV+ HNSC tumors also expressed significantly higher levels of cytotoxic
mediators, including granzyme A (GRZA), granzyme B (GRZB), and perforin (PRF1)
compared to both HPV– HNSC or normal control tissues. Taken together, these results
indicate that T-cells are not only present at higher levels in HPV+ HNSC, but also appear
more active and likely producing effector molecules.
An expected consequence of higher levels of infiltrating CD8+ T-cells producing IFNγ
would be induction of expression of interferon-responsive genes in tumor cells in close
proximity to the infiltrating T-cells. Indeed, in Chapter 3, I reported that multiple interferon
responsive components of the MHC-I antigen presentation apparatus were upregulated in
HPV+ HNSC. I therefore wanted to extend my studies to PDL1 and IDO1, which are
immunomodulatory genes known to be expressed by tumor cells in response to IFNγ. Both
PDL1 and IDO1 were significantly upregulated in HPV+ HNSC compared to normal
control samples. Notably, these observations provide a scientific rationale for combining
immunotherapy of HPV+ HNSC with immune checkpoint and IDO inhibitors in treatmentnaïve patients.
Based on the observed increase in the number of infiltrating CD8+ and CD4+ T-cells into
the TME of HPV+ HNSC, I hypothesized that this could be explained by the presence of
a dendritic cell (DC) signature in these tumors. Indeed, DCs play an important role in
migrating into these tumors, phagocytosing antigens, and presenting them to T-cells in the
context of MHC-II (Spranger et al., 2015). Therefore, I performed an analysis of DC
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signatures in these tumors, utilizing mRNA associated with DCs, as well as molecules
expressed by activated DCs that include chemokines that are pivotal in attracting them into
the TME. In my analysis, I observed high levels of transcripts from DC-associated genes,
but also high levels of molecules expressed by activated DCs, such as chemokines, in
HPV+ HNSC. Overall, these results indicate a higher level of DC involvement in HPV+
compared to HPV– HNSC, with higher levels of effector cytokines that could be
responsible for the elevated levels of T-cell infiltration into the TME of these samples.
T-cell-inflamed tumors show high levels of immune regulatory genes including IDO1 and
PDL1, and high infiltration of FoxP3+ Tregs (Gajewski et al., 2017), secondary to
cytotoxic T-cell infiltration into the TME. The presence of these immunosuppressive
events in a T-cell-inflamed microenvironment is often accompanied by increased levels of
multiple T-cell immune checkpoint molecules indicative of T-cell anergy. Indeed, once
activated, T-cells upregulate expression of multiple cell surface receptors that negatively
regulate their proliferation and moderate their level of activation. These so-called
“exhaustion markers” include LAG3, PD1, TIGIT, and TIM3 (Anderson et al., 2016).
Notably, they are important targets for immune checkpoint blockade therapies that are
currently approved or under development. My analysis revealed that all 4 of these
checkpoint genes were significantly upregulated in HPV+ HNSC compared to HPV– or
normal control samples. In addition, I also examined the expression of the
immunosuppressive molecule CD39 (Jie et al., 2013), which was recently shown to be
exclusively expressed on tumor antigen-specific CD8+ T-cells and not bystander CD8+ Tcells in colorectal and lung tumors (Simoni et al., 2018). My analysis showed significantly
higher CD39 RNA expression levels in HPV+ HNSC tumors compared to HPV– or normal
control samples. Collectively, my results indicate that HPV+ HNSC display a markedly
different immune signature from HPV– HNSC, revealing sustained CD8+ T-cell activation
in HPV+ HNSC. Furthermore, these observations provide a mechanistic insight into the
processes that shape the immune structure of HPV+ HNSC as a T-cell-inflamed tumor.
Moreover, they also suggest that combined immunotherapy with drugs that target more
than one of these inhibitory molecules have potential to be effective in overcoming
resistance to antitumor immunity in HPV+ HNSC tumors. Interestingly, there are no such
trials currently under way, but these findings strongly indicate that initiation of such
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clinical studies are justified once elevated protein levels are confirmed in a secondary
validation cohort.
High T-cell infiltration into HNSC, regardless of HPV status, has been reported as a
positive prognostic factor (Nguyen et al., 2016). Moreover, expression of checkpoint
molecules such as PD1 on circulating CD8+ T-cells is a biomarker of tumor antigen
specificity (Gros et al., 2016). I therefore analyzed 5-year overall survival outcomes in both
HPV+ and HPV– subsets of patients dichotomized by median expression of LAG3, PD1,
TIGIT, TIM3, or CD39. Furthermore, a second set of survival outcomes were done to
compare tumors expressing high levels of each combination of 2 of these markers. I
observed that high levels of transcripts from 1 or any combination of 2 genes expressing
immune checkpoint molecules (PD1, TIM3, TIGIT, LAG3) or CD39 in HPV+, but not
HPV–, HNSC can predict patient survival after surgery. Collectively, these results suggest
that the co-expression of high levels of CD39, LAG3, PD1, TIGIT, and TIM3 in HPV+, but
not HPV–, HNSC reflect the successful development of T-cell-based antitumor immunity
and a T-cell-inflamed phenotype, which contributed to long-term remission. This immune
signature could be used as a predictive biomarker of HPV+ HNSC patient outcome after
surgery. However, these findings require confirmation by prospective clinical studies to
pave the way for the development of immune-predictive biomarkers for HPV+ HNSC
patients that may ultimately lead to treatment deintensification in this patient population.
I next applied the Cox Proportional Hazards Model to identify clinical variables (sex, age,
smoking history, subsite, T stage, N stage, Overall stage, and HPV type) and
immunological markers predictive of overall survival. By univariate analysis, high
expression of TIGIT, TIM3, PD1, and CD39 were correlated with favorable prognosis
(HzR = 0.29, 0.24, 0.22, and 0.15 respectively, p < 0.05), while an HPV type other than
HPV16 was associated with a markedly poorer survival (HzR = 3.22, p = 0.03).
Furthermore, oral cavity tumors had significantly worse survival compared to those in the
oropharyngeal subsite (HzR = 3.05, p = 0.03). In addition, stepwise bidirectional
multivariate analysis was used to identify the best multivariate model of survival, and the
final model included N stage, HPV type, and CD39. Notably, CD39 (HzR = 0.07, p =
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0.0007), and HPV type (HzR = 9.23, p = 0.001) remained as significant predictors of
survival in this multivariate model.
Taken together, this study provides comprehensive evidence that the immune landscape of
HPV+ HNSC represents a T-cell-inflamed phenotype that is very different from HPV–
HNSC. Importantly, I demonstrate that multiple mechanisms that negatively regulate the
antitumor immune response are significantly upregulated in the majority of HPV+ HNSC
cases. Furthermore, high levels of gene transcripts from these negative regulators—CD39,
PD1, TIM3, LAG3, and TIGIT—correlate strongly with improved clinical outcome.
Notably, many of these negative regulators of the immune response are targets of
clinically-approved immune checkpoint inhibitors or inhibitors currently under
investigation in clinical trials. Therefore, HPV+ HNSC has many immunological features
that suggest that it would be highly amenable to immune checkpoint inhibition therapy.
Based on this study, I propose that HPV+ HNSC is a T-cell-inflamed disease and should
be treated differently in the clinic compared to HPV– HNSC, specifically with
combinations of immune checkpoint inhibitors.

6.3.3

Impact of HPV on the MHC-II antigen presentation network

In the previous chapters, I have noted significant differences in the epigenetic and immune
landscapes between the tumor microenvironments of HPV+ and HPV− carcinomas.
Furthermore, other studies have also concluded that HPV+ tumors are distinct from their
HPV– counterparts from a molecular perspective, with distinct genetic, epigenetic, and
protein expression profiles (Seiwert et al., 2015; Sepiashvili et al., 2015; Worsham et al.,
2013). Moreover, in Chapter 4, I have also shown that HPV+ HNSC is a T-cell-inflamed
malignancy, with increased infiltration by T-cells that express high levels of CD39 and
multiple exhaustion markers that correlated with improved survival. In order for an
effective T-cell-specific antitumor response to occur, a tumor associated antigen must be
presented in the context of either MHC-I or MHC-II (Rock et al., 2016). Indeed, in Chapter
3, I reported that HPV+ cancers express high levels of MHC-I and that this observation
could be a consequence of the increased levels of intratumoral IFNg present in the HPV+
TME. While expression of MHC-II molecules is typically restricted to professional APCs,
such as DCs, macrophages, and B-cells (van den Elsen et al., 2004), epithelial cells can be
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stimulated by IFNg to express MHC-II and function as accessory APCs to stimulate T-cell
responses (Boss and Jensen, 2003; Collins et al., 1984; Kim et al., 2009). In this final
chapter, I sought to determine the impact of HPV status on the expression of MHC-II genes
and related genes involved in their regulation, antigen presentation, and T-cell costimulation by analyzing my large HNSC cohort from the TCGA.
I began by analyzing my large HNSC transcriptomic dataset for expression of the α- and
β-chain genes that form the classical MHC-II heterodimers on the cell surface (van den
Elsen et al., 2004). Uniformly, all HPV+ patient samples expressed significantly higher
levels of mRNA for all MHC-II genes analyzed compared to HPV− patient samples and
virtually all normal control tissues. Notably, the normalized read levels of these genes were
expressed at levels several orders of magnitude above any lineage-defining markers of
professional APCs, such as CD19 (B-cells) (Wang et al., 2012), CCL13 (DCs) (Danaher et
al., 2017), and CD84 (macrophages) (Zaiss et al., 2003). However, these normalized read
levels were comparable to that of an established epithelial cell marker, E-cadherin (CDH1)
(Gall and Frampton, 2013). Therefore, it is likely that these MHC-II genes are being
expressed by epithelial cells within the actual tumor. Collectively, these results indicate
that HPV+ head and neck tumors express high levels of the mRNAs encoding the α- and
β-chain heterodimers of the classical MHC-II molecules, providing key evidence that
epithelial cells could be functioning as accessory APCs.
Next, I wanted to analyze the genes encoding key components of the MHC-II presentation
pathway. Specifically, I analyzed the non-classical α- and β-chains and the invariant γ chain
that are required for proper MHC-II antigen loading and trafficking. Similar to the classical
MHC-II genes, HPV+ samples expressed significantly higher levels of the invariant chain
and MHC-II-like genes compared to their HPV− counterparts and normal control tissues.
Collectively, the upregulation of these genes suggests that key components of the MHC-II
antigen presentation pathway are transcribed in HPV+ HNSC at levels that are significantly
higher than observed in HPV− tumors or normal control tissues. Furthermore, these genes
are also expressed at very high levels, indicative of being expressed by epithelial cells
within the actual tumor.
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Based on the observations that HPV+ head and neck carcinomas display high mRNA levels
for virtually all MHC-II genes analyzed above, I wanted to assess the impact of HPV on
the expression of transcriptional regulators of MHC-II gene expression. Transcriptional
control of MHC-II genes and the related genes that encode key components of the MHCII antigen presentation pathway is among one of the best understood systems in mammals.
It is a complex transcriptional system with a unique method of regulation that is completely
dependent on the master transcriptional regulator CIITA (Boss and Jensen, 2003; van den
Elsen, 2011). Analysis of the TCGA data revealed significantly higher levels of CIITA in
HPV+ samples compared to HPV− or normal control tissues. In addition, RFX5—another
important transcriptional regulator of MHC-II genes (Boss and Jensen, 2003)—was
similarly expressed at significantly higher levels in HPV+ samples with respect to HPV−
tumors or normal control tissues.
In Chapters 3 and 4, I showed that HPV+ carcinomas had increased levels of intratumoral
IFNγ, which as mentioned above, is able to stimulate the expression of MHC-II genes in
epithelial cells. To illustrate this IFNγ-specific coordinated upregulation of MHC-II genes
and related genes that encode products essential for antigen processing and presentation, I
generated a correlation matrix for both HPV+ and HPV− samples. As expected, regardless
of HPV status, I found that expression of all MHC-II antigen presentation-specific genes
were statistically correlated in a pairwise fashion in each patient sample. Therefore, the
upregulated expression of CIITA, RFX5, and subsequent expression of all the classical
MHC-II genes and related genes required for antigen loading and presentation observed in
HPV+ head and neck carcinomas are likely a consequence of IFNγ exposure. Furthermore,
the correlation matrix illustrates the unique simultaneous coordination of the MHC-II
transcriptional control system that has been shown to be dictated by the master
transcriptional regulator CIITA (Boss and Jensen, 2003; van den Elsen, 2011).
Next, I wanted to assess the impact of HPV on the expression of T-cell co-stimulatory
molecules. After generation and programming in the thymus, CD8+ and CD4+ T-cells
circulate in the body until they encounter their specific antigen presented on either class I
or class II MHC molecules. (Luckheeram et al., 2012; Pennock et al., 2013; Zhang and
Bevan, 2011). This interaction between TCR and antigen-loaded MHC complex represents
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signal 1, which triggers the activation of T-cells. However, in order for the activated T-cell
to fully respond to the presented threat, it requires a secondary signal mediated by costimulatory molecules (Chen and Flies, 2013). My analysis found higher levels of CD28 in
HPV+ tumors compared to their HPV− counterparts and normal control tissues. It is well
established that the binding of T-cell-specific CD28 with either CD80 or CD86 leads to the
clonal expansion of the T-cell pool that is specific to the recognized antigen (Beier et al.,
2007; Chen and Flies, 2013). In order to attenuate this response, the aforementioned
interaction leads to the induction of the co-inhibitory molecule CTLA-4, which is encoded
by the gene CD152. This co-inhibitory molecule will then compete with CD28 for binding
to either CD80 or CD86 to attenuate the T-cell response (Chen and Flies, 2013; Rudd et
al., 2009). I found that CD152 was significantly upregulated in the HPV+ cohort.
Collectively, this data indirectly illustrates and further confirms what has been shown in
previous chapters, that HPV+ tumor microenvironments have a higher number of
infiltrating T-cells. In addition, it provides good evidence that the interaction of costimulatory molecules in HPV+ HNSC is effective, given that I detected significantly
higher levels of expression of CD152 mRNA, which encodes for the inducible coinhibitory molecule CTLA-4.
Finally, I wanted to look at the impact of HPV on the expression of activation-inducible Tcell survival molecules. In order for proliferating T-cells to persist and survive after
antigen-recognition and subsequent stimulation with co-stimulatory molecules, they
require survival signals that are delivered through the cross-linking of various molecules
(Beier et al., 2007; Chen and Flies, 2013). Importantly, unlike CD28 that is found
constitutively expressed on T-cells, the molecules that convey these survival signals are
encoded by genes that are only expressed following TCR-mediated antigen-specific T-cell
activation (Beier et al., 2007; Chen and Flies, 2013). Utilizing my HNSC dataset, I looked
at these genes that encode for the inducible, T-cell activation-dependent, survival signal
molecules. I found that all inducible T-cell survival genes analyzed, with the exception of
TNFSF9, were expressed at significantly higher levels in HPV+ tumors compared to HPV−
and normal control tissues. This data indirectly illustrates that the HPV+ tumor
microenvironment contains increased levels of activated and proliferating T-cells via the
observation of an increase in expression of genes that encode for survival signal molecules
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that are only induced following TCR-mediated antigen-specific T-cell activation.
Furthermore, these results agree with my previous work on the immune landscape
(Chapters 3 and 4) and with previous reports by others that HPV+ tumor
microenvironments contain more T-cells (Chen et al., 2018; Mandal et al., 2016; Nguyen
et al., 2016; Solomon et al., 2018).
In summary, this final chapter provided further evidence that the HPV+ HNSC tumor
microenvironments are remarkably different from their HPV− counterparts. Importantly,
while some of this MHC-II signal can be attributed to professional APCs, the extremely
high relative level of expression supports a model whereby the T-cell inflamed
environment in HPV+ HNSC induces a functionally effective MHC-II presentation system
based on tumor epithelial cells. As MHC-II-dependent antigen presentation is critical for
CD4+ help in CD8+ T-cell responses, which are essential for the control and clearance of
cancerous cells (Pluhar et al., 2015), it is likely that the expression of non-self-derived viral
antigens or tumor derived neoantigens, combined with intact MHC-II presentation and
appropriate co-stimulation, contributes to the markedly better patient outcomes observed
for those with HPV+ head and neck carcinomas.
Taken together, the aforementioned studies profiled the immune landscape of HPV+ TMEs
(Chapters 3–5) and illustrated a microenvironment that consisted of increased MHC-I and
MHC-II expression that seemed to be induced from exposure to the proinflammatory
cytokine IFNγ that is mainly produced by infiltrating T- and NK-cells. Furthermore, we
observed an HPV+ TME that exhibited a strong bias towards a Th1 response which was
characterized by increased infiltration with multiple types of immune cells and expression
of their effector molecules. In addition, the HPV+ TME also expressed higher levels of
multiple T-cell exhaustion markers that were indicative of a T-cell-inflamed phenotype.
This predominantly immune “hot” HPV+ tumor microenvironment is summarized in the
following proposed schematic model (Figure 6.1).

6.4 Limitations of Study Design
The use of transcriptomic “big” data acquired through next-generation “-omics”
technologies from bulk tumor samples is a powerful approach that allows for an insightful
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Figure 6.1. Proposed schematic model of an HPV+ tumor microenvironment.
Schematic of an immune “hot” HPV+ tumor microenvironment that is characterized by an
increase in expression of the MHC-I and MHC-II antigen presentation systems, infiltration
with various immune cell subtypes, abundance of effector molecules, and upregulation of
T-cell exhaustion markers. Created with BioRender.
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elucidation of mechanistic processes under the influence of a native heterogeneous
environment. However, this in silico method that has been employed in this body of work
contains unavoidable limitations. The first limitation is the use of RNA-seq data acquired
through bulk tissue RNA sequencing platforms. This bulk tissue method measures the
mRNA expression levels of genes from an admixture of cells that include cancerous cells,
fibroblasts, immune cells, endothelial cells, and normal-adjacent cells (The Cancer
Genome Atlas Research Network et al., 2013). This could lead to confounding results
where you have expression of certain genes that can be expressed by different cell types.
However, in our study design, we looked at genes that have been shown to be expressed
by specific cell types, such as those of the immune system. In terms of tumor purity, the
TCGA consortium set a quality threshold that required tumor samples to be composed of
at least 60% tumor nuclei, as determined by visual analysis (Aran et al., 2015). Another
limitation is the lack of protein data in the TCGA cohorts to corroborate our mRNA
analyses, which is important because mRNA expression does not always mirror their
respective protein levels (Fortelny et al., 2017). Finally, as with any high throughput
analysis, the cohorts used are susceptible to batch effects that result from data processing
(Leek et al., 2010).

6.5 Concluding Remarks
In conclusion, these analyses provide significant insight into the validity of epigenetic and
immunological models of HPV-mediated sabotage, which have been proposed from
experiments conducted on relatively artificial in vitro culture systems. Importantly, these
studies have illustrated, in great detail, the strikingly profound differences in both the
epigenetic and immune landscapes between the tumor microenvironments of HPV+ and
HPV– carcinomas. In addition, this body of work has also identified a potentially useful
therapeutic target in KDM6A, and strongly advocates for the use of promising
immunotherapy strategies in the treatment of HPV+ HNSC. Furthermore, I also show that
expression of negative regulators of T-cell responses could potentially serve as predictive
biomarkers of clinical outcomes that could allow for treatment deintensification for patients
with favorable prognosis. Notably, the novel hypotheses that have been generated by this
work can also feedback into the laboratory and allow for further exploration in an
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experimental setting where relevant models, based on these studies, can be generated and
biologically manipulated. Lastly, it is in my hope that the accumulated knowledge gained
from this thesis will help advance the field of tumor virology and provide a positive clinical
impact on patients who live their daily lives with the burden of these devastating HPVinduced malignancies.
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Steven F. Gameiro, B.Sc. (Hon.)
EDUCATION
Doctor of Philosophy (Ph.D.)
Supervisor: Dr. Joseph Mymryk
Department of Microbiology and Immunology
Schulich School of Medicine and Dentistry
The University of Western Ontario

September 2013 – November 2019

Bachelor of Science (Hon.)
Major in Biology and Major in Medical Sciences
The University of Western Ontario

September 2007 – April 2013

SCHOLARSHIPS AND AWARDS
2019 PSAC GTA Scholarship for Outstanding Research Contributions
• valued at $500
Morris Kroll Memorial Scholarship in Cancer Research

November 2019
July 2019

(Schulich School of Medicine and Dentistry wide competition for an outstanding cancer research trainee)

•

valued at $500

Dr. FW Luney Graduate Travel Award in Microbiology & Immunology
• valued at $2,000

July 2018

Oncology Research and Education Day Top Poster Presentation Award
• valued at $100

June 2018

Dr. RGE Murray Graduate Scholarship

September 2017

(Awarded annually to students in the Microbiology & Immunology Graduate Program, based on academic
achievement and research merit)

•

valued at $10,000

Cancer Research and Technology Transfer Scholar

September 2017 – August 2018

(Competitive program that provides trans-disciplinary training links among basic and clinical researchers)

•

valued at $18,000 over one year

Dr. FW Luney Graduate Travel Award in Microbiology & Immunology
• valued at $2,000

July 2017
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American Society for Virology Travel Award
• valued at $500 (USD)

June 2017

Oncology Research and Education Day Poster Presentation Award
• valued at $100

June 2016

Dr. FW Luney Graduate Travel Award in Microbiology & Immunology
• valued at $2,000

June 2016

Ontario Graduate Scholarship

May 2016 – May 2017

(Awarded annually to graduate students in Ontario, based on academic achievement and research merit)

•

valued at $15,000 over one year

Schulich Graduate Scholarship

May 2015 – May 2018

(Awarded annually to graduate students registered in the Schulich School of Medicine and Dentistry)

•

valued at $2,000 over one year

Western Graduate Research Scholarship-M&I

September 2013 – September 2018

(Awarded annually to students in the Microbiology & Immunology Graduate Program)

•

valued at $4,500 over one year

Cancer Research and Technology Transfer Scholar

September 2013 – August 2014

(Competitive program that provides trans-disciplinary training links among basic and clinical researchers)

•

valued at $18,100 over one year

Robert and Ruth Lumsden Undergraduate Award
• valued at $1,000 over one year
Cancer Research and Technology Transfer Studentship
• valued at $6,500 over 4 months
Dean’s Honor List

September 2012 – April 2013
May 2012 – August 2012
2011 – 2013

ACADEMIC POSITIONS
Teaching Assistantship
September 2018 – December 2018
MICROIMM 2500A: Biology of Infection and Immunity
Course Coordinator: Dr. Kelly Summers
Teaching Assistantship (2) January 2017 – April 2017; January 2018 – April 2018
MICROIMM 4200B: Molecular Virology
Course Coordinator: Dr. Joseph Mymryk
Teaching Assistantship (2) January 2015 – April 2015; January 2016 – April 2016
MICROIMM 3620G: Immunology Laboratory
Course Coordinator: Dr. Kelly Summers
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Laboratory Manager/Ordering Technician
Mymryk Laboratory
Summer Research Assistant
Mymryk Laboratory
Research Assistant—CaRTT Summer Studentship
Turley Laboratory

June 2013 – Present
May 2013 – September 2013
January 2012 – April 2013

GUEST LECTURER
Fanshawe College: Current Topics in Biotechnology
Course Coordinator: Dr. Pieter Anborgh

April 12, 2019

MICROIMM 3820A: Nursing Students Course
Fungi Lecture
Course Coordinator: Dr. Kelly Summers

November 9, 2018

SUPERVISORY EXPERIENCE
4th year Honors Research Project Student Supervisor
Trainee: Matt Wong

October 2017 – April 2018

Partners in Experiential Learning Student Supervisor
Trainee: Bowen Zhang

October 2015 – June 2016

Partners in Experiential Learning Student Supervisor
Trainee: Estefani Romero

March 2014 – June 2014

4th year Honors Research Project Student Supervisor
Trainee: Lisa Newhook

October 2013 – April 2014
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oncoprotein targets RNF168 to hijack the host DNA damage response. PNAS. 2019;
116(39): 19552–19562 [IF – 9.580]
2. Gameiro SF, Ghasemi F, Barrett JW, Nichols AC, Mymryk JS. High Level Expression
of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve
an Important Role as Accessory Antigen Presenting Cells. Cancers. 2019; 11(8): 1129
[IF – 6.162]
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3. Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, and
Maleki Vareki S. DIY: Visualizing the immune landscape of tumors using transcriptome
and methylome data. Methods in Enzymology. 2019; (In Press) [IF – 1.862]
4. Ghasemi F, Prokopec SD, MacNeil D, Mundi N, Gameiro SF, Howlett CJ, Stecho W,
Plantinga P, Pinto N, Ruicci KM, Khan MI, Yoo J, Fung K, Sahovaler A, Palma DA,
Winquist E, Mymryk JS, Barrett JW, Boutros PC, Nichols AC. Mutational analysis of
Head and Neck Squamous Cell Carcinoma stratified by smoking status. JCI Insight.
2019; 4 (1): e123443. [IF – 6.014]
5. Zhang A, Tessier TM, Galpin KJC, King CR, Gameiro SF, Anderson WA, Yousef AF,
Qin WT, Li SSC, and Mymryk JS. The transcriptional repressor BS69 is a conserved
target of the E1A proteins from multiple human adenovirus species. Viruses. 2018;
10(12): E662. [IF – 3.811]
6. Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, and
Maleki Vareki S. Treatment-naïve HPV+ head and neck cancers display a T-cellinflamed phenotype distinct from their HPV- counterparts that has implications for
immunotherapy. OncoImmunology. 2018; 7(10): e1498439 [IF – 5.333]
7. King CR, Zhang A, Tessier TM, Gameiro SF, and Mymryk JS. Hacking the cell:
Network intrusion and exploitation by adenovirus E1A. mBio. 2018; 9(3): e00390-18.
[IF – 6.747]
8. King CR, Gameiro SF, Tessier TM, Zhang A, and Mymryk JS. Mimicry of cellular A
kinase anchoring proteins is a conserved and critical function of E1A across various
human adenovirus species. Journal of Virology. 2018; 92(8): e01902-17. [IF – 4.324]
9. Gameiro SF, Zhang A, Ghasemi F, Barrett JW, Nichols AC, and Mymryk JS. Analysis
of class I major histocompatibility complex gene transcription in human tumors caused
by human papillomavirus infection. Viruses. 2017; 9(9): E252. [IF – 3.811]
10. Gameiro SF*, Kolendowski B*, Zhang A, Barrett JW, Nichols AC, Torchia J, and
Mymryk JS. Human papillomavirus dysregulates the cellular apparatus controlling the
methylation status of H3K27 in different human cancers to consistently alter gene
expression regardless of tissue of origin. Oncotarget. 2017; 8(42): 72564-72576. [IF –
5.168]
MEDIA PUBLICATIONS
Steven F. Gameiro. Promise in Cancer Research—Young Researcher Series. Published in
The Londoner. Research Information Outreach Team Article Series. Thursday, November
16, 2017.
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Steven F. Gameiro and Joseph S. Mymryk. HPV-Induced Cancers—A Warty Problem!
Published in The Londoner. Research Information Outreach Team Article Series.
Thursday, May 26, 2016.
ORAL PRESENTATIONS
Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct
from their HPV- counterparts that has implications for immunotherapy. Presented at the
Infection and Immunity Research Forum (IIRF), held in Stratford, Ontario, Canada.
November 11, 2018
Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct
from their HPV- counterparts that has implications for immunotherapy. Presented at the
Molecular Biology of DNA Tumor Viruses Conference, held in Madison, Wisconsin, USA.
July 31-August 4, 2018
Human papillomavirus dysregulates the cellular apparatus controlling the methylation
status of H3K27 in different human cancers to consistently alter gene expression regardless
of tissue of origin. Presented at the Infection and Immunity Research Forum (IIRF), held
in London, Ontario, Canada. October 27, 2017
Human papillomavirus dysregulates the cellular apparatus controlling the methylation
status of H3K27 in different human cancers to consistently alter gene expression regardless
of tissue of origin. Presented at the Molecular Biology of DNA Tumor Viruses Conference,
held in Birmingham, England. July 17-22, 2017
HPV16 intratypic variants in head & neck cancers: A Southwestern Ontario perspective.
Presented at the American Society for Virology Annual Meeting, held in Madison,
Wisconsin, USA. June 24-28, 2017
HPV16 intratypic variants in head & neck cancers: A Southwestern Ontario perspective.
Presented at the Molecular Biology of DNA Tumor Viruses Conference, held in Montreal,
Quebec, Canada, July 18-23, 2016
Reduction of MHC I by HPV16 E7 and its role in head & neck cancers. Presented at the
Molecular Biology of DNA Tumor Viruses Conference, held in Madison, Wisconsin, USA.
July 21-26, 2014
INVITED ORAL PRESENTATIONS
HPV-induced Cancers. Presented at World Cancer Day, held at the Covent Garden
Market, London, Ontario, Canada. February 4, 2018
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The Epigenetic dysregulation of p16 by HPV in head and neck cancers is a potential target
for therapy. Presented at the Oncology Grand Rounds, held at Victoria Hospital, London
Regional Cancer Program, London, Ontario, Canada. December 5, 2017
Surgical Management of Aortic Dissection—A Patient’s Perspective. Presented at the
Canadian Society of Vascular Nursing (London Chapter) held at the Four Points Sheraton
in London, Ontario, Canada. November 2, 2011
POSTER PRESENTATIONS
Human papillomavirus-positive head and neck cancers express high levels of class II major
histocompatibility complex. Abstract and poster presented at the Molecular Biology of
DNA Tumor Viruses Conference, held in Trieste, Italy. July 9-14, 2019
*Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype
distinct from their HPV- counterparts that has implications for immunotherapy. Abstract
and poster presented at Oncology Research and Education Day, held in London, Ontario,
Canada. June 8, 2018
*HPV16 intratypic variants in head & neck cancers: A Southwestern Ontario perspective.
Abstract and poster presented at Oncology Research and Education Day, held in London,
Ontario, Canada. June 17, 2016
HPV16 intratypic variants in head & neck cancers: A Southwestern Ontario perspective.
Abstract and poster presented at the Infection and Immunity Research Forum (IIRF), held
in London, Ontario, Canada. November 6, 2015
Reduction of MHC I by HPV16 E7 and its role in head & neck cancers. Abstract and poster
presented at the Molecular Biology of DNA Tumor Viruses Conference, held in Trieste,
Italy. July 21-26, 2015
Reduction of MHC I by HPV16 E7 and its role in head & neck cancers. Abstract and poster
presented at the Infection and Immunity Research Forum (IIRF), held in London, Ontario,
Canada. November 6, 2014
Reduction of MHC I by HPV16 E7 and its role in head & neck cancers. Abstract and poster
presented at the Molecular Biology of DNA Tumor Viruses Conference, held in Madison,
Wisconsin, USA. July 21-26, 2014
Elucidating the mechanism by which HPV16 E7 modulates MHC I and defining its role in
OSCC. Abstract and poster presented at the London Health Research Day (LHRD), held
in London, Ontario, Canada. March 18, 2014
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Elucidating the mechanism by which HPV16 E7 modulates MHC I and defining its role in
OSCC. Abstract and poster presented at the Infection and Immunity Research Forum
(IIRF), held in London, Ontario, Canada. November 1, 2013
*Denotes award-winning presentation
SCHOLARLY ACTIVITIES
Chair
October 2017 – August 2018
Translational Seminar Speaker Selection Committee
Cancer Research and Technology Transfer Program
• Act as liaison between the selection committee and administrative staff
Student Representative
September 2017 – August 2019
American Society for Virology
Department of Microbiology and Immunology
• Convey information regarding the annual general meeting, funding opportunities,
and other relevant information from the society to M&I graduate students
Student Representative
September 2015 – August 2017
Seminars Committee
Department of Microbiology and Immunology
• Responsible for attending meetings throughout the year to discuss potential
speakers for the R.G.E Murray Seminar Series
Grad Coordinator
January 2014 – May 2015
Microbiology & Immunology Student Association (MISA)
• Mentor in the MISA mentorship program
• Aid in organizing events to educate undergraduate students about graduate studies
in the Microbiology and Immunology program at The University of Western
Ontario
Organizing Committee Member
November 2013 – August 2018
Infection and Immunity Research Forum (IIRF)
• The IIRF is an annual scientific conference that is organized and run by the
graduate students of The University of Western Ontario in the department of
Microbiology and Immunology. This conference showcases undergraduate,
graduate, and post-doctoral research in the fields of microbiology, immunology,
and virology
Committee Member
October 2013 – August 2016
Microbiology and Immunology Social Committee
• Organizing and running social events, including fundraising for the department of
Microbiology and Immunology
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MEMBERSHIPS
American Society for Virology Student Member

February 2017 – Present

VOLUNTEER WORK
Research Information Outreach Team
September 2017 – Present
Canadian Cancer Society—London Chapter
• Help plan and organize annual activities such as: World Cancer Day and Let’s
Talk Cancer
• Spread the word about progress and promise in cancer research through a monthly
column in The Londoner and through social media postings
Undergraduate Science Case Competition Judge
March 2016
SciNapse Science—The University of Western Ontario
• Evaluated undergraduate poster presentations and their understanding of the
research project
The American Society for Virology (ASV) Volunteer
34th annual ASV meeting—The University of Western Ontario
• Organized and ran oral presentation workshops

June 2015

Outreach Volunteer
December 2012 – January 2015
Let’s Talk Science -The University of Western Ontario
• Deliver science learning programs and services that turn children and youth on to
science
Volunteer Speaker
December 2012 – March 2014
Canadian Blood Services Volunteer Speakers’ Bureau Program
• Share my personal story at organized events to expand Canadian Blood Services’
capacity to recruit blood donors and help raise awareness of the increasing need
for blood and new blood donors
In-Community Volunteer
November 2012 – May 2013
Canadian Blood Services
• Sign up blood donors for upcoming clinics
• Monitor donors after they have given blood
• Promote public awareness about the importance of blood donation through
handing out flyers

